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SCIENTIFIC OPINION 
Scientific Opinion on the public health risks of bacterial strains producing 
extended-spectrum β-lactamases and/or AmpC β-lactamases in food and 
food-producing animals1 
EFSA Panel on Biological Hazards (BIOHAZ)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The potential contribution of food-producing animals or foods to public health risks by ESBL and/or AmpC-
producing bacteria is related to specific plasmid-mediated ESBL and/or AmpC genes encoded by a number of 
organisms. The predominant ESBL families encountered are CTX-M, TEM, and SHV; the predominant AmpC-
family is CMY. The most common genes associated with this resistance in animals are blaCTX-M-1 (the most 
commonly identified ESBL), and blaCTX-M-14, followed by blaTEM-52 and blaSHV-12. Among the genes encoding 
AmpC-type β-lactamases, blaCMY-2 is the most common.The bacterial species most commonly identified with 
these genes are Escherichia coli and non-typhoidal Salmonella. ESBL/AmpC transmission is mainly driven by 
integrons, insertion sequences, transposons and plasmids, some of which are homologous in isolates from both 
food-production animals and humans. Cefotaxime is used as the drug of choice for optimum detection of blaESBL 
and/or blaAmpC genes. The preferred method for isolation of ESBL- and/or AmpC-producers is screening on 
selective agar preceded by selective enrichment in a broth.The establishment of risk factors for occurrence of 
ESBL/AmpC-producing bacteria is particularly complicated by the data unavailability or lack of its accuracy. 
The use of antimicrobials is a risk factor for the selection and spread of resistant clones, resistance genes and 
plasmids. Since most ESBL- and AmpC-producing strains carry additional resistances to other commonly-used 
veterinary drugs, generic antimicrobial use is a risk factor for ESBL/AmpC and it is not restricted specifically to 
the use of cephalosporins. An additional risk factor is extensive trade of animals in EU MS. There are no data on 
the comparative efficiency of individual control options in reducing public health risks caused by ESBL and/or 
AmpC-producing bacteria related to food-producing animals. Prioritisation is complex, but it is considered that a 
highly effective control option would be to stop all uses of cephalosporins/systemically active 3rd/4th generation 
cephalosporins, or to restrict their use (use only allowed under specific circumstances). As co-resistance is an 
important issue, it is also of high priority to decrease the total antimicrobial use in animal production in the EU. 
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SUMMARY 
Following a request from the European Commission, the Panel on Biological Hazards (BIOHAZ) was 
asked to deliver a Scientific Opinion on the public health risks of bacterial strains producing 
extended-spectrum beta (β)-lactamases (ESBL) and/or AmpC β-lactamases (AmpC) in food and food-
producing animals. In particular, the Panel was asked: (i) to propose a definition of the ESBL- and/or 
AmpC-producing bacterial strains and genes relevant for public health and linked to food-producing 
animals or food borne transmission; (ii) to review the information on the epidemiology of acquired 
resistance to broad spectrum cephalosporins including the genes coding for such resistance in food-
producing animals and food, ensuring that differentiation was made between transmission of resistant 
bacterial strains and/or genes to humans by consumption or handling of contaminated food; and 
transmission of resistant bacterial strains and/or genes to humans through the food animal production 
environment; (iii) to perform a critical analysis of the methods (phenotypic and genotypic) and the 
interpretive criteria currently used for detection (isolation and identification) and characterisation of 
ESBL- and/or AmpC-producing bacterial strains, ESBL- and/or AmpC-encoding genes and associated 
mobile elements; (iv) to make recommendations for a harmonised monitoring of resistance 
(phenotypic eand genotypic) caused by ESBL- and/or AmpC in food and food-producing animals in 
the EU; (v) to the extent possible, to identify risk factors contributing to the occurrence, emergence 
and spread of ESBL- and/or AmpC-producing bacterial strains in food producing animals and food; 
and finally, (vi) to identify and rank possible control options, taking into account the expected 
efficiency in reducing public health risk caused by ESBL and/or AmpC-producing bacterial strains 
transmitted via the food chain or via food animal production environment, and consider the 
advantages and disadvantages of different options. 
The BIOHAZ panel concluded that ESBLs may be defined as plasmid-encoded enzymes found in the 
Enterobacteriaceae, frequently in Escherichia coli and Klebsiella pneumoniae, that confer resistance 
to a variety of ß-lactam antibiotics, including penicillins, 2nd-, 3rd- and 4th-generation cephalosporins 
and monobactams (eg aztreonam), but usually not the carbapenems or the cephamycins (e.g. 
cefoxitin). In contrast, AmpC β-lactamases are intrinsic cephalosporinases found on the chromosomal 
DNA of many Gram-negative bacteria, which confer resistance to penicillins, 2nd- and 3rd-generation 
cephalosporins including β-lactam/inhibitor combinations, cefamycins (cefoxitin), but usually not to 
4th-generation cephalosporins (cefepime, cefquinome) and carbapenems; a growing number of these 
AmpC enzymes are now plasmid-borne.  
The potential contribution of food-producing animals or foods to public health risks by ESBL and/or 
AmpC-producing bacteria is related to specific plasmid-mediated ESBL and/or AmpC genes encoded 
by a number of organisms. Although there are a large number of genes which encode ESBL and 
AmpC enzymes not all are equally prevalent among human and animal bacteria. The predominant 
ESBL families encountered are CTX-M, TEM, and SHV. The predominant AmpC-family is CMY. 
The bacterial species most commonly identified with these genes are Escherichia coli and non-
typhoidal Salmonella. Among E. coli, the clonal lineages: B2-E. coli O25:H4-ST131, D-E. coli O25a-
ST648 and D- E. coli-ST69, -ST393, are being increasingly detected among both humans and 
animals. Among Salmonella the most common serovars are Typhimurium, Newport, and Heidelberg; 
ESBL/AmpC transmission is mainly driven by integrons, insertion sequences, transposons and 
plasmids, some of which are homologous in isolates from both food-production animals and humans. 
Cefotaxime is used as the drug of choice for optimum detection of blaESBL and/or blaAmpC genes in 
Salmonella and E. coli. From the results presented in the Community Summary Report it can be 
concluded that the prevalence of resistance to cefotaxime in food animals varies by country and 
animal species. High levels are observed in E. coli and Salmonella from poultry in Spain, Italy, the 
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EFSA Journal 2011;9(8):2322 3
Netherlands and Poland. From raw meat from poultry only limited cefotaxime resistance prevalence 
data are available. Belgium and the Netherlands reported high to moderate cefotaxime resistance 
prevalences in Salmonella and E. coli from poultry meat. In pigs and cattle the prevalences were low. 
Since 2000, the presence of ESBL- and/or AmpC-producing Salmonella and E. coli in animals and 
food has been increasingly reported in both Europe and globally. Although these enzymes have been 
described in bacteria from all major food-producing animals, poultry and poultry products are most 
frequently reported to carry ESBL and/or AmpC-producing bacteria. The most frequently reported 
ESBL subtypes in the EU in both Salmonella and E. coli in food-producing animals and foods are 
CTX-M-1, CTX-M-14, TEM-52 and SHV-12; the predominant plasmidic AmpC variant described 
globally to occur in Salmonella and E. coli from food-producing animals or foods since the mid-1990s 
is CMY-2. A wide range of additional CTX-M subtypes (CTX-M-1, -2, -3, -8, -9, -14, -15, -17/18, -
20, -32, -53) have been detected in food-producing animals and food in European countries. A range 
of additional TEM (TEM-20, -52, -106, -126) and SHV (SHV-2, -5, -12) variants have similarly been 
detected in different European countries. Epidemic plasmids belonging to the incompatibility groups 
F, A/C, N, HI2, I1 and K groups carrying particular ESBL-encoding genes (blaTEM-52, blaCTX-M-1, -9, -14, -
32,) or AmpC-encoding genes (blaCMY-2) have been detected among farm and companion animals, food 
products and humans. There are few studies that describe clear evidence of direct transmission of 
ESBL- or AmpC-producing E. coli isolates from food-producing animals or food to humans. Data do 
exist about common clones of ESBL- and/or AmpC-producing E. coli isolates in humans and food-
producing animals and foods, which provide indirect evidence about this transmission. Comparison of 
E. coli derived from humans and poultry has shown that antibiotic-resistant E. coli isolates from both 
reservoirs are more frequently genetically related than antibiotic-susceptible isolates. Recent findings 
indicate transmission of ESBL genes, plasmids and clones from poultry to humans is most likely to 
occur through the food chain.There is limited evidence for spread of ESBL/AmpC-carrying organisms 
via direct contact with animals or indirectly via the environment. Nevertheless people working with 
poultry have a higher risk for intestinal carriage of ESBL/AmpC-producing bacteria. 
The preferred method for selective isolation of ESBL- and/or AmpC-producers is using 
cephalosporin-supplemented agar preceded by selective enrichment in a broth. The preferred method 
for selective isolation of ESBL- and/or AmpC-producers is chromogenic (e.g. MacConkey agar) with 
1 mg/L cefotaxime or ceftriaxone. Using low concentrations will result in optimum sensitivity to 
detect all relevant beta-lactamase families. Pre-enrichment may be performed in a general broth like 
Mueller-Hinton, Brain Heart Infusion or Luria-Bertani broth with 1 mg/L cefotaxime or ceftriaxone.  
Identification is performed by determination of susceptibility to cefotaxime, ceftazidime and 
cefoxitin. ESBL producers are resistant to cefotaxime, variably resistant to ceftazidime and 
susceptible to cefoxitin. Confirmation of ESBLs is performed by testing for synergy with clavulanic 
acid by combination disks, ESBL-etests or broth micro-dilution including cefotaxime, and ceftazidime 
as single drugs, and in combination with clavulanic acid. Confirmation of AmpC producers is 
performed by determination of susceptibility to cefepime. AmpC producers are susceptible to 
cefepime and resistant to cefotaxime, ceftriaxone and cefoxitin. To identify ESBL and/or AmpC-
suspected Enterobacteriaceae by broth micro-dilution susceptibility tests, optimum breakpoints or 
interpretive criteria need to be used. Although CLSI has recently redefined MIC breakpoints for 3rd- 
and 4th-generation cephalosporins, the R-breakpoints for ceftazidime, cefoxitin and cefepime are still 
one to two dilution steps higher than those defined by the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST). In order to harmonize the interpretation of susceptibility data and 
for optimum phenotypic detection of ESBL and/or AmpC producers, it is important to use EUCAST 
clinical breakpoints for interpretation of susceptibility or resistance and EUCAST epidemiological 
cut-off values (ECOFFs), to determine if an isolate belongs to the wild-type population or not.  
All isolates confirmed phenotypically to be either ESBL or AmpC producers may be screened for β-
lactamase gene families using micro-array or (multiplex) PCR. The ESBL and/or AmpC subtypes may 
be identified by dedicated PCRs and sequence analysis of the amplicons. Characterisation of plasmids 
on which blaESBL and/or blaAmpC-genes are located is essential to study the epidemiology of these 
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genes and plasmids. Since in Enterobacteriaceae several different plasmids are often present in each 
isolate, a structured approach is needed to identify the characteristics of the plasmid on which the β-
lactamase genes are located. If the presence of an ESBL and/or AmpC gene in a bacterial isolate is 
confirmed, plasmid isolation is performed to determine the number and sizes of plasmids present. 
Subsequently, by conjugation or electroporation, tranconjugants or transformants are isolated on 
selective agar plates with only the plasmid that harbours the β-lactamase gene present. The plasmid 
can be typed using replicon typing and sub-typed by fingerprinting or plasmid MLST. Ultimately 
whole plasmid sequence analyses may replace the current typing and subtyping techniques. The 
choice of the molecular typing method to be used for isolates is determined by epidemiological 
relatedness of the isolates. Next to phenotypic methods such as serotyping and phage typing, PFGE or 
MLVA can be used to identify clusters of isolates that are related to a certain ‘outbreak’ in a restricted 
time frame. MLST is generally the method of choice to identify relatedness of isolates of the same 
species from different backgrounds (eg. animal versus human). 
 The establishment of risk factors for occurrence of ESBL/AmpC-producing bacteria is particularly 
complicated by the data unavailability or lack of its accuracy. Few studies designed to assess risk 
factors for ESBL and/or AmpC occurrence in animals are available. The use of antimicrobials is a risk 
factor for selection and spread of resistant clones, resistance genes and plasmids. Most ESBL- and 
AmpC-producing strains carry additional resistances such as to sulphonamides and other commonly-
used veterinary drugs. Therefore, generic antimicrobial use is a risk factor for ESBL/AmpC and it is 
not restricted specifically to the use of cephalosporins. Currently there are no pan-European data 
available on the use of antimicrobials. The European Surveillance of Veterinary Antimicrobial 
Consumption (ESVAC), coordinated by the European Medicines Agency (EMA), is collecting 
information. An additional risk factor is extensive trade of animals in EU member states (MS), with 
few countries leading the production and the export, and with a small number of companies producing 
pure line breeding animals. How widespread ESBL-carrying bacteria are in food-producing animals in 
the breeding/rearing/fattening sectors is generally unknown, although a few reports suggest that 
ESBL/AmpC are not uncommon in the top of some production pyramids (breeding). ESBL- and/or 
AmpC-producing E. coli are introduced in poultry production chain through day-old grandparent 
chickens. Moreover, some data indicate that the occurrence of these organisms in the different levels 
of the poultry production chain is the result of vertical transmission, local recirculation and selection. 
There are no data on the comparative efficiency of individual control options presented in this 
document in reducing public health risks caused by ESBL and/or AmpC-producing bacteria related to 
food-producing animals. Prioritisation is complex, and the effectiveness of measures discussed in this 
Opinion is based on the best available evidence and expert opinion. As such it is considered that a 
highly effective control option to reduce selection of ESBL/AmpC-producing bacteria at an EU level, 
would be to stop all uses of cephalosporins/systemically active 3rd/4th generation cephalosporins, or to 
restrict their use (use only allowed under specific circumstances). Measures intended to minimize off 
label use should focus on increased compliance with existing legislation. As co-resistance is an 
important issue, it is also of high priority to decrease the total antimicrobial use in animal production 
in the EU. Also of importance (more so after the ESBL/AmpC-producing microorganisms have 
emerged) are the measures to control dissemination, for example by implementing increased farm 
biosecurity and controls on animal trade (of ESBL/AmpC-carriers), and by improving hygiene 
throughout the food chain, and implementing other general post-harvest controls for food-borne 
pathogens. Because most evidence is available for high prevalence of ESBL/AmpC-producing 
bacteria in the poultry production pyramid, and their consequent involvement in public health, it is of 
high priority to reduce selection pressure impossed by the use of antimicrobials, to prevent vertical 
transmission from the top of the poultry production pyramid, and to prevent local recirculation within 
subsequent flocks.  
Recommendations for the harmonised monitoring of resistance caused ESBL- and/or AmpC-
producing bacteria have been provided. 
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BACKGROUND AS PROVIDED BY EC 
A number of documents on public health concern of food-borne or other zoonotic spread of 
antimicrobial resistance have recently been published by the Commission4 and relevant agencies 
(EFSA5, EMEA6 and ECDC7). One of the new concerns highlighted in all of these documents is the 
increased occurrence of bacterial strains producing extended-spectrum beta (β)-lactamases (ESBLs) 
and/or acquired AmpC β-lactamases, thus causing it difficult to treat severe infections in humans, and 
their possible link to food or food producing animals. Many different kinds of bacteria are able to 
produce such enzymes, which deteriorate the effects of 3rd- and 4th-generation cephalosporin and 
monobactam antimicrobials. These antimicrobials are considered to be critically or highly important 
medicines for humans according to the report of the second World Health Organization (WHO) 
Expert Meeting8. They are also listed as antimicrobials of veterinary importance by the World 
Organisation for Animal Health (OIE)9. 
EMEA's reflection paper on the use of 3rd- and 4th-generation cephalosporins in food producing 
animals in the EU (2009)3 stresses that the rapid emergence of resistance caused by ESBL and/or 
AmpC in Enterobacteriaceae in Europe is a major public health concern, in particular regarding the 
increasing frequency of community-acquired infections. It is also said that it is possible that spread 
from animal reservoirs via food or via the environment may contribute to the dissemination of 
resistance in the community.  
It is stated in the EMEA's reflection paper that strains of E. coli producing ESBL and/or AmpC have 
been isolated from many types of food producing animals such as calves, cattle, swine, poultry, 
broilers, horses and rabbits in different countries in the EU. ESBL and/or AmpC producing 
Salmonellas have been detected in poultry and poultry meat samples. An occurrence of resistance 
caused by ESBL and/or AmpC has been linked to the use of antimicrobials in food producing animals, 
in particular 3rd generation cephalosporins, but increase in ESBL and/or AmpC-producing strains of 
Salmonella and Escherichia coli have also been detected without any prior use of cephalosporins. 
According to the report studies have also shown that humans can be exposed to ESBL- and/or AmpC-
producing pathogens causing clinical illness via food or via direct contact with infected animals, or to 
ESBL- and/or AmpC-encoding genes via direct contact, via contaminated food or indirectly through 
the environment. These genes can be transferred to bacteria with potential to cause infections in 
humans. EMA is proposing monitoring of resistance caused by ESBL and/or AmpC, including 
commensals in the zoonoses monitoring programmes.  
According to the EFSA opinion on food-borne antimicrobial resistance as a biological hazard (2008)2, 
the potential role of food and environmental sources in the epidemiology of transferable resistance 
genes has gained increased attention in relation to the rapid and recent emergence of resistance to 3rd 
generation cephalosporins. It is stated in the opinion that genes coding for the production of ESBL 
and/or AmpC are found in bacteria causing infections in hospitals, but also infections acquired in the 
community, in Salmonella from cases of human infections and food animals and commensal E. coli 
                                                     
 
4 Staff working paper of the services of the Commission on antimicrobial resistance SANCO/6876/2009r6 
5 Scientific Opinion of the Panel on Biological Hazards on a request from the European Food Safety Authority on food-borne 
antimicrobial resistance as a biological hazard. The EFSA Journal (2008) 765, 1-87 
6 Revised reflection paper on the use of 3rd and 4th generation cephalosporins in food producing animals in the European 
Union: Development of resistance and impact on human and animal health EMEA/CVMP/SAGAM/81730/2006-Rev. 1 
7 Scientific Opinion of the European Centre for Disease Prevention and Control; Scientific Opinion of the Panel on 
Biological Hazards; Opinion of the Committee for Medicinal Products for Veterinary Use; Scientific Opinion of the 
Scientific Committee on Emerging and Newly Identified Health Risks: Joint Opinion on antimicrobial resistance (AMR) 
focused on zoonotic infections. EFSA Journal 2009; 7(11): 1372 
8 FAO/WHO/OIE 2008. Joint FAO/WHO/OIE Expert Meeting on Critically Important Antimicrobials. Report of a meeting 
held in FAO, Rome, Italy, 26-30 November 2007; third revision 2009. 
9 OIE list of antimicrobials of veterinary importance. Resolution No. XXVIII, 75th General Session in May 2007. 
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isolated from animals. The ESBL- and/or AmpC-encoding genes have also been linked to transferable 
fluoroquinolone resistance and other resistance genes.  
According to the Joint opinion of ECDC, EFSA, EMEA and Scientific Committee on Emerging and 
Newly Identified Health Risks (SCENIHR) on antimicrobial resistance focused on zoonotic agents 
(2009)4 extra-intestinal and urinary tract infections in humans caused by resistant E. coli strains are 
becoming increasingly common and further work to elucidate the sources of such strains is necessary. 
In the joint opinion it is proposed in order to improve surveillance activities and risk assessment to 
further explore of the origin and transmission of ESBL-producing E. coli through the food chain. It is 
also proposed to develop strategies to explore the occurrence of resistance caused by ESBL and/or 
AmpC in non-pathogenic commensal micro-organisms (e.g. E. coli) together with their ability to 
develop, harbour and transmit resistance genes. Identification and characterisation of those 
environments that facilitate bacterial ESBL and/or AmpC gene transfer focusing on both zoonotic 
bacteria and other bacteria such as E. coli are also included in the proposals. Common 
recommendation of the above mentioned papers is to put resistance caused by ESBL and/or AmpC in 
place as a matter of priority. 
The staff working paper of the services of the Commission on antimicrobial resistance (2009)1, which 
is meant to serve as a basis of further discussions and needs in combating the issue of antimicrobial 
resistance (AMR), notices also the importance of ESBL and/or AmpC producing bacteria by 
reflecting that specific surveys could be carried out for resistance caused by ESBL and AmpC. 
The risk of spread of antimicrobial resistance via companion and other animals in direct contact with 
humans has also been addressed in several opinions of the agencies. This issue should, however, be 
subject of a separate future request from the Commission. 
In view of the above, there is a need to: 
• Assess the public health risk posed by ESBL- and/or AmpC-producing bacterial strains in food 
producing animals and food;  
• Assess the need to establish harmonised monitoring and control of ESBL- and/or AmpC- 
producing bacterial strains in food producing animals and food in the EU. 
TERMS OF REFERENCE AS PROVIDED BY EC 
EFSA is asked to issue a scientific opinion on the public health risk of ESBL- and AmpC-producing 
bacterial strains in food and food-producing animals and, in particular: 
1. To propose a definition of the ESBL- and/or AmpC-producing bacterial strains and genes relevant 
for public health and linked to food-producing animals or food borne transmission;  
2. To review the information on the epidemiology of acquired resistance to broad spectrum 
cephalosporins including the genes coding for such resistance in food-producing animals and 
food. Differentiation should be made between: 
• Transmission of resistant bacterial strains and/or genes to humans by consumption or 
handling of contaminated food. 
• Transmission of resistant bacterial strains and/or genes to humans through the food animal 
production environment.    
3. To perform a critical analysis of the methods (phenotypic and genotypic) and the interpretive 
criteria currently used for detection (isolation and identification) and characterisation of ESBL- 
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and/or AmpC-producing bacterial strains, ESBL- and/or AmpC-encoding genes and associated 
mobile elements.  
4. To make recommendations for a harmonised monitoring of resistance (phenotypic and genotypic) 
caused by ESBL- and/or AmpC in food and food-producing animals in the EU.  
5. To the extent possible to identify risk factors contributing to the occurrence, emergence and 
spread of ESBL- and/or AmpC-producing bacterial strains in food producing animals and food. 
6. To identify and rank possible control options taking into account the expected efficiency in 
reducing public health risk caused by ESBL- and/or AmpC-producing bacterial strains transmitted 
via the food chain or via food animal production environment. Advantages and disadvantages of 
different options should be considered.    
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ASSESSMENT 
1. INTRODUCTION 
In the last decade a variety of plasmid-mediated beta (ß)-lactamases, have emerged in Gram-negative 
bacteria, resulting in reduced susceptibility to broad spectrum ß-lactams. These ß-lactamases included 
both extended spectrum ß-lactamases (ESBLs) and AmpC ß-lactamases (AmpC). 
More specifically, ESBLs are plasmid-encoded enzymes in Enterobacteriaceae, frequently found in 
Escherichia coli and Klebsiella pneumoniae, but also present in other members of this bacterial 
family. ESBLs confer resistance to a variety of ß-lactam antibiotics, including penicillins, 2nd-, 3rd- and 
4th-generation cephalosporins and monobactams (eg aztreonam), but usually not the carbapenems or 
the cephamycins (e.g. cefoxitin). ESBL-producing organisms are frequently co-, or multiresistant, 
exhibiting resistance to other antimicrobial classes such as fluoroquinolones, aminoglycosides and, 
trimethoprim-sulphamethoxazole due to associated resistance mechanisms, which may be either 
chromosomally- or plasmid-encoded (Jacoby and Munoz-Price, 2005; Paterson and Bonomo, 2005). 
The most frequently encountered ESBLs in Enterobacteriaceae belong to the TEM, SHV and CTX-M 
families (Paterson and Bonomo, 2005). 
AmpC β-lactamases are intrinsic cephalosporinases found on the chromosomal DNA of many Gram-
negative bacteria, including many members of the Enterobacteriaceae (but, notably, not in Klebsiella 
or Salmonella), and opportunistic pathogens such as Pseudomonas and Acinetobacter. These enzymes 
confer resistance to penicillins, 2nd- and 3rd-generation cephalosporins including β-lactam/inhibitor 
combinations, cefamycins (cefoxitin), but usually not to 4th-generation cephalosporins (cefepime, 
cefquinome) and carbapenems. It is a serious concern that a growing number of AmpC enzymes have 
“escaped” on to plasmids. These are the so called ‘acquired’ or ‘plasmidic’ AmpCs. 
Over the past decade another type of clinically important ß-lactamases, the carbapenemases, have 
emerged and spread in Enterobacteriaceae. Klebsiella-producing carbapanemase (KPC) was the first 
carbapenemase reported in a Klebsiella pneumoniae isolate (Nordmann et al., 2009). The emergence 
and spread of carbapenemase-producing Enterobacteriaceae is a matter of great concern for the 
treatment of human infections, because carbapenemases hydrolyze all ß-lactams, including 
carbapenems and frequently aztreonam, making these organisms extremely drug–resistant. Moreover, 
all types of carbapenemases that so far have been found in Enterobacteriaceae are spreading globally 
(Nordmann et al., 2009; Struelens et al., 2010; Walsh, 2008). Such carbapenemase-producing strains 
are usually only susceptible to the polymyxins (e.g. colistin), fosfomycin and variably susceptible to 
tigecycline, although there are recent reports of colistin-resistant Enterobacteriaceae (Endimiani et 
al., 2008; Nordmann et al., 2009; Zarkotou et al., 2010). These carbapenemases are outside the remit 
of this report as they have not yet been identified in animal isolates. Nevertheless the recent global 
emergence of these new resistances deserves particular attention for the near future. 
Different classification systems have been suggested for these enzymes. The most commonly used are 
those introduced by (Bush et al., 1995), based on functional similarities and by Ambler, based on 
structural similarities (Ambler, 1980), or a combination of both (Bush and Jacoby, 2010). A 
simplified overview is provided in Table 1. 
The current β-lactamase classifications have become extremely complex (Tables 2 and 3), making 
them less accessible to clinicians, infection control professionals, hospital management and 
politicians, thus facilitating a debate about the usefulness of using traditional classification schemes 
(Giske et al., 2009; Livermore, 2008). The term ‘ESBL’ is usually restricted to enzymes belonging to 
functional class 2be/molecular class A, inhibited by clavulanic acid and showing activity against 
extended-spectrum cephalosporins. Recently, it has been proposed to expand the definition and to 
include mutants with borderline ESBL activity (e.g. TEM-12) and acquired ß-lactamases with activity 
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against extended-spectrum cephalosporins and/or carbapenems, which may fit the definition for group 
2be (e.g. KPC) or not (e.g. OXA and AmpC type derivatives with increased activity against 
cefepime). In this classification scheme it is suggested to keep the term 'ESBL', always accompanied 
by mention of the enzyme's family as, e.g., in 'TEM ESBL' or 'OXA ESBL', not as a sole 
moniker/designation (Giske et al., 2009). In this document we will follow the “classical” system for 
classification and nomenclature for ESBLs. 
There are some class D ß-lactamases (so-called oxacillinases) that might also be considered as 
“extended-spectrum” enzymes. Indeed, the class D ß-lactamase OXA-1 (that is also named OXA-30 
in some publications, both enzymes actually having the same sequence) possess the ability to 
compromise the efficacy of penicillins, but also that of 4th-generation cephalosporins such as cefepime 
or cefpirome (Aubert et al., 2001). By contrast to “classical” ESBLs, OXA-1 is poorly inhibited by 
clavulanic acid and tazobactam, and does not include ceftazidime in its hydrolysis spectrum. 
1.1. ESBLs 
1.1.1. SHV and TEM ESBLs 
Before 2000 SHV and TEM types of ESBLs were the predominant variants found in Klebsiella and E. 
coli that caused nosocomial infections. These ESBLs developed by mutations of the broad spectrum 
TEM-1 and SHV-1 and 2 genes were transferred between bacteria by plasmids, which were in turn 
spread by clonal distribution between hospitals and countries through patient mobility (Baraniak et 
al., 2005; Damjanova et al., 2007; Jacoby and Munoz-Price, 2005; Paterson and Bonomo, 2005). 
1.1.2. CTX-M ESBLs 
Since the early 2000s the CTX-M group of genes, named after their ability to produce enzymes 
capable of hydrolysing cefotaxime, emerged in human isolates. These genes were also located on 
highly transmissible plasmids, thus facilitating fast and efficient spread of resistance (Bonnet, 2004; 
Canton and Coque, 2006; Canton et al., 2008; Hunter et al., 2010; Livermore and Hawkey, 2005; 
Pitout et al., 2005a; Pitout and Laupland, 2008). Bacteria that express CTX-M enzymes are also 
commonly co-resistant or multiresistant, exhibiting resistance to multiple antimicrobials including 
fluoroquinolones (Jacoby et al., 2006). In the last decade the epidemiology of ESBLs in humans has 
changed. Successful international bacterial clones harbouring members of the CTX-M family have 
emerged and spread globally. As a result the CTX-M-ß-lactamases have become the most prevalent 
ESBLs in human Enterobacteriaceae worldwide (Livermore et al., 2007; Pitout et al., 2005a; Pitout et 
al., 2005b). The epidemiology of bacteria that produce CTX-M enzymes has also changed. Since the 
early 2000s, E. coli producing CTX-M enzymes (specifically CTX-M-15) have increasingly been 
found in the community in uncomplicated and complicated (including bacteraemias) community-
acquired urinary tract infections, as well as in serious intra-abdominal and skin and soft-tissue 
infections (Canton et al., 2008; Livermore et al., 2007; Peirano et al., 2010; Pitout and Laupland, 
2008; Rodriguez-Bano et al., 2008; Rodriguez-Bano et al., 2004; Rodriguez-Bano et al., 2006; 
Woodford et al., 2004).  
TEM, SHV and CTX-M ESBL-producing Enterobacteriaceae (mainly E. coli and Salmonella) have, 
in the last decade, also been increasingly reported in food-producing animals and food. 
1.2. AmpC β-lactamases 
The ‘acquired’ or ‘plasmidic’ AmpC enzymes fall into six phylogenetic groups 
(www.bellinghamresearchinstitute.com), CMY-2 being the most commonly-found enzyme. 
Resistance due to production of these enzymes is also a significant public health concern. Several of 
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these plasmidic AmpC enzymes have also been found with increasing frequency in 
Enterobacteriaceae isolated from food-producing animals and food (Jacoby, 2009; Smet et al., 2009). 
1.3. Significance and public health threat of human infections with ESBL/AmpC-β 
lactamase-producing bacteria.  
The broad resistance profile in bacteria that follows the production of ESBL/AmpC β-lactamases (and 
also those that produce carbapenemases), is significant in human infections, and poses an ongoing and 
worrisome public health threat (Pitout and Laupland, 2008; Rodriguez-Bano et al., 2010). This is 
primarily because many community infections, and also infections treated or transmitted within 
hospitals, are caused by bacteria that are no longer sensitive to 2nd, 3rd and 4th generation 
cephalosporins (Ben-Ami et al., 2006). These antimicrobials are administered many times as first-line 
therapy for a wide variety of infections found in the community and in the hospital, which include 
mild to extremely severe infections, ranging from an uncomplicated cellulitis or urinary tract 
infection, to pyelonephritis, bacteraemia or septic shock (Ben-Ami et al., 2006; Marchaim et al., 2010; 
Rodriguez-Bano et al., 2008; Rodriguez-Bano and Navarro, 2008; Rodriguez-Bano et al., 2004; 
Rodriguez-Bano et al., 2006; Rodriguez-Bano et al., 2010).  
The multiresistant nature of bacteria that produce ESBLs and AmpCs can affect the selection and 
timely administration of appropriate antimicrobials for community-acquired and healthcare-associated 
infections, since many first-line antimicrobials are no longer active against them. Examples are, 
fluoroquinolones, frequently used in urinary tract infections (UTI) and cephalosporins, as part of an 
antimicrobial regimen for intra-abdominal infections. Furthermore, infections with such resistant 
organisms are associated with poorer patient outcomes, increased morbidity, mortality, increased 
length of stay and increased costs (Anderson et al., 2006; Ben-Ami et al., 2009; Cosgrove et al., 2003; 
Ibrahim et al., 2000; Lautenbach et al., 2001; Roberts et al., 2009; Schwaber and Carmeli, 2007).    
1.4. Incidence of human infection 
The total burden of human infection of ESBL-producing bacteria is not entirely known, nor is the 
prevalence of human faecal carriage. The data on frequency of occurrence in invasive infections in 
humans in Europe come from the European Antibiotic Resistance Surveillance System (EARS-Net 
www.ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/index.aspx) (formerly EARSS). 
EARS-Net reports annual rates of antimicrobial resistance in bloodstream infections (BSI) and 
infections of cerebrospinal fluid (CSF) from hospitals in Europe. Such reports have demonstrated a 
steady increase in the rates of invasive E. coli and K. pneumoniae isolates that are resistant to 3rd 
generation cephalosporins since 2000. In 2009, 28 countries reported E. coli isolates to EARS-Net, of 
which 7.4% were resistant to 3rd generation cephalosporins (a surrogate marker for presence of an 
ESBL/AmpC-producing bacteria). Trends over the period 2006-2009 showed a rapid and substantial 
increase in the proportions of E. coli isolates resistant to 3rd-generation cephalosporins in 16 of the 28 
countries included in this surveillance system. Third-generation cephalosporin resistance in human 
clinical K. pneumoniae isolates has also increased substantially.  
Trends in faecal carriage of ESBL/AmpC-producing Enterobacteriaceae (predominantly E. coli), in 
the community are also of relevance, since these resistant organisms have emerged globally as a 
significant pathogen in the community and in hospitals. Various studies report faecal carriage of 
ESBL/AmpC-producing Enterobacteriaceae to be 3.7-5.5% in non-hospitalized patients (Valverde et 
al., 2004), or 10.8% in patients admitted to the hospital (Ben-Ami et al., 2006). In a study, 14% of 
blood-stream infections in non-hospitalised patients have been reported to be caused by 
Enterobacteriaceae resistant to 3rd- generation cephalosporins (Ben-Ami et al., 2006). Another report 
(Rodriguez-Bano et al., 2008) states that the estimated population-based incidence of community-
acquired infection due to ESBL-producing organisms was 2.2 cases per 100,000 population per year. 
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The risk of human colonisation or infection with ESBL and/or AmpC ß-lactamase-producing 
organisms is a complex matter. From observational studies risk factors for the acquisition of these 
bacteria were related to human health care and involved prior use of antimicrobial agents, breaches in 
infection control practices, and mobility of patients, invasive medical devices, lengthy hospital stay 
and compromised host defences. Overall, prior use of antimicrobials is a known risk factor for patient 
colonisation or infection with ESBL-producing organisms. Many antimicrobials have been associated 
with either or both of these, but those most frequently found in various studies are oxyimino ß- 
lactams (cefuroxime, cefotaxime, ceftriaxone, ceftazidime, or aztreonam), fluoroquinolones, ß-lactam- 
ß- lactamase inhibitor combinations (Park et al., 2009; Paterson et al., 2004; Rodriguez-Bano and 
Navarro, 2008; Wener et al., 2010).  
1.5. Possible reservoirs of ESBL/AmpCβ- lactamase-producing-bacteria.  
Although person-to-person spread is recognised as the main method of spread of ESBL/AmpC-β-
lactamase-containing E. coli both in hospitals and the community, the primary reservoirs of such 
organisms are contentious. ESBL-producing E. coli have been isolated from food animals in many 
European countries, particularly poultry and cattle, and farm animals are now recognised as important 
carriers of ESBL/AmpC-producing E. coli and Salmonella (Carattoli, 2008). Similarly there have 
been an increasing number of reports of ESBL-producing E. coli being isolated from foods of animal 
origin (Bergenholtz et al., 2009). This raises questions about the possible role of animal- and food-
related reservoirs on this phenomenon. 
Table 1:  Main hydrolytic characteristics of ESBLs and AmpC  
ß-lactamase Hydrolysis profilea Inhibited by  
clavulanic acid CAZ/CTX FOX FEP IPM 
ESBL + - + - Yes 
AmpC + + - - No 
aCAZ, ceftazidime; CTX, cefotaxime; FOX, cefoxitin; FEP, cefepime; IPM, imipenem 
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Distinctive substrate(s) Inhibited by Representative enzyme(s)
CA/TZBa EDTA 
1 1 C Cephalosporins No No E. coli AmpC, P99, ACT-1, 
CMY-2, FOX-1, MIR-1 
1e Ib C Cephalosporins No No GC1, CMY-37 
2a 2a A Penicillins Yes No PC1 
2b 2b A Penicillins, cephalosporins Yes No TEM-1, TEM-2, SHV-1 
2be 2be A Extended-spectrum 
cephalosporins (ESCs), 
monobactams 
Yes No TEM-3, SHV-2, CTX-M-
15, PER-1, VEB-1 
2br 2br A Penicillins No No TEM-30, SHV-10 
2ber NI A ESCs, monobactams No No TEM-50 
2c 2c A Carbenicillin Yes No PSE-1, CARB-3 
2ce NI A Carbenicillin, cefepime Yes No RTG-4 
2d 2d D Cloxacillin Variable No OXA-1, OXA-10 
2de NI D ESCs Variable No OXA-11, OXA-15 
2df NI D Carbapenems Variable No OXA-23, OXA-48 
2e 2e A ESCs Yes No CepA 
2f 2f A Carbapenems Variable No KPC-2, IMI-1, SME-1 
3a 3 B (B1) Carbapenems No Yes IMP-1, VIM-1, NDM-1, 
SPM-1 
  B (B3)    L1, GOB-1, FEZ-1 
3b 3 B (B2) Carbapenems No Yes CphA, Sfh-1 
NI 4 Unknown     
aCA; clavulanic acid; TZB, tazobactam. 
bNI, not included 
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Functional group or 
subgroup 
No. of 
enzymesb,c Representative enzymes 
CMY 1, 1e 68 CMY-2, CMY-4 
ACT 1, 1e 9 ACT-1 
ACC 1, 1e 4 ACC-1 
DHA 1, 1e 8 DHA-2 
MOX 1, 1e 8 MOX-1 
FOX 1, 1e 9 FOX-2 
TEM 2b, 2be, 2br, 2ber 172  
 2b 12 TEM-1, TEM-2, TEM-13 
 2be 79 TEM-3, TEM-10, TEM-26 
 2br 36 TEM-30 (IRT-2), TEM-31 (IRT-1), TEM-163 
 2ber 9 TEM-50 (CMT-1), TEM-158 (CMT-9) 
SHV 2b, 2be, 2br 127  
 2b 30 SHV-1, SHV-11, SHV-89 
 2be 37 SHV-2, SHV-3, SHV-115 
 2br 5 SHV-10, SHV-72 
CTX-M 2be 90 CTX-M-1, CTX-M-44 (Toho-1) to CTX-M-92 
PER 2be 5 PER-1 to PER-5 
VEB 2be 7 VEB-1 to VEB-7 
GES 2f 15d GES-2 to GES-7 (IBC-1) to GES-15 
KPC 2f 9 KPC-2 to KPC-10 
OXA 2d, 2de, 2df 158  
 2d 5 OXA-1, OXA-2, OXA-10 
 2de 9 OXA-11, OXA-14, OXA-15 
 2df 48e OXA-23 (ARI-1), OXA-51, OXA-58 
IMP 3a 26 IMP-1 to IMP-26 
VIM 3a 23 VIM-1 to VIM-23 
NDM 3a 3 NDM-1 
a Enzyme families include those for which numbers have been assigned based on primary amino acid structures (G. 
Jacoby and K. Bush, http://www.lahey.org/Studies/). 
b Compiled through December 2009. 
c The sum of the subgroups in each family does not always equal the total number of enzymes in each family, because 
some enzyme numbers have been withdrawn, and some enzymes have not been assigned a functional designation by the 
investigators who provided the amino acid sequence. 
d GES-1, unlike other members of the GES family, has little detectable interaction with imipenem. 
e Nine clusters of OXA carbapenemases with their individual members have been designated. 
 
2. ESBL- AND AMPC-PRODUCING BACTERIAL STRAINS AND GENES RELEVANT FOR PUBLIC 
HEALTH AND LINKED TO FOOD-PRODUCING ANIMALS OR FOODBORNE TRANSMISSION 
2.1. ESBL and/or AmpC encoding resistance genes  
A large number of genes encode ESBL and AmpC enzymes conferring reduced susceptibility to 
broad-spectrum ß-lactams (see http://www.lahey.org/Studies/, a site that contains additional 
information and GenBank accession number references for β-lactamases from various functional 
groups). Despite this, not all of such genes are equally prevalent among human and animal bacteria. 
In the last few years some ESBLs relevant to human medicine have been described in isolates from 
animals. By far the most common genes associated with this resistance have been those encoding 
CTX-M enzymes (the most commonly identified ESBL), followed by blaTEM-52 and blaSHV-12  
(Bortolaia et al., 2010b; Chiaretto et al., 2008; Cloeckaert et al., 2007; Escudero et al., 2010; Hasman 
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et al., 2005; Jensen et al., 2006; Machado et al., 2008; Randall et al., 2011; Smet et al., 2008). The 
ESBL enzymes associated with animals correspond to CTX-M (-1, -2, -3, -8, -9, -14, -15, -17/18, -20, 
-32, -55), TEM (TEM-20, -52, -106, -126) and SHV (SHV-2, -5 and -12). PER variants have been 
identified among fish and environmental samples (Carattoli, 2008). 
Among the AmpC-type β-lactamases, blaCMY-2 is the most common, while blaACC-1 and blaDHA-1 have 
only been scarcely reported (Arlet et al., 2006; Carattoli, 2008; Coque et al., 2008a; Cortes et al., 
2010; Dierikx et al., 2010a; Hasman et al., 2005; Rayamajhi et al., 2010; Rayamajhi et al., 2008; 
Rodriguez et al., 2009). Noteworthy, whereas ESBL producers have been mostly found in Europe, 
AmpC producers have been mostly encountered in the US, mirroring the trends observed among 
human isolates.  
Broad-spectrum SHV-1-, TEM-1- and OXA-type (e.g. OXA-1) β-lactamases have been frequently 
recovered from animals and food of animal origin in EU countries. It is important to note that OXA-1-
like enzymes may confer reduced susceptibility to 4th-generation cephalosporins, and in addition they 
confer high level of resistance to ß-lactam/ß-lactamase inhibitor combinations. Since the blaOXA-1 gene 
is commonly associated with plasmids carrying the blaCTX-M-15 ESBL gene, carriage of this gene 
significantly adds to the overall ß-lactam resistance pattern of the corresponding producers. In 
addition blaOXA-1 has also commonly been identified in association with many other ß-lactamase genes 
among all enterobacterial species. 
As mentioned above, OXA-1-like enzymes may confer reduced susceptibility to 4th-generation 
cephalosporins, and in addition they confer high level of resistance to ß-lactam/ß-lactamase inhibitor 
combinations. Isolates belonging to OXA-1-producing S. Typhimurium have been described over 
several years in Portugal, Spain and the UK as a cause of food-borne infections (Antunes et al., 2010; 
Herrero et al., 2009; Herrero et al., 2008; Hopkins et al., 2006). In addition, OXA-1 was shown to be 
responsible for high level resistance to ampicillin in S. Typhimurium isolates recovered from fish in 
India (Ruiz et al., 1999). Recently, a study conducted in Japan showed that among a series of 
ampicillin-resistant enterobacterial isolates recovered from traditional Egyptian Domiati cheese, some 
were producing OXA-1 (Hammad et al., 2009). 
2.2. ESBL and/or AmpC-producing microorganisms  
ESBL- (e.g. TEM, SHV, CTX-M) and AmpC (e.g. CMY, DHA-1, ACT-1)-producing organisms have 
been detected in a variety of food-producing animals (poultry, swine, bovine, horse, rabbit, ostrich, 
wild boars), and food of animal origin (Blanc et al., 2006; Carattoli, 2008; Carneiro et al., 2010; 
Cortes et al., 2010; Dierikx et al., 2010a; Escudero et al., 2010; Hunter et al., 2010; Poeta et al., 2009; 
Rodriguez et al., 2009; Vo et al., 2007). From these hosts, the species more commonly identified have 
been E. coli and non-typhoidal salmonellae and to a lesser extent, Klebsiella pneumoniae, Citrobacter 
freundii or Enterobacter spp. (Arlet et al., 2006; Dierikx et al., 2010a; Hasman et al., 2005; Machado 
et al., 2008; Rayamajhi et al., 2010; Rayamajhi et al., 2008). A wide diversity of Salmonella serovars 
producing ESBLs or AmpCs has been reported. Although the most common serovars are 
Typhimurium, Newport, and Heidelberg, such enzymes have also been detected in an expanding 
number of other serovars (Gonzalez-Sanz et al., 2009).  
Few data are available from marine aquaculture production systems in Europe. ESBLs (CTX-M, 
PER) and/or AmpC (CMY-2) enzymes have been detected among potential human and fish pathogens 
in these settings, such as Salmonella, Aeromonas, Vibrio, and Edwarsiella ictaluri (Doublet et al., 
2009; Girlich et al., 2010, 2011; McIntosh et al., 2008; Picao et al., 2008; Welch et al., 2009).  
Other ESBL- or AmpC–producing Enterobacteriaceae (such as Proteus, Morganella, Pseudomonas, 
or Acinetobacter) have not been identified in isolates from food-producing animals.  
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2.3. Specific ESBL and/or AmpC-producing clones 
Although ESBL/AmpC transmission is mainly driven by plasmids, there are specific human 
pathogenic clones, particularly of E. coli and Salmonella, which have been linked to food-producing 
animals and food. This situation is considered to be dynamic and it is likely that in the future new 
resistant clones could emerge. 
Escherichia coli 
Among E. coli, the clonal lineages: phylogroup B2-E. coli O25:H4-ST131, phylogroup D-E. coli 
O25a-ST648 and phylogroup D-E. coli-ST69, -ST393, are being increasingly detected among both 
humans and animals (Cortes et al., 2010; Mora et al., 2011; Vincent et al., 2010). Recently, E. coli 
ST57, ST156, and ST371, all producing ESBLs, have been recovered from chickens and turkeys in 
different countries in Europe and North America (Bonnedahl et al., 2010; Randall et al., 2011; Simoes 
et al., 2010) and ESBL-producing, verocytotoxin-producing E. coli (VTEC) isolates have also been 
described10. 
Salmonella 
Among Salmonella, global spread of multi-drug resistant (MDR) (to chloramphenicol, florfenicol, 
streptomycin, spectinomycin, sulphonamides, tetracyclines and trimethoprim) clones belonging to 
serovars Agona with SGI-1 (Salmonella Genomic Island 1)-A, or Typhimurium of definitive phage 
type (DT) 104 carrying SGI-1 have been linked to TEM-52 production (Cloeckaert et al., 2007). 
Particular clones of S. Infantis seem to be widespread among poultry in some EU countries, for 
example, in France and Belgium as well Japan (Cloeckaert et al., 2007; Dahshan et al., 2010; Yang et 
al., 2010). A recent report has also described this serovar among pigs (Dahshan et al., 2010). 
A summary of this information is presented in Table 4.  
2.4. Mobile genetic elements involved in transmission of ESBL and/or AmpC resistance 
2.4.1. Integrons 
Integrons are genetic tools that play a role in the acquisition of resistance genes, and also in their 
expression. Noteworthy, they are not self-mobile genetic platforms, and are usually identified onto 
transposon and/or plasmid elements that may vehiculate these integrons. Even if integrons are 
common vehicles for some ESBL determinants (encoding VEB, GES, or BEL enzymes), they do not 
correspond to those involved in the acquisition of ESBL determinants identified among ESBL-
producing animal isolates (namely TEM, SHV, and CTX-M).  
ESBL and AmpC genes originally came into the chromosomes of different species of 
Enterobacteriaceae. Mobilization of these bla homologues housekeeping genes from original 
chromosomal backgrounds is mediated by widespread integrases (class1 integrases), transposases 
(ISEcp1, IS26, ISCR1), and to a lesser extent phage-related and repeated ReAv elements. Further 
successful spread of ESBL and AmpC genes occurs by different lateral genetic transfer processes 
involving insertion sequences, transposons, Class 1 integrons and overall, the transferable plasmids in 
which they are located (Arduino et al., 2002; Eckert et al., 2006; Girlich et al., 2011; Oliver et al., 
2005; Poirel et al., 2008; Toleman et al., 2006). Among animal isolates, studies focused on these 
genetic features have shown that, overall, these mobile elements were the same as those identified in 
human isolates (Carattoli, 2009; Cloeckaert et al., 2007; Leverstein-van Hall et al., 2011). This 
                                                     
 
10 http://www.efsa.europa.eu/en/efsajournal/doc/2274.pdf 
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observation has reinforced some of the hypotheses suggestive of direct links between the two bacterial 
populations.  
2.4.2. Insertion sequences and transposons 
Over 150 TEM β-lactamases variants have so far been identified, many of them displaying an ESBL 
phenotype (www.lahey.org/Studies/). All are TEM-1 or TEM-2 derivatives, and most of the structures 
surrounding the blaTEM ESBL genes derive from Tn3-like structures. The Tn3 class II transposon 
possesses 38-bp inverted repeats and is able to transpose efficiently the blaTEM ampicillin resistance 
gene marker, together with resistance to expanded-spectrum β-lactams when the TEM determinant 
encodes an ESBL variant.  
SHV ESBLs are point mutants of either narrow-spectrum chromosomal SHV-1 or SHV-2 β-
lactamases which originate from the chromosome of K. pneumoniae. Complete copies of insertion 
sequence (IS)26 at the boundaries of different chromosomal regions led to the genesis of different 
putative IS26-composite transposons containing blaSHV genes. Thus it is not surprising to identify 
some DNA fragments originating from the K. pneumoniae chromosome in the immediate vicinity of 
the blaSHV-like genes.  
Insertion sequences Ecp1 and CR1 (part of the so-called sul1-type integron structures) are involved in 
the mobilization of different blaESBL and blaAmpC genes by a mechanism named “one ended 
transposition”. This means that only one copy of the IS element is enough to mobilize right-ended 
located sequences by contrast to composite transposons that are made of two copies of some given IS 
elements bracketing the mobilized fragment. Also, by providing some strong promoter sequences, 
ISEcp1 and ISCR1 are involved in the expression of the genes they mobilize (Poirel et al., 2008; 
Toleman et al., 2006). 
Copies of IS26 at the boundaries of different regions led to the genesis of different putative IS26-
composite transposons. The high recombinational potential of all these IS26-mosaic structures 
contributes to the mosaicism of current mobile genetic elements (MGE) encoding antibiotic resistance 
and facilitates rearrangements between different genetic elements. IS26 has also been associated with 
the mobilization of CTX-M and AmpC genes (Ford and Avison, 2004). 
Phage-related elements are associated with blaCTX-M genes (Oliver et al., 2005) and Re1-like 
sequences have been identified in association with blaVEB-like and blaPER genes (Girlich et al., 2011). 
2.4.3. Plasmids 
Several major plasmid families have emerged in MDR Enterobacteriaceae isolated worldwide and 
carrying ESBL and AmpC enzymes. These enzymes have been mainly spread by plasmids of the 
incompatibility FII, A/C, L/M, N, K, and I1 groups (Antunes et al., 2010; Carattoli, 2009; Mataseje et 
al., 2009). IncF, IncI and IncN plasmid families are largely prevalent in commensal faecal flora of 
healthy animals (51,1%, 17,4% and 10.9%, respectively), regardless of resistance genes (Johnson et 
al., 2007b), suggesting that these plasmids are naturally occurring in commensal isolates and may 
occasionally acquire ESBL or AmpC genes by gene exchanges. Highly transmissible IncFII plasmids 
carrying blaCTX-M-15 or the IncI11 carrying the blaTEM-52 are of particular interest as they are globally 
spread among E. coli populations from humans and animals (Carattoli, 2009). In contrast, IncA/C, 
IncL/M and IncK plasmids have not been identified in faecal flora of antibiotic-free humans and in 
commensals from healthy animals. Their occurrence in resistant bacteria of different origin and 
sources seems tightly linked to positive selection exerted by antimicrobial use, incrementing their 
prevalence compared to that observed in bacterial populations that have not been pre-selected for 
antimicrobial resistance. These plasmids can be considered as “epidemic associated with the 
emergence of specific ESBL or AmpC gene variants. For instance, the IncA/C plasmids were 
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associated with the emergence of blaCMY-2 in the USA and UK (Hopkins et al., 2006; Randall et al., 
2011), the IncL/M plasmids were associated to the spread of blaCTX-M-3 in European Eastern countries 
(Golebiewski et al., 2007), while IncK plasmids carrying blaCTX-M-14 have become diffused in Spain 
and UK (Cottell et al., 2011; Liebana et al., 2006; Valverde et al., 2009). 
The knowledge that some plasmid types are prevalent in resistant populations is useful for tracing 
their global spread among enterobacterial populations from humans, animals and the environment. 
Further details of plasmid incompatibility groups and the methods for their identification are provided 
in Section 4.4 below.  
A summary of this information is presented in Table 5. 
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Table 4:  Clones associated with the spread of genes encoding ESBL and AmpC resistance  
Species Clones ESBL/AmpC genes Animals/Food Humansa Spreadb Reference 
E. coli  B2-O25b:H4-ST131c blaCTX-M-14, blaCTX-M-15, 
blaCTX-M-9, blaSHV-12, 
blaCMY-2 
Poultry, swine Yes Global (Cortes et al., 2010; Mora et al., 2011; Vincent et 
al., 2010) 
 D-O25a-ST648 blaCTX-M-32 Poultry, Swine Yes Global (Cortes et al., 2010; Mora et al., 2011) 
 ST69 blaCTX-M-14 YES Yes Global (Cortes et al., 2010) 
 ST156 blaCTX-M-15 Poultry, gulls No Portugal, UK (Bonnedahl et al., 2010; Randall et al., 2011; 
Simoes et al., 2010) 




O26 blaCTX-M-3, blaCTX-M-18, 
blaTEM-52 
Food-borne Yes Belgium (Buvens et al., 2010) 
 O157 blaCTX-M-2 Food-borne Yes Belgium (Buvens et al., 2010) 
Salmonella Agona  blaTEM Poultry Yes Global (Cloeckaert et al., 2007) 
 Typhimurium -DT104  blaTEM Poultry Yes Global (Cloeckaert et al., 2007) 
 Infantis  blaTEM-52 Poultry, Swine Yes France, Belgium, Japan (Cloeckaert et al., 2007; Dahshan et al., 2010; 
Yang et al., 2010)  
 Virchow blaCTX-M-2, blaCTX-M-9 Poultry Yes Spain, France (Bertrand et al., 2006; Riano et al., 2009; Riano et 
al., 2006; Weill et al., 2004). 
 Westhampton/ 
Senftenberg  
blaCTX-M-53 Cockles No French supermarkets (Doublet et al., 2009) 





Yes EU, USA (Aarestrup et al., 2004; Folster et al., 2009). 
 Newport lineage II (ST45 
and single locus variant 
ST116)  
blaCMY-2 cattle, bovine, and 
horse meat or pets 
treats 
Yes EU, USA (Harbottle et al., 2006; Pitout et al., 2003; 
Sangal et al., 2010). Espié and Weill, 2003; 
www.eurosurveillance.org/ew/2003/030703.asp#2 
a Clones detected in humans 
b Geographical areas in which these clones have been reported 
c O25b:H4-ST131-B2 clonal group carrying additional virulence factors ibeA and capsule K1 is often detected in poultry farms  
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Table 5:  Major plasmid families associated with genes encoding ESBL and AmpC resistance  
Plasmid 
group 
ESBL/AMPc genes Species Animals Humans Reference 
 
IncFII blaCMY-2, blaCTX-M-1-2-3-9-14-15-24-27, blaDHA-1, 
blaSHV-2-5-12, blaTEM-1, 
E. coli, Salmonella, E. aerogenes, E. cloacae, Klebsiella 
pneumoniae, Serratia marcenscens, Shigella sonnei 
Yes Yes (Carattoli, 2009; Marcade et al., 
2009; Mnif et al., 2010) 
IncI1 blaCMY-2-7-21, blaCTX-M-1-2-3-9-14-15-24, blaSHV-12, 
blaTEM-1-3-52, blaVIM-1, 
E. coli, K. pneumoniae, Salmonella, S. sonnei Yes Yes (Carattoli, 2009; Cloeckaert et al., 
2007; Dierikx et al., 2010a; Jensen 
et al., 2006; Randall et al., 2011) 
IncI2 blaCMY-2 Salmonella Yes Yes (Antunes et al., 2010; Mataseje et 
al., 2009)  
IncK blaCTX-M-14, blaCMY-2 E. coli, K. pneumoniae, Salmonella Yes Yes (Dierikx et al., 2010a; Liebana et 
al., 2006; Valverde et al., 2009) 
IncA/C blaCMY-2-4, blaCTX-M-2-3-14-15-56, blaSHV-2-5-12, 
blaTEM-3-21-24, blaIMP-4-8-13, blaVIM-4, blaVEB-1, 
E. coli, Salmonella, Citrobacter freundii, Citrobacter 
koseri, E. cloacae, Klebsiella oxytoca, K. pneumoniae, 
Proteus mirabilis, Providencia stuartii, Serratia 
marcescens, Edwarsiella, Aeromonas 
Yes Yes (Hopkins et al., 2006; McIntosh et 
al., 2008; Randall et al., 2011; 
Welch et al., 2009) 
IncL/M blaCTX-M-1-3-15-42, blaTEM-3-10, blaSHV-5,        
blaIMP-4-8, 
E. coli, C. amalonaticus, C. freundii, E. aerogenes, 
E. cloacae, K. oxytoca, K. pneumoniae, M. morganii, 
P. mirabilis, Salmonella, S. flexneri, S. marcescens 
No Yes (Carattoli, 2009; Golebiewski et al., 
2007) 
IncHI2 blaCTX-M-2-3-9-14, blaSHV-12, blaIMP-4, blaVIM-1, E. coli, S. enterica, K. pneumoniae, C. youngae, 
E. cloacae,  
Yes Yes (Carattoli, 2008, 2009; Novais et 
al., 2006) 
IncN blaKPC-2, blaCTX-M-1-3-15-32-40, blaVIM-1 E. coli, K. ascorbata, K. pneumoniae, Salmonella Yes Yes (Blanc et al., 2006; Bortolaia et al., 
2010b; Cavaco et al., 2008; Girlich 
et al., 2007; Moodley and 
Guardabassi, 2009; Randall et al., 
2011; Zong et al., 2010) 
IncQ blaGES-1 Aeromonas , Enterobacteriaceae No* Yes (Poirel et al., 2010) 
(*)  Reported in fish 
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3. THE EPIDEMIOLOGY OF ACQUIRED RESISTANCE TO BROAD SPECTRUM CEPHALOSPORINS IN 
FOOD-PRODUCING ANIMALS AND FOOD. 
3.1. Occurrence of ESBL and AmpC in food-producing animals and food. 
3.1.1. Harmonised monitoring of resistance to third-generation cephalosporins: EFSA 
Community Summary Report (CSR)11 and National reports. 
In order to harmonise monitoring of AMR, the establishment of optimum phenotypic testing systems 
for sensitive, specific and rapid detection of ESBL- and AmpC-producing organisms has been 
recognised as a very important component of antimicrobial resistance monitoring programmes 
(Livermore et al., 2001).  
The European Food Safety Authority (EFSA, http://www.efsa.europa.eu) has prepared detailed 
specifications on minimum requirements for harmonised monitoring of antibiotic resistance in food-
producing animals to obtain comparable data across the EU. Guidelines for monitoring of AMR in 
Salmonella and Campylobacter12 and also in indicator E. coli and enterococci13 are available on the 
EFSA website. To enable the comparison of the occurrence of resistance between different countries 
the EFSA guidelines request harmonization of (i) protocols on sampling strategies, (ii) the method of 
susceptibility testing, (iii) the antibiotics to be tested and (iv) the criteria for categorising isolates as 
susceptible or resistant, as well as quality control and reporting. 
The EFSA guidelines state that cefotaxime is a good substrate for what are currently the most 
common and important ESBLs in humans in Europe, the CTX-M enzymes. This was confirmed in a 
recent study, in which it was concluded that for detection of ESBL- and AmpC-producing E. coli or 
Salmonella harbouring TEM, SHV, CTX-M, and various AmpC gene families, usage of cefotaxime, 
cefpodoxime or ceftriaxone with epidemiological cut-off values (ECOFFs) > 0.5, > 2 and > 0.125 
mg/L, respectively, were the most efficient cephalosporins for detection of these ß-lactamase gene 
families. Ceftazidime, ceftiofur and cefquinome were less efficient (Aarestrup et al., 2010). 
In the 2007-2009 Member State (MS) reports, summarised in Tables 13 and 14 (Appendix A), the 
occurrence of resistance is given, where available, for cefotaxime, ceftazidime and ceftiofur. The 
recent implementation of EFSA’s recommendations by MSs has resulted in a more frequent 
monitoring of resistance to third-generation cephalosporins, as based on cefotaxime susceptibility 
patterns, over the period 2007-2009, this is an important improvement to the EU-wide surveillance 
programme. Since reports cover only phenotypic monitoring, it is not possible to determine the class 
or exact type of ß-lactamase enzyme which is likely to confer the resistance detected to 3rd-generation 
cephalosporins. Since in the tables per country and animal species, data are included if as a minimum 
10 isolates are tested, the results need to be interpreted with care. 
                                                     
 
11 EFSA, ECDC; European Community Summary Report on antimicrobial resistance in zoonotic and indicator bacteria from 
humans, animals, and food in the European Union in 2009 
12 EFSA, 2007. Report of the Task Force of Zoonoses Data Collection including a proposal for a harmonized monitoring 
scheme of antimicrobial resistance in Salmonella in fowl (Gallus gallus), turkeys, and pigs and Campylobacter jejuni and 
C. coli in broilers, the EFSA Journal (2007), 96,1-46. Available at: http://www.efsa.europa.eu/en/scdocs/scdoc/96r.htm 
13 EFSA, 2008. Report from the Task Force on Zoonoses Data Collection including guidance for harmonized monitoring and 
reporting of antimicrobial resistance in commensal Escherichia coli and Enterococcus spp. from food animals. The EFSA 
Journal (2008) 141, 1-44. Available at: http://www.efsa.europa.eu/en/scdocs/scdoc/141r.htm 
ESBL/AmpC in food-producing animals and foods
 
EFSA Journal 2011;9(8):2322 23
Poultry 
Many countries did not detect cefotaxime resistance among the isolates of Salmonella from poultry 
tested. The occurrence of cefotaxime resistance among countries reporting such resistance was low 
for 2009, at 1-3% for France, Italy, Spain and the Czech Republic and moderate for the Netherlands at 
12%. These figures can be compared with the figures obtained in 2008, when the Netherlands and 
Italy reported an occurrence of cefotaxime resistance in Salmonella of 13% and 12% respectively, 
whereas in the remaining countries which detected resistance, occurrences varied between 0% and 
1%. In the Netherlands the most predominant serovar in which cefotaxime resistance was observed 
was S. Paratyphi B variant Java, which is common in Dutch broiler farms. It should not be confused 
with other serovar Paratyphi B variant Java isolates exhibiting multiple resistances and associated 
with tropical fish, which appear highly pathogenic for humans (Threlfall et al., 2005). Other 
cefotaxime-resistant serovars found in Dutch poultry or poultry meat products include Virchow, 
Hadar, Infantis, Kottbus, Mbandaka, Agona, Cubana, Rissen, Senftenberg and Heidelberg (MARAN 
2008)14. In poultry raw meat products, Belgium reported a high occurrence of resistance (26%) in 
200815, while the Netherlands reported a moderate occurrence of resistance (18% for Salmonella and 
15% for E. coli) (MARAN 2008). From 2003 to 2008, a dramatic increase in occurrence of 
cefotaxime-resistant E. coli and Salmonella isolates from Dutch broiler chickens has been observed 
(3% to 18% for E. coli randomly isolated from faecal samples using non-selective plates) (MARAN- 
2009)16. 
In Sweden, since 2008 healthy food animals are screened for ESBL- or AmpC-producing E. coli by 
culture of intestinal content on media supplemented with cefotaxime. In 2010, ESBL and /or AmpC-
producing E. coli were found in 34% of the samples from broilers (SVARM, 2010)17. 
In 2009 eight MS and two non-MS tested more than 10 isolates of E. coli for cefotaxime resistance in 
poultry (Gallus gallus) isolates. Resistance to cefotaxime for the eight reporting MSs was 8.5%, 
although the occurrence of resistance reported by individual MSs ranged from 0% to 26%. The 
resistance ranged from low level of around 3% (Austria, Germany and France) to high level of 26% 
(Spain) with the Netherlands and Poland reporting moderate proportions of 18% and 11%, 
respectively. 
Cattle 
Cefotaxime resistance in Salmonella isolates from cattle in 2009 was only reported by Germany, 
where the occurrence of resistance was 1 %. Considering all reporting MS, the overall occurrence of 
cefotaxime resistance was less than 1 %. In E. coli the prevalence of resistance to cefotaxime was 
1.6% for all reporting MSs (10 MSs) and ranged from 0% to 6.5% (Hungary) for individual MSs. 
Pigs  
In 2009, cefotaxime resistance in Salmonella was only reported in Germany and Spain. In these 
countries the levels were low (2% and 1% respectively). In E. coli the prevalence of resistance to 
cefotaxime was low (2.3%) for all reporting MS and ranged from 0% to 3.8% for individual MS. 
Cefotaxime resistance was not detected in isolates of animal origin from Denmark, Estonia or 
Switzerland. 
                                                     
 
14  MARAN-2008 Monitoring of Antimicrobial Resistance and Antibiotic Usage in Animals in the Netherlands in 2008. 
http://www.cvi.wur.nl/NR/rdonlyres/A906A4C0-A458-423E-B932-28F222385988/105836/MARAN_2008.pdf 
15  The Community Summary Report on antimicrobial resistance in zoonotic and indicator bacteria from animals and food in 
the European Union in 2008. http://www.efsa.europa.eu/en/efsajournal/doc/1658.pdf 
16  MARAN-2009 Monitoring of Antimicrobial Resistance and Antibiotic Usage in Animals in the Netherlands in 2009. 
http://www.lei.wur.nl/NR/rdonlyres/4ED137F2-5A0D-4449-B84E-61A3A8AC4A42/135753/MARAN_2009.pdf 
17  SVARM 2010, Swedish Veterinary Antimicrobial Resistance Monitoring. The National Veterinary Institute (SVA), 
Uppsala, Sweden, 2011. www.sva.se. 
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In Denmark (DANMAP, 2009)18, a low occurrence (0.7%-3.3%) of cefotaxime-resistant E. coli from 
poultry meat, pork and beef meat of domestic origin was found, while a high level of resistance (36%) 
was observed among imported broiler meat.  
3.1.2. Data from published studies targeted to detect ESBL and/or AmpC 
A large number of studies have been performed in different European countries as well as in countries 
in other continents, focused on the analysis of the prevalence of ESBL- and AmpC-carrying 
Enterobacteriaceae (especially E. coli and non-typhoidal Salmonella) in faecal samples from food-
producing animals or in food derived from them. Reviews about this topic have been published by 
different authors (Carattoli, 2008; Li et al., 2007; Smet et al., 2009; Torres and Zarazaga, 2007). 
Tables 6 and 7 (and Tables 16 and 17 of Appendix B) show most of the reports published about the 
detection of ESBL- or AmpC-carrying Enterobacteriaceae in food-producing animals or foods 
derived from such animals. 
The methodology used in the different studies to detect ESBL-carrying bacteria in food-producing 
animals or in derived foods is heterogeneous and comparisons are therefore difficult. Some studies 
have reported the percentage of ESBL-carrying E. coli obtained in media not supplemented with 
antibiotics; others have analysed the carriage of ESBL-positive isolates in faecal samples of food-
producing animals or food samples using media supplemented with broad-spectrum cephalosporins 
(cefotaxime +/- ceftazidime). Additionally some studies have been performed at slaughterhouse level, 
and others at farm level.  
3.1.2.1. Prevalence of ESBL-producing E. coli and Salmonella in food-producing animals and food 
The first report of the detection of ESBLs in food-producing animals was performed in E. coli isolates 
recovered during 2000-2001 from faecal samples of healthy chickens at the slaughterhouse level 
obtained as part of the Spanish antimicrobial resistance surveillance programme (Brinas et al., 
2003b). In that study, 120 E. coli isolates were obtained from faecal samples in non-antibiotic 
supplemented media and CTX-M-14 and SHV-12 were detected in 1.6% of them. An increase in the 
percentage of ESBL-producing E. coli isolates among commensal faecal isolates (8 of 158 isolates, 
5%) was found in a second screening performed in 2003, with a higher diversity of ESBLs detected 
(CTX-M-9, CTX-M-14 and SHV-12) (Brinas et al., 2005). 
Prevalence data from other countries are more difficult to compare, because methodologies used have 
varied. Percentages of samples of food-producing animals or food in which ESBL-carrying E. coli 
isolates were detected varied from 0.2% to 40.1%, according to the country and the methodology used 
[(Smet et al., 2009); Table 6]. Occurrences in the range of 10-40% were found when healthy poultry 
or pigs were analysed for the presence of ESBL-positive E. coli isolates in Portugal (Costa et al., 
2009; Goncalves et al., 2010; Machado et al., 2008), Netherlands (Dierikx et al., 2010a), France 
(Girlich et al., 2007), and slightly lower percentages were identified in Czech Republic (Kolar et al., 
2010). Moreover, ESBL-carrying E. coli isolates were found in most of pig and poultry farms tested 
in Spain (Blanc et al., 2006), and also in five poultry farms tested in Italy (Bortolaia et al., 2010b). 
ESBL-producing E. coli isolates were also detected in two of four flocks of poultry in farms with no 
previous antibiotic use in Denmark (Bortolaia et al., 2010a). In a study in Belgium (Smet et al., 2008), 
45% of  295 ceftiofur-resistant E. coli isolates obtained from 489 cloacal samples collected at five 
different Belgian broiler farms were ESBL producers.  
The prevalence of ESBLs among Salmonella isolates of food-producing animals or derived food is 
much lower than that among E. coli. In a study in Germany of 22679 Salmonella isolates of the 
                                                     
 
18  DANMAP 2009 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, 
foods and humans in Denmark. www.danmap.org. 
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National Salmonella Laboratory Collection, sixteen isolates produced CTX-M enzymes (1 CTX-M-
15; 15 CTX-M-1) and four isolates produced the TEM-52 or TEM-20 enzymes located on IncI1 
plasmids. The ESBL-producers represented only 0.09% of the total number of isolates tested 
(Rodriguez et al., 2009). In another study in Spain among isolates obtained through the Spanish 
Veterinary-Antimicrobial-Resistance-Surveillance Network (VAV), 4 of 556 (0.7%) Salmonella 
organisms obtained from faecal samples of healthy food animals (pigs and poultry) at the 
slaughterhouse level were ESBL producers, representing 0.2% in the case of pigs and 2.5% of all 
isolates in the case of poultry (Riano et al., 2006). ESBL-producing Salmonella prevalences of 0.5-
0.6% were detected in Italy, Korea and Japan (Chiaretto et al., 2008; Hur et al., 2010; Matsumoto et 
al., 2007). 
In a pilot study in 2010 on 26 broilers production farms in the Netherlands, the prevalence of ESBL 
and/or AmpC-producing E. coli was determined. Faecal samples were collected from the cloaca from 
25 to 41 animals per farm. All farms were found positive. In 85% of the farms, 80% or more of the 
chickens examined were positive for ESBL- and/or AmpC-producing E. coli (Dierikx et al., 2010b). 
Imported meat could be an important source of ESBL/AmpC- E. coli producers. A recent survey of 
frozen chicken meat imported into Sweden showed that 92% of meat from South America had 
ESBL/AmpC E. coli producers, compared with 19% for meat from elsewhere in Europe.  Moreover, 
E. coli from South American meat were resistant to a wider range of antibiotics and had a higher 
diversity of ESBL/AmpC genes (Borjesson et al., 2011). Other studies conducted in chicken meat 
imported into Denmark and United Kingdom from the same geographical region indicated an 
occurrence of ESBL/AmpC E. coli producers in 30-36% of samples analyzed (Bergenholtz et al., 
2009; Dhanji et al., 2010). 
3.1.2.2. ESBL-subtypes detected in E. coli and Salmonella from food-producing animals or food 
The following ESBL subtypes have been detected in food-producing animals and food in European 
countries (table 6):  
i) CTX-M class: CTX-M-1 (Spain, Portugal, France, Belgium, Denmark, Italy, Netherlands, UK, 
Germany and Czech Republic), CTX-M-2 (Belgium, Denmark, Netherlands, UK, Ireland), CTX-M-9 
(Spain, France, Denmark, UK), CTX-M-14 (Spain, Portugal, France, Belgium, Denmark and UK), 
CTX-M-15 (France, Belgium, UK, Germany, Denmark), CTX-M-32 (Spain, Portugal, Italy and 
Greece), and other CTX-M- variants (CTX-M-53 in France, CTX-M-3, -8, -17/18, -20 in UK);  
ii) SHV class: SHV-2 (Spain, Portugal, and Netherlands), SHV-5 (Spain), and SHV-12 (Spain, 
France, Italy, Netherlands, Denmark, Ireland and Czech Republic). 
iii) TEM-class: TEM-52 (Spain, Portugal, Belgium, Netherlands, Ireland, Denmark and Germany); 
TEM-20 (Netherlands, Ireland and Germany), TEM-106 (Belgium) and TEM-126 (France).  
According to these results, CTX-M-1 appears to be well disseminated in food-producing animals and 
food in most of the European countries for which reports exist. On the other hand, CTX-M-14 and 
CTX-M-32 appear more associated with food-producing animals or food in Mediterranean and 
Southern European countries (Blanc et al., 2006; Bortolaia et al., 2010a; Bortolaia et al., 2010b; 
Brinas et al., 2005; Brinas et al., 2003b; Carneiro et al., 2010; Costa et al., 2009; Madec et al., 2008; 
Politi et al., 2005), although CTX-M-14 was also found in food-producing animals in UK and 
Belgium (Hopkins et al., 2006; Hunter et al., 2010; Smet et al., 2008; Warren et al., 2008). CTX-M-2 
was observed in Central and Northern European countries, including UK and Ireland (Bertrand et al., 
2006; Bortolaia et al., 2010a; Boyle et al., 2010; Cloeckaert et al., 2007; Dhanji et al., 2010; Dierikx 
et al., 2010a; Hasman et al., 2005; Hopkins et al., 2006; Liebana et al., 2006; Morris et al., 2009; 
Randall et al., 2011; Smet et al., 2008; Warren et al., 2008). CTX-M-15, the ESBL considered to have 
spread in a pandemic fashion in humans, was only detected incidentally in food-producing animals or 
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food and in only in a few countries in E. coli (isolated in France from diseased cattle, in Belgium from 
healthy poultry, and in UK in broiler chickens and turkey) and in Salmonella isolates (Germany, one 
S. Typhimurium from horse origin) (Madec et al., 2008; Randall et al., 2011; Rodriguez et al., 2009; 
Smet et al., 2008). ESBLs of the SHV class were frequently detected throughout the EU, especially 
SHV-12 and SHV-2 (Blanc et al., 2006; Bortolaia et al., 2010b; Boyle et al., 2010; Brinas et al., 
2003a; Brinas et al., 2003b; Chiaretto et al., 2008; Cortes et al., 2010; Costa et al., 2009; Dierikx et 
al., 2010a; Doi et al., 2009; Escudero et al., 2010; Goncalves et al., 2010; Hasman et al., 2005; 
Hopkins et al., 2006; Kolar et al., 2010; Machado et al., 2008; Madec et al., 2008; Morris et al., 2009; 
Riano et al., 2006). In relation to the ESBLs of the TEM class, the most frequently detected 
throughout the EU was TEM-52 (Blanc et al., 2006; Brinas et al., 2005; Carneiro et al., 2010; 
Cloeckaert et al., 2007; Costa et al., 2009; Dierikx et al., 2010a; Jensen et al., 2006; Machado et al., 
2008; Morris et al., 2009; Randall et al., 2011; Rodriguez et al., 2009; Smet et al., 2008). To a lesser 
extend TEM-20 was detected in countries as Netherlands, Ireland and Germany (Boyle et al., 2010; 
Dierikx et al., 2010a; Hasman et al., 2005; Hopkins et al., 2006; Rodriguez et al., 2009).  
The ESBLs detected in food-producing animals or food in other non-European countries were: China 
(CTX-M-3, -13, -14, -15, -22, -24, -55, -64, -65; SHV-2, -12; TEM-52), Japan (CTX-M-2 and -14), 
Korea (CTX-M-15), USA (CTX-M-1, -29, SHV-12), Tunisia (CTX-M-1, CTX-M-8, CTX-M-14; 
SHV-5; TEM-20) and Senegal (SHV-12) (Ben Slama et al., 2010; Cardinale et al., 2001; Doi et al., 
2009; Duan et al., 2006; Jouini et al., 2007; Kojima et al., 2005; Li et al., 2010a; Li et al., 2010b; Lim 
et al., 2009; Matsumoto et al., 2007; Rayamajhi et al., 2008; Shiraki et al., 2004; Tian et al., 2008; 
Wittum et al., 2010). These data show that mainly in Asian countries a higher diversity of CTX-M- 
variants was observed. The presence of CTX-M-15 in E. coli of healthy and sick poultry and pigs in 
China and Korea may reflect a different epidemiology of ESBLs in these countries (Li et al., 2010a; 
Li et al., 2010b; Lim et al., 2009; Tian et al., 2008). 
3.1.2.3. Prevalence and types of AmpC in E. coli and Salmonella from food-producing animals or 
food 
The following ESBL subtypes have been detected in food-producing animals and food in European 
countries (table 7):  
Poultry origin 
In samples of poultry origin, the percentage of AmpC-carrying E. coli isolates ranged from 0.8 to 
3.3% in different European (Spain, Belgium, Netherlands, Czech Republic) (Brinas et al., 2005; 
Brinas et al., 2003b; Dierikx et al., 2010a; Smet et al., 2008) and non-European countries (Japan, 
Taiwan and China) (Kojima et al., 2005; Li et al., 2010b; Yan et al., 2004). For Salmonella, 
percentages of detection in the range of 0.1-10% were identified for poultry or derived food in 
Ireland, USA, Canada or Japan (Allen and Poppe, 2002; Boyle et al., 2010; Taguchi et al., 2006; Zhao 
et al., 2008). 
Cattle origin 
In samples of cattle origin, AmpC β-lactamases were detected in 0.01% of 8426 Salmonella isolates 
in a Canadian study (Allen and Poppe, 2002). In samples of pig origin, the percentages of AmpC-
carrying Salmonella or E. coli isolates ranged from 2.4 to 23% in Canada, Taiwan and México (Kozak 
et al., 2009; Yan et al., 2004; Zaidi et al., 2007).  
The type of AmpC β-lactamase detected in food-producing animals or derived food has been almost 
always the CMY-2 variant, and the DHA-1 variant was also identified in K. pneumoniae of pig origin 
in Korea (Rayamajhi et al., 2008). ACC-1 has also been reported to occur on unidentified plasmids in 
S. Braenderup (Dierikx et al., 2010a; Hasman et al., 2005). 
ESBL/AmpC in food-producing animals and foods
 
EFSA Journal 2011;9(8):2322 27
Table 6:  Type of ESBLs detected in food-producing animals or food in studies performed in European and non-European countries  
Country Source Microorganism ESBL CTX-M ESBL ESBL References 
G-1 G- 2 G-9 Other 
group 
TEM SHV 
Spain Ha-poultry E. coli -1, -32  -9, -14  -52 -2, -5, 
-12 
(Blanc et al., 2006; Brinas et al., 2005; Brinas et 
al., 2003b; Cortes et al., 2010; Doi et al., 2009) 
 H-poultry Salmonella   -9    (Riano et al., 2006) 
 Pigs E. coli -1  -9, -14   -12, -5 (Escudero et al., 2010) 
 Pigs Salmonella      -12 (Riano et al., 2006) 
 Rabbits E. coli   -9, -14    (Blanc et al., 2006) 
 Food  E. coli G-1  G-9   -12 (Doi et al., 2009) 
 Sb-animals E. coli -1, -32  -9, -14  -52 -12 (Brinas et al., 2005; Brinas et al., 2003a) 
Portugal H-poultry/meat E. coli -1, -32  -14  -52 -2 (Costa et al., 2009; Machado et al., 2008)  
 Pigs E. coli 
C. freundii 
-1      
-12 
(Machado et al., 2008) 
(Goncalves et al., 2010) 
 Ostrich E. coli   -14  -52  (Carneiro et al., 2010) 
France H-poultry E. coli -1      (Girlich et al., 2007) 
 H-poultry/meat Salmonella -1  -9    (Cloeckaert et al., 2010; Weill et al., 2004)  
 H-Cattle E. coli -1  -14   -12 (Madec et al., 2008) 
 Cockles Salmonella -53      (Doublet et al., 2009) 
 S-Cattle E. coli -1, -15  -14  -126  (Madec et al., 2008; Meunier et al., 2006)  
 S-poultry/pigs E. coli -1      (Meunier et al., 2006) 
UK Poultry/meat E. coli -1, -3, -15 -2 
G-2 
-14, -55 -8 
G-8 
-52  (Dhanji et al., 2010; Liebana et al., 2006; Randall 
et al., 2011; Warren et al., 2008) 
 S-Cattle/bovines E. coli -1, -3, -15,
-32 
-20 -14    (Hopkins et al., 2006; Hunter et al., 2010; Kirchner 
et al., 2011) 
Ireland Poultry/cattle Salmonella  -2   -52, -20 -12 (Boyle et al., 2010; Hopkins et al., 2006; Morris et 
al., 2009)  
Belgium H-poultry E. coli -1, -15 -2 -14  -52, -106  (Smet et al., 2008) 
 H-poultry/meat Salmonella  -2   -52  (Bertrand et al., 2006; Cloeckaert et al., 2007)  
Netherlands H-poultry E. coli -1 -2   -52 -2 (Dierikx et al., 2010a) 
 H-poultry/meat Salmonella -1 -2   -52, -20 -2, -12 (Dierikx et al., 2010a; Hasman et al., 2005) 
Italy H-poultry E. coli -1, -32     -12 (Bortolaia et al., 2010b) 
 H-poultry Salmonella      -12 (Chiaretto et al., 2008) 
Denmark H-poultry E. coli G-1 G-2 G-9    (Bortolaia et al., 2010a) 
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Country Source Microorganism ESBL CTX-M ESBL ESBL References 
G-1 G- 2 G-9 Other 
group 
TEM SHV 
 Cattle E. coli     -52  (Jensen et al., 2006) 
 Quail meat Salmonella   -9    (Aarestrup et al., 2005) 
 Pigs E. coli -1      (Aarestrup et al., 2006; Wu et al., 2008) 
 Poultry meat E. coli -1      (Bergenholtz et al., 2009) 
Czech 
Republic 
H-poultry E. coli -1     -12 (Kolar et al., 2010) 
Germany Livestock animals 
and food 
Salmonella -1, -15    -52, -20  (Rodriguez et al., 2009) 
Greece Poultry meat Salmonella -32      (Politi et al., 2005) 
China H/S-poultry E.- coli -3, -15  -14, -55, 
-65, -24 
-64*,    (Li et al., 2010a; Li et al., 2010b) 
 Pigs E. coli -3, -15, -22  -14   -2 (Duan et al., 2006; Tian et al., 2008)  
 Pigeons E. coli   -14    (Duan et al., 2006) 
Japan H-poultry E. coli  -2 -14    (Kojima et al., 2005) 
 Poultry meat Salmonella   -14    (Matsumoto et al., 2007) 
 Cattle Coli  -2     (Shiraki et al., 2004) 
Korea Poultry/meat Salmonella CTX-M      (Hur et al., 2010) 
 Pigs/ cows E. coli/ 
Klebsiella 
-15  -14  -20, -52 -28 (Lim et al., 2009; Rayamajhi et al., 2008)  
USA S/H-cattle Coli -1, -29      (Wittum et al., 2010) 
 Food E. coli G-1      (Doi et al., 2009) 
Tunisia Poultry meat E. coli -1  -14 -8  -5 (Ben Slama et al., 2010; Jouini et al., 2007) 
 Cattle meat E. coli -1      (Ben Slama et al., 2010; Jouini et al., 2007) 
 Sheep meat E. coli -1    -20  (Ben Slama et al., 2010) 
Senegal Poultry meat Salmonella      -12 (Cardinale et al., 2001) 
* CTX-M-64: hybrid between CTX-M-15 and CTX-M-14. aHealthy, bSick 
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Table 7:  Type of plasmidic AMPc detected in food-producing animals or food in studies performed in European and non-European countries  
Country Source Microorganism CMY-2 Other plasmidic AmpC References 
Spain Ha-poultry E. coli +  (Blanc et al., 2006; Brinas et al., 2005; Brinas et al., 2003b) 
 Rabbit E. coli +  (Blanc et al., 2006) 
 Sick-animals E. coli +  (Brinas et al., 2005; Brinas et al., 2003a) 
Belgium H-poultry E. coli +  (Smet et al., 2008) 
Netherlands H-poultry E. coli + AAC-1 (Dierikx et al., 2010a; Hasman et al., 2005) 
Czech 
Republic 
H-poultry E. coli +  (Kolar et al., 2010) 
Germany Various livestock and food 
samples 
Salmonella  +  (Rodriguez et al., 2009) 
Ireland H-poultry Salmonella  +  (Boyle et al., 2010) 
Denmark Imported poultry meat E. coli +  (Bergenholtz et al., 2009) 
Japan H-poultry E. coli +  (Kojima et al., 2005) 
 Retail meat poultry Salmonella  +  (Taguchi et al., 2006) 
China H-poultry E. coli +  (Li et al., 2010b) 
Taiwan H-poultry 
Food of chicken and pork origin 
E. coli +  (Yan et al., 2004) 
 Pigs E. coli +  (Yan et al., 2004) 
Korea Sb-pigs K. pneumoniae + DHA-1 (Rayamajhi et al., 2008) 
USA Retail meat poultry Salmonella +  (Zhao et al., 2008) 
 Cattle E. coli +  (Donaldson et al., 2006) 
 Various food samples E. coli   (Doi et al., 2009)
 Various livestock and food 
samples 
E. coli and 
Salmonella 
+ CMY-2-like (Heider et al., 2009) 
 Sick-Cattle Salmonella  + AmpC (Frye et al., 2008; Gupta et al., 2003) 
 Sick-Cattle and pigs E. coli, 
Salmonella 
+  (Winokur et al., 2000) 
Canada H-Poultry, cattle Salmonella  +  (Allen and Poppe, 2002) 
 Pigs E. coli +  (Kozak et al., 2009) 
México Pigs Salmonella +  (Zaidi et al., 2007) 
 aHealthy, bSick 
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3.2. Transmission of ESBL/AmpC-resistant bacterial strains and/or resistance genes to 
humans by consumption or handling of contaminated food. 
In order to discuss and evaluate transmission of ESBL/AmpC-producing Enterobacteriaceae from 
consumption or handling of food, it is necessary to examine the many possible reservoirs and reasons 
for existence of such resistant bacteria within the ecosystem.  
The emergence and spread of ESBL/AmpC-producing microorganisms in the environment is a 
complex process and has mainly been due to point mutations that arise and are selected (Knox, 1995), 
and to the spread of resistant mobile genetic elements through the environment, especially plasmids 
between bacteria (Bonnet, 2004; Carattoli, 2001, 2008). The role of antibiotic selection pressure is 
also important, from agents used in both animal husbandry and human medicine (Blazquez et al., 
2000; Jorgensen et al., 2007; Medeiros, 1997; Rice et al., 1996) in the selection of resistance in 
commensal bacteria in the gut of food animals (van den Bogaard et al., 2001). Resistance can also 
emerge in bacteria in soil as a result of pressure from antibiotic residues resulting from the use of 
antimicrobials in animal husbandry; such residues have been found in all components of the 
ecosystem, including the farm environment (Sayah et al., 2005), with recent reports of ESBL-
producing E. coli found along with antibiotic residues in animal manure (Furtula et al., 2010).  
Evidence for the transmission of MDR Enterobacteriaceae resulting from food consumption to 
humans has been documented and is well established for resistant Salmonella and E.coli (Gerner-
Smidt and Whichard, 2009). Multiple reports exist, showing the direct association of food with 
outbreaks of multidrug resistant Salmonella in humans, some of which are also connected to 
outbreaks in the source-animals. Outbreaks associated with raw milk (Bezanson et al., 1983; Cody et 
al., 1999; Villar et al., 1999), and raw, ground beef (Dechet et al., 2006), pork (Molbak et al., 1999), 
and breakdowns in pasteurization (Walker et al., 2000) have been reported.  
With regard to the possibility of bacteria that produce ESBLs and/or AmpC being transmitted to 
humans, there are reports that provide circumstantial evidence that ESBL-producing E. coli can be 
associated with its transmission from food to humans (Lavilla et al., 2008), studies whose findings 
suggest transmission of E. coli that produce ESBL, from poultry to humans (Leverstein-van Hall et 
al., 2011), but also evidence of direct association of transmission of Salmonella resistant to 3rd-
generation cephalosporins during an outbreak in humans (Fey et al., 2000; Zansky et al., 2002). 
In a recent study (Leverstein-van Hall et al., 2011), 35% of human clinical ESBL-producing E. coli 
contained ESBL-genes that were also detected in E. coli from poultry origin. 19 % human clinical 
ESBL-producing E. coli contained IncI1 plasmids (harbouring ESBLs) genetically indistinguishable 
by plasmid MLST (pMLST) from those found in E. coli of poultry origin. 39 % of ESBL-producing 
E. coli from poultry origin belonged to genotypes (MLST types) also present in human samples. 
These findings are suggestive of transmission of ESBL genes, plasmids and clones from poultry to 
humans most likely through the food chain.  
As described in chapter 2 the epidemiology of ESBL/AmpC-producing bacteria and/or the genes 
encoding for such enzymes is complex. The genes themselves are transferable within bacteria by 
insertion sequences and transposons and between bacteria by plasmid transfer. This process has 
resulted in the emergence and spread of epidemic plasmids and clones that have been associated with 
transmission of ESBL/AmpC between food-producing animals/foods and humans. The demonstration 
of identical genes, clones or plasmids in hospitals and farms is not sufficient to draw conclusions on 
the epidemiological relatedness in the different environments. For such conclusions to be valid, 
epidemiological relatedness should be based on the demonstration of genetic relatedness of genes 
and/or plasmids and/or clones in combination with quantitative information on their prevalence in 
food-producing animals, foods, the community and health care.       
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For food-borne pathogens such as Salmonella and enteropathogenic strains of E. coli, transmission of 
ESBL/AmpC-producing variants can be expected to follow the same route as for susceptible bacteria. 
There are still only a few reports in Europe where such spread has been reliably documented. Other 
reports describe the same clone of bacteria in humans and food although it might not be clearly stated 
that the food caused the disease. The pattern gets even more complicated in cases where the same 
genes are found in food and human patients but detected in different kinds of bacteria. In such 
instances it is of relevance to map the occurrence in humans of resistant commensal bacteria with a 
similar gene pattern as those in food as these genes might, at a later stage, transfer to human 
pathogens. Food could thereby be an indirect cause of resistant infections in humans, although the 
pathogen itself may not be food-borne. Due to possible lag time between human colonisation with the 
commensal and transfer of genes to a pathogen such indirect links between occurrence in food and 
disease in humans would be very difficult to prove.  
In summary, there are few studies that provide clear evidence of direct transmission of ESBL- and/or 
AmpC-producing E. coli isolates from food-producing animals or food to humans. Nevertheless, data 
do exist about common clones of ESBL- and/or AmpC-producing E. coli isolates in humans and food-
producing animals and foods, thus providing indirect evidence about this transmission. 
3.2.1. Clonal transmission of resistance 
Expansion of E. coli clones (producing ESBL) and Salmonella (producing ESBL or AmpC) with 
zoonotic potential have been reported. Recent studies have showed that E. coli isolates from poultry 
and pig farms differ with respect to ESBL and CMY-2 enzymes, phylogenetic group, virulence genes, 
and serotype (Cortes et al., 2010). It has been suggested that E. coli isolates from poultry are 
genetically-related to human pathogenic E. coli. In a study comparing genetic similarities of E. coli 
derived from humans and poultry, antibiotic-resistant E. coli isolates from both reservoirs were more 
frequently genetically related than antibiotic-susceptible isolates (Johnson et al., 2007a; Johnson et 
al., 2007b; Vincent et al., 2010). 
Escherichia coli 
E. coli O25b:H4-ST131 is a globally-spread, highly virulent pathogen identified among 
fluoroquinolone-resistant isolates causing human urinary tract infections (Johnson et al., 2009). This 
clone is able to acquire different plasmids carrying ESBL genes and it has driven the pandemic spread 
of blaCTX-M-15 among hospitalised patients and community-based individuals (Coque et al., 2008b; 
Livermore et al., 2007; Peirano et al., 2010; Woodford et al., 2004). E. coli O25b:H4-ST131, 
sometimes associated with ESBL production, has recently emerged among avian isolates (retail 
chicken and sick animals) (Mora et al., 2010; Peirano et al., 2010; Vincent et al., 2010). In Canada, 
Vincent et al. recovered such isolates, although lacking ESBL genes, from 0.4% of 250 retail chickens 
(Vincent et al., 2010). Recent studies from Spain have reported the emergence among poultry of a 
CTX-M-9-producing variant of the E. coli O25b:H4-ST131clonal group isolates containing additional 
virulence factors, ibeA and capsule K1 (Cortes et al., 2010; Mora et al., 2010). Another widespread 
extra-intestinal E. coli clone (O25a-ST648-D) has been identified in poultry farms linked to CTX-M-
32 production (Cortes et al., 2010). Both O25b:H4-ST131 and O25a-ST648-D strains from poultry 
were indistinguishable from those recovered from human infections, highlighting the zoonotic risk of 
these E. coli lineages (Mora et al., 2010; Vincent et al., 2010). Some other extra-intestinal E. coli 
clones have been detected in both human and poultry isolates (Johnson et al., 2007a; Vincent et al., 
2010). Although these strains did not contained blaESBL or blaAMPc genes, the possibility that they 
might acquire plasmids carrying these genes, as has been reported for other widespread E. coli clones 
(Cortes et al., 2010; Vincent et al., 2010), should be considered. In addition, E. coli ST57 and 371 
producing ESBLs have been recovered from chickens in UK, Germany and Canada (Randall et al., 
2011) and ESBL-producing, verocytotoxin-producing E. coli (VTEC) isolates of serogroups O26 
(CTX-M-3, CTX-M-18, TEM-52) and O157 (CTX-M-2) have been described (Buvens et al., 2010). 
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CTX-M-15-producing E. coli ST156 in gulls sampled in southern France, chickens and turkeys in 
Portugal and the UK has recently been reported (Bonnedahl et al., 2010; Randall et al., 2011; Simoes 
et al., 2010). CMY producers of major clonal complexes have been reported among poultry, although 
transmission to humans has not been demonstrated (Cortes et al., 2010).  
Salmonella 
Antimicrobial-resistant Salmonella clones are often associated with the spread of ESBL and AmpC 
genes among humans and/or food-borne animals. Some examples are the dissemination of CTX-M-2-
producing S. Virchow isolates with reduced susceptibility to ciprofloxacin in Belgium and France 
(Bertrand et al., 2006), the spread of the related serovars Westhampton and Senftenberg producing 
CTX-M-53 among living cockles in French supermarkets (Doublet et al., 2009), the detection of 
CTX-M-9 S. Virchow producers from human and poultry origins with pulsed-field gel electrophoresis 
(PFGE)-indistinguishable patterns (Riano et al., 2009), or the spread of MDR S. Infantis carrying IncI-
blaTEM-52 in Belgium and France (Cloeckaert et al., 2007). The spread of MDR clones Salmonella 
serovars. Heidelberg and Newport producing CMY-2, and also of S. Typhimurium have similarly 
been documented (Arlet et al., 2006). Outbreaks of CMY-2 producers due to clonal expansion of S. 
Heidelberg caused by imported live animals, meat consumption and unpasteurized dairy products 
were described in the EU and the US (Aarestrup et al., 2004; Folster et al., 2009; Zhao et al., 2008). 
Human infections by S. Newport lineage II comprises most of MDR-AmpC clones of this serotype, 
which are linked to ST45 (and single locus variant ST116) and associated with consumption of cattle, 
bovine, and horse meat or pets treats (Espie and Weill, 2003; Harbottle et al., 2006; Pitout et al., 
2003; Sangal et al., 2010). In 1984, a strain of S. Newport with resistance to cephalosporins 
originating in cattle in the USA, was traced through the food chain to humans (Holmberg et al., 1984). 
In a US FoodNet case-control study of sporadic multiple-resistant S. Newport infections, (Varma et 
al., 2006) concluded that patients were more likely to have consumed uncooked ground beef or runny 
scrambled eggs or omelettes prepared in the home.  
Salmonella clones belonging to serovars Agona with SGI-1-A, or Typhimurium DT104 carrying SGI-
1 have been linked to TEM-52 production (Cloeckaert et al., 2007). Particular clones of S. Infantis 
seem to be widespread among poultry in EU countries as France or Belgium as well Japan (Cloeckaert 
et al., 2007; Dahshan et al., 2010; Yang et al., 2010). A recent report has also reported this serovar 
among pigs (Dahshan et al., 2010). There are no data about the possible transmission of particular 
clones between swine and humans. 
Although the characterization of the clones has not been fully accomplished in many studies, it is of 
interest to highlight the increasing rates of blaOXA-1 gene as a sole ß-lactamase gene among E. coli or 
Salmonella isolates, in which it confers resistance to penicillins and amoxicillin-clavulanate. 
3.2.2. Plasmid analysis studies from animals, food, and humans 
Epidemic plasmids belonging to incompatibility groups F, A/C, N, HI2, I1 and K carrying particular 
ESBL (TEM-52, CTX-M-1, -32, -9, -14) or AmpC (CMY-2) genes have been detected among farm 
and companion animals, food products and humans.  
Plasmids of the IncF group are commonly recovered from animals, mainly associated with E. coli and 
Salmonella (Carattoli, 2003; Johnson et al., 2007b) although they are also linked to other 
enterobacterial species (Villa et al., 2010). IncF plasmids greatly differ in the content of the replicons 
and maintenance systems (Coque et al., 2008b; Mnif et al., 2010; Villa et al., 2010; Woodford et al., 
2009), and often carry ESBLs (blaCTX-M-1-2-3-9-14-15-24-27, blaSHV-2-5-12) or AmpC genes (Carattoli, 2009). 
Highly transmissible epidemic IncFII plasmids carrying blaCTX-M-15 are of particular interest as they 
are globally-spread among E. coli and K. pneumoniae populations from humans and animals. The 
presence of multiple addiction systems seems to influence the persistence of IncF plasmids carrying 
blaCTX-M-15 or bla CTX-M-9 in bacterial E. coli backgrounds (Marcade et al., 2009; Mnif et al., 2010). 
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Plasmids of IncI groups (both IncI1 and IncI2) are also common among E. coli and Salmonella from 
animals and humans (Johnson et al., 2007b). Those of the I1 incompatibility group have been linked 
to a diversity of genes coding for ESBLs (TEM-52, CTX-M-1,-2, -3, -9, -14,-15, -24) and CMY-2 
while the group IncI2 (also known as Incγ) is increasingly associated with blaCMY-2 (Antunes et al., 
2010; Mataseje et al., 2009). The blaTEM-52 located on a Tn3 transposon is disseminated on epidemic 
IncI1 plasmids among the Salmonella serovars Agona, Derby, Infantis, Paratyphi B variant Java, and 
Typhimurium from poultry and humans in Belgium and France (Cloeckaert et al., 2007). TEM-52- 
producing isolates of seven other Salmonella serovars (mainly serovar Blockey), from poultry, poultry 
meat and humans have been detected in The Netherlands and France, although plasmids were not 
fully characterized in these cases (Hasman et al., 2005). IncI1 plasmids producing TEM-52C have 
been recovered from E. coli in chicken and turkey meat in Denmark and the UK (Jensen et al., 2006; 
Randall et al., 2011). An IncI1 plasmid carrying blaCTX-M-15 and blaTEM-1 is also associated with the 
current 2011 outbreak of E. coli O104:H4 in Northern Europe.19 
IncK plasmids have facilitated the diffusion of blaCTX-M-14 among animals and humans from different 
European countries (Liebana et al., 2006; Valverde et al., 2009). They have recently found in E. coli 
from animals and foods carrying CMY-2 (Bergenholtz et al., 2009; Dierikx et al., 2010a).  
Plasmids of the incompatibility group HI2 are able to disseminate ESBLs genes (blaCTX-M-2-9-14, blaSHV-
12) among humans and animals (Carattoli, 2008, 2009; Novais et al., 2006). Both blaCTX-M-9, deriving 
from Kluyvera georgiana and blaCTX-M-2, deriving from Kluyvera ascorbata, were identified 
embedded in related sul1-class 1 integrons bearing ISCR1, which are located within mercury-Tn21 
platforms (Arduino et al., 2002; Eckert et al., 2006; Novais et al., 2006).  
IncA/C plasmids carrying ESBL and CMY genes have been recovered from a diversity of 
Enterobacteriaceae of poultry and human origin and from Aeromonas and Edwarsiella among fish 
(Hopkins et al., 2006; McIntosh et al., 2008; Randall et al., 2011). These plasmids have facilitated the 
widespread dissemination of blaCMY-2 among poultry and fish in Canada, the USA and some EU 
countries (Hopkins et al., 2006; McIntosh et al., 2008; Mulvey et al., 2009; Randall et al., 2011; 
Welch et al., 2007). In the IncA/C2 plasmids, the insertion of the ISEcp1-blaCMY-2-blc-sugE-DecnR 
fragment occurred within the conjugative transfer locus of the plasmid, impairing their self-
conjugative property (Poole et al., 2009). Recently, IncA/C plasmids carrying multiple replicons and 
virulence genes have been detected (Garcia et al., 2011). IncA/C plasmids carrying blaCTX-M-2 have 
been recovered from E. coli and Salmonella from poultry and human isolates in the UK (Hopkins et 
al., 2006; Randall et al., 2011).  
IncN plasmids are widely distributed among poultry, swine and humans. They have been linked to a 
diversity of CTX-M (1, 3, -15, -65) and SHV genes (Zong et al., 2010). The blaCTX-M-1 is widely 
spread among poultry and swine (Blanc et al., 2006; Bortolaia et al., 2010a; Cavaco et al., 2008; 
Girlich et al., 2007; Moodley and Guardabassi, 2009; Randall et al., 2011). IncI1 and IncN plasmids 
are both involved in the transmission of the this gene among poultry and swine strongly suggests an 
animal reservoir for this ESBL gene variant, since either IncN or IncI1 plasmid types have been 
demonstrated to be highly prevalent in E. coli of the avian faecal flora and in Salmonella from retail 
meat and food-producing animals. These IncI1 and IncN plasmids are highly related to those in the 
community and hospitals (Girlich et al., 2007; Novais et al., 2006; Randall et al., 2011). IncI1 
plasmids have been more frequently recovered from avian isolates while IncN plasmids are more 
prevalent among swine.  
Plasmids belonging to the IncL/M family are mostly responsible for the spread of blaCTX-M-3 in 
European eastern countries, France, Belgium and Korea and often the aminoglycoside resistance gene 
                                                     
 
19  European Food Safety Authority; Urgent advice on the public health risk of Shiga-toxin producing Escherichia coli in 
fresh vegetables. EFSA Journal 2011; 9(6):2274 http://www.efsa.europa.eu/en/efsajournal/doc/2274.pdf  
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armA has been co-localized on the same IncL/M plasmid with the blaCTX-M-3 gene. It should be noted 
that as yet, IncL/M plasmids have not been recovered from bacteria isolated from animals. The blaCTX-
M-3 gene expression is driven by the ISEcp1 insertion sequence; the fragment placed directly 
downstream from ISEcp1 was identified to be a chromosomal fragment from a K. ascorbata strain 
and contains 343 bp of a Kluyvera orf477. The 3’-end of the insert is terminated by an 18-bp sequence 
which is a part of orf477 that most probably mimicked the right IR of ISEcp1 in the transposition 
event that mobilized blaCTX-M-3 from the K. ascorbata chromosome (Golebiewski et al., 2007).  
The IncQ plasmid family is currently becoming of increasing epidemiological relevance since some 
plasmids of this type have acquired resistance genes such as qnr and blaGES-1. IncQ plasmids carrying 
resistance genes have been identified in Aeromonas in the environment from France and Switzerland, 
in plasmid DNA from a water waste treatment plant from Germany and in E. coli from a human 
patient from Switzerland (Bonemann et al., 2006; Cattoir et al., 2008; Picao et al., 2008; Poirel et al., 
2010). The IncQ plasmids are not self-transmissible by conjugation, but may be mobilized at high 
frequency in the presence of a helper plasmid (for instance, the IncP plasmids are particularly 
efficient mobilisers of these plasmids). The IncQ plasmids have been successfully mobilised, not only 
to a large number of Gram-negative hosts but also to several Gram-positive bacteria, including 
Arthrobacter spp., Streptomyces lividans and Mycobacterium smegmatis, cyanobacteria and plant and 
animal cells. They may therefore contribute to broad host range spread of relevant antimicrobial 
resistances (Lawley et al., 2004).  
3.3. Transmission of resistant bacterial strains and/or genes to humans through the food 
animal production environment. 
There is limited evidence for spread of ESBL/AmpC-carrying organisms via direct contact with 
animals or indirectly via the environment. In cases where a similar gene pattern in humans and 
animals has been documented it is often not clear whether this has been spread through contact or via 
food (Fey et al., 2000). It seems as if the “one medicine concept” applies which means that an 
increase in number of ESBL/AmpC carrying organisms in either animals or humans (or in different 
animal populations) could make resistance emerge in other human or animal populations but the links 
might be indirect and thus difficult to map. 
In general, the ecosystem acts as a reservoir, a “resistome” (Wright, 2007). Resistant bacteria which 
can be found in faeces and soil in the farm environment (Cobbold et al., 2006; Goncalves et al., 
2010), aquatic systems (Machado et al., 2009), plants (Ruimy et al., 2009) can be transferred from 
these sources to animals and humans through the food chain (Silbergeld et al., 2008). 
These bacteria can infect animals or colonise their gut (Alexander et al., 2009; Hinton et al., 1982). A 
natural consequence of animal gut colonisation is shedding of resistant bacteria into the farm 
environment. Although the duration of persistence and shedding is not known, in an outbreak in cows 
caused by ESBL-producing Salmonella, shedding continued for 68 days after the start of the outbreak 
(Lanzas et al., 2009). 
Strong evidence supporting the potential for transmission and colonisation of Enterobacteriaceae 
between animals and farm staff has been provided from reports where farmers were colonised with 
indistinguishable strains of antimicrobial-resistant E. coli from food animals on the farm. Such 
colonisation was initially reported for E. coli from poultry and humans (Levy et al., 1976a, 1976b), 
and followed by many subsequent reports on E. coli (Ojeniyi, 1989; van den Bogaard et al., 2001)  
(Linton et al., 1977; Price et al., 2007). Transmission of CTX-M1 between pigs and pig farmers has 
also been reported (Moodley and Guardabassi, 2009). 
(Dierikx et al., 2010a) have demonstrated that people working with poultry have a higher risk for 
intestinal carriage of ESBL-producing bacteria. The ESBL prevalence in poultry farmers was higher 
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than in the general population (around 30% versus 5%, respectively), which suggests that direct 
transmission from poultry to humans may also be a possible route of transmission. 
4. CRITICAL ANALYSIS OF THE METHODS (PHENOTYPIC AND GENOTYPIC), AND THE 
INTERPRETIVE CRITERIA CURRENTLY USED FOR DETECTION (ISOLATION AND 
IDENTIFICATION) AND CHARACTERISATION OF ESBL AND/OR AMPC-PRODUCING 
BACTERIAL STRAINS, ESBL- AND/OR AMPC-ENCODING GENES AND ASSOCIATED MOBILE 
ELEMENTS 
In this chapter the methods for isolation, identification and characterization of bacteria that produce 
ESBL and or AmpC-genes are described. Isolation from faeces or foods is performed with selective 
growth media with low concentrations of cefotaxime or ceftriaxone. Suspected isolates are identified 
and confirmed as ESBL or AmpC by dedicated susceptibility tests using harmonized interpretive 
criteria. For molecular identification of ESBL and/or AmpC genes (e.g. blaTEM-52, blaSHV-12 or blaCTX-M-
15), PCR or microarray and sequence analysis is performed. Characterization of plasmids on which 
ESBL and/or AmpC-genes are located is essential to study the epidemiology of these genes, which are 
located on transferable plasmids. Purified plasmids can be typed using replicon typing and subtyped 
by fingerprinting, multi locus sequence typing or whole plasmid sequence analyses. To identify clonal 
distribution, isolates can be typed by phenotypic methods as serotyping, and phage typing, or 
genotyping methods such as pulsed field gel electrophoresis (PFGE), multiple loci analysis of variable 
number of tandem repeats (MLVA) or MLST. All these methods are described in more detail in the 
following subsections. 
4.1. Selective isolation, phenotypic detection and identification of ESBL- and/or AmpC-
producing bacteria 
Selective isolation of ESBL and/or AmpC-producers can be performed by adding 3rd generation 
cephalosporins to selective or non-selective growth media as indicated in Table 8. The concentrations 
advised vary slightly, but given the known diversity of cephalosporin resistance phenotypes, the 
concentrations should preferably be not too high. Nevertheless, too low concentrations will affect the 
specificity and lead to possible false positive results, which will greatly affect the workload. Also the 
usage of certain drugs affects the sensitivity and specificity of the isolation. Cefpodoxime is 
considered to be not the ideal drug to include in broth or agar plates because of lack of specificity. 
Ideally, cefotaxime or ceftriaxone should be used separately or in combination with ceftazidime in 
selection processes. 
Several chromogenic selective agars have become available for the purpose of selective isolation of 
ESBL-producers. The advantage of these media is that ESBL-producers can easily be detected based 
on specific colours of colonies of different species. The disadvantage of some selective chromogenic 
agars is that AmpC-producers may fail to grow (Randall et al., 2009). 
Selective isolation always needs a confirmation of the presence of an ESBL and/or AmpC gene by 
either phenotypic or molecular methods. This can be done phenotypically by diffusion or dilution 
assays for susceptibility using (combinations of) cephalosporins. A synergistic effect of the 
combination of a 3rd generation cephalosporin with clavulanic acid indicates the presence of an ESBL 
gene. Resistance against cefoxitin could be associated with the presence of an AmpC gene. 
Unfortunately, resistant strains can contain several ESBL and/or AmpC genes. This can interfere with 
the result of the confirmatory phenotypic testing. Therefore, confirmation of the presence of an ESBL 
and/or AmpC producer often requires genotypic verification (see chapter 4.3). 
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Table 8:  Methods for selective isolation, phenotypic detection and identification of ESBL and/or AmpC-producing bacteria 
Method Specification Comments References 
Selective Isolation of ESBL 
and/or AmpC producing bacteria 
Mueller-Hinton broth (Cation adjusted) with 4 
mg/l cefpodoxime, 1 mg/L cefotaxime, 
ceftazidime, ceftriaxone, or aztreonam 
1.       Recommended by CLSI for 
screening of ESBLs (M100-S20)  
1.       CLSI M100 – S20  
 Selective agar (MacConkey or Levine agar with: 1 
– 2 mg/L cefotaxime or 1 – 2 mg/L ceftazidime  
2.       Includes ESBL and AmpC-
producers  
2.       (Cavaco et al., 2008; Cohen et al., 
2006; Costa et al., 2009; Duan et al., 2006; 
Girlich et al., 2007; Komatsu et al., 2000) 
 Selective chromogenic agars (ChromID, 
bioMerieux, Brilliance ESBL-agar Oxoid, ESBL-
Bx bioMerieux, CHROMagar-CTX CHROMagar 
microbiology 
3.       Some may miss AmpC-
producers  
3.       (Glupczynski et al., 2007; Huang et al., 
2010; Randall et al., 2009; Reglier-Poupet 
et al., 2008; Sharma et al., 2008)  
Phenotypic identification 
(screening)  
In E. coli, K. pneumoniae, and Salmonella, 
reduced susceptibility to cefotaxime, ceftazidime, 
cefopodoxime, ceftriaxone, aztreonam, cafoxitin 
/cefepim (AmpC) by disk diffusion, agar/broth 
dilution or automated systems (eg Vitek)  
The use of more than one 
antimicrobial agent for screening 
will improve the sensitivity of 
detection. 
CLSI, HPA-BSAC, SRGA, EUCAST 
 For detection of organisms with plasmid mediated 
ESBL genes: E. coli, Klebsiella, Proteus 
mirabilis, Salmonella, Shigella, use cefotaxime in 
combination with ceftazidime 
Cefpodoxime not advised because 
of insufficient specificity  
(Biedenbach et al., 2006; Hope et al., 2007; 
Kim et al., 2004; Lee et al., 2006) 
 For plasmid mediated AmpC-producers, use 
cefoxitin 
  
Phenotypic confirmation Combination disks, ESBL E-test  VITKEK II ESBL confirmation test 
is not advised because of limited 
and conflicting published 
information 
(Livermore and Woodford, 2006) 
 Confirmatory testing requires use of both 
cefotaxime and ceftazidime, alone and in 
combination with clavulanic acid to test for 
synergy with clavulanic acid  
Double disk test not advised 
because of low sensitivity 
(Bedenic et al., 2007; Paterson and 
Bonomo, 2005) 
 For cefoxitin resistant organisms, susceptibility to 
cefepime will confirm the presence of an AmpC.  
Cefepime is not inactivated by AmpC enzymes, 
but will be hydrolysed by most ESBLs.   
The cefepime confirmation test 
does not distinguish between 
plasmidic and chromosomal AmpC-
genes. 
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The preferred method for selective isolation of ESBL and/or AmpC producers is a chromogenic agar 
(e.g. MacConkey agar) with 1 mg/L cefotaxime or ceftriaxone. The use of low concentrations will 
result in optimum sensitivity to detect all relevant β-lactamase families. Pre-enrichtment may be 
performed in a general broth like Mueller-Hinton, Brain Heart Infusion or Luria-Bertani broth with 1 
mg/L cefotaxime or ceftriaxone. 
Identification is performed by determination of susceptibility to cefotaxime, ceftazidime and 
cefoxitin. ESBL producers are resistant to cefotaxime, variable to ceftazidime and susceptible to 
cefoxitin.  
Confirmation of ESBL is performed by testing for synergy with clavulanic acid by combination disks, 
ESBL-etests or broth microdilution including cefotaxime, ceftazidime as single drugs and in 
combination with clavulanic acid. 
Confirmation of AmpC producers is performed by determination of susceptibility to cefepime; AmpC 
producers are susceptible to cefepime and resistant to cefotaxime, ceftriaxone and cefoxitin.  
4.2. Interpretive criteria and MIC breakpoints  
The interpretive criteria described in this document can only be used for Enterobacteriaceae, since 
for other microorganisms such as Vibrio or Aeromonas no criteria have been established. 
In table 9 the MIC breakpoints or epidemiological cut-off (ECOFF) values of the European EUCAST 
and the Clinical and Laboratory Standards Institute (CLSI) are presented. National organisations like 
the British Society of Antimicrobial Chemotherapy (BSAC), Swedish Reference Group of Antibiotics 
(SRGA), Norwegian Working Group on Antibiotics (NWGA) and Societe Francaise de Microbiologie 
(CASFM) have agreed to follow the recommendations for clinical breakpoints as defined by 
EUCAST and are therefore not included in table 9. EFSA advocates the usage of ECOFFs for 
antimicrobial resistance surveillance since their usage will detect acquired resistance with optimum 
sensitivity. 
Table 9:  MIC-breakpoints (S/R) as prescribed by EUCAST, and CLSI for cefotaxime, ceftazidime, 














































EUCAST a ≤1/>2 ≤1/>4 ≤1/>2 NA ≤1/>4 NA www.eucast.org 
EUCAST  
ECOFFc ≤0.5 – 0.064
b ≤0.125 – 2b ≤0.125 – 0.5b ≤8 ≤0.12 ≤1 – 2b www.eucast.org 
CLSI a ≤1/≥4 ≤4/≥16 ≤1/≥4 ≤8/≥32 ≤8/≥32 NA CLSI M100-S20
EUCAST: European Committee on Antimicrobial Testing;  CLSI:  Clinical and Laboratory Standards Institute 
(a) Clinical breakpoints are not primarily intended to detect resistance mechanisms. Cut-offs are adequate for 
this objective. Values are not provided for all species associated with ESBL or AmpCs 
(b) Range comprises values corresponding to different Enterobacteriaceae species 
(c) ECOFF: This value separates microorganisms without (wild type) and with acquired resistance mechanisms 
(non-wild type) to the agent in question. The ECOFF is the lowest possible value for the clinical breakpoint 
(d) NA – not available 
Although CLSI has recently redefined MIC breakpoints for 3rd- and 4th-generation cephalosporins, the 
R-breakpoints for ceftazidime, cefoxitin and cefepime are still one to two dilution steps higher than 
those defined by EUCAST. To harmonize the interpretation of susceptibility data and for optimum 
phenotypic detection of ESBL and/or AmpC producers we advise to use EUCAST clinical 
breakpoints for interpretation of susceptibility or resistance and EUCAST ECOFF’s to determine if an 
isolate belongs to the wild-type population or not. 
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4.3. Molecular methods for detection and identification of ESBL, and/or AmpC genes  
Detection of ESBL, and/or AmpC genes can be performed by polymerase chain reaction (PCR), and 
microarray. The specificity of these methods depends upon the choices of the oligonucleotide primers 
(PCR), the probes included in a microarray, or used for hybridization. The choice of the primers 
determines the possibility to detect certain genes. Recently a list of primers was published for the 
most important β-lactamases that occur in Enterobacteriaceae (Dallenne et al., 2010). These β-
lactamases include genes encoding the OXA-1-like broad spectrum β-lactamases, ESBLs, plasmid-
mediated AmpC β-lactamases and class A, B and D carbapenemases. Several commercial microarrays 
have been developed for rapid and specific detection of β-lactamase genes. The limitations of these 
tests are determined by the probes included. Microarrays can detect most β-lactamase families, and 
some are also able to identify variants within families (see table 3), by means of sophisticated choices 
of different probes targeted to the detection of certain Single Nucleotide Polymorphisms (SNPs). This 
is of specific relevance for TEM and SHV-genes where multiple variants exist that need to be 
differentiated from the commonly present narrow spectrum β-lactamases TEM-1 and SHV-1. 
Identification of the subtype of the ESBL and/or AmpC genes detected by PCR or microarray is 
normally conducted by sequence analysis of PCR fragments. For this purpose the primers used should 
be able to amplify DNA fragments of sufficient size including all point mutations to be able to 
identify the genetic variations based on which a subtype is designated. 
Table 10:  Methods for genotypic detection and identification of ESBL-, and AmpC genes   
Method Specification Comments References 
Polymerase Chain 
Reaction (PCR) and 
sequencing 
Specific PCR reactions 
have been designed for 
detection of all relevant β-
lactamase genes encoding 
ESBLs and AmpC 
 
To identify individual 
ESBL/AmpC variants, PCR 
products should be 
sequenced and compared to 
previously sequenced 
genes. 
A strain might carry more 
than one ESBL and/or 
ampC gene. Therefore, 
there is a risk of not 
detecting all ESBL and/or 
ampC genes present.  
 
Also, some species 
(Citrobacter, Enterobacter 
and to some extend also E. 
coli) carry AmpC genes on 
the chromosome. These 
might not be detected by 
the standard PCR 
protocols. 
 (Dallenne et al., 2010; 
Voets et al., 2011) 
DNA arrays Several commercially 
available DNA arrays have 
been designed. In these, the 
most common gene 
(groups) associated with 
ESBL and/or AmpC 
production is detected. 
Often only the gene related 
to the ESBL/AmpC 
phenotype is detected at the 
group level. Further 
analysis using methods like 
PCR and sequencing (see 
above) is also required. 
Commercial arrays can be 
purchased from several 
sources: 
 




Check-points array system: 
www.check-points.com 
 
(Batchelor et al., 2008; 
Cohen Stuart et al., 2010) 
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For molecular identification of ESBL and/or AmpC genes, PCR or microarray are used to screen 
which β-lactamase families are present (e.g. TEM, SHV, or CTX-M). To study the genetic and 
epidemiological relatedness of genes present in different backgrounds (eg. animal or human bacteria) 
subtyping is essential. This is performed by dedicated PCRs aimed at the β-lactamases detected by the 
screening method to obtain an amplicon of sufficient size. Sequence analysis of the amplicon will 
result in designation of the ESBL subtype present (e.g. TEM-52, SHV-12 or CTX-M-15). 
4.4. Detection and classification of plasmids carrying ESBL and/or AmpC-genes  
The horizontal transfer of plasmids carrying ESBL and/or AmpC genes is an important contributory 
factor in the epidemiology of these genes within the bacterial ecosystem. 
To be able to associate a certain β-lactamase gene with a specific plasmid several techniques are 
available, as listed in table 11. Plasmid isolation and further electrophoresis of S1-digested genomic 
DNA in agarose gels will provide information on number and mass/size of plasmids present in one 
isolate. The ability to recognize and categorize plasmids in homogeneous groups on the basis of their 
phylogenetic relatedness can be helpful to analyse their distribution in nature, the relationship to host 
cells, and to assist into elucidating their evolutionary origins (Francia et al., 2004). 
Identification and classification of plasmids should be based on genetic traits that are present and 
constant. These criteria are best met by traits concerned with plasmid maintenance, especially 
replication controls (DeNap and Hergenrother, 2005). In 1971 Datta and Hedges proposed a plasmid 
classification scheme based on the stability of plasmids during conjugation, a phenomenon called 
plasmid incompatibility (Datta and Hedges, 1971). In 1988 Couturier and colleagues proposed a 
genetic plasmid typing scheme, based on Southern blot hybridization using cloned replication regions 
(replicons) as probes (Couturier et al., 1988). Since 2005, a PCR-based replicon typing (PBRT) 
scheme has been available, targeting the replicons of the major plasmid families occurring in 
Enterobacteriaceae (HI2, HI1, I1-γ, X, L/M, N, FIA, FIB, FIC, W, Y, P, A/C, T, K, B/O) and also 
including PCR assays (FrepB and FIIAs PCRs) detecting the FII, FIII, FIV, FIV variants and the FII 
replicon of the Salmonella virulence plasmids, respectively (Carattoli et al., 2005). Typing analysis by 
identification of replicons associated with predominant conjugative plasmids of Enterobacteriaceae, 
and Acinetobacter has been extensively used. The PBRT scheme has still several limitations since the 
classification is currently based on plasmids belonging to the classic Inc groups and can fail the 
identification of divergent or novel replicons. 
The most accurate method to characterize a plasmid is based on the determination of the full-length 
DNA sequence and up to date, more than 800 plasmids from Gamma-proteobacteria have been fully 
sequenced (http://www.ncbi.nlm.nih.gov/genomes/), contributing to the identification of novel 
plasmid families. Plasmids can also be classified according to the relaxase type since relaxases have 
been shown to be excellent markers of plasmid backbones by systematic database analysis (Garcillan-
Barcia et al., 2009; Smillie et al., 2010). Typing of relaxases can help to further characterise plasmids 
which contain either more than one replication genes or harbour replication and conjugation genes 
from different plasmid origins (Antunes et al., 2010; Valverde et al., 2009).  
Transfer of plasmids to well identified recipients by conjugation or electroporation will facilitate the 
typing of individual plasmids carrying β-lactamase genes. Once an association has been identified 
between a certain replicon/relaxase-type plasmid and an ESBL and/or an AmpC gene by Southern 
hybridization, fingerprinting of these plasmids can be performed by restriction enzyme analysis. 
Further characterization of plasmids belonging to the incompatibility groups I, F and HI can be 
performed by recently developed plasmid MLST schemes (pMLST) (http://pubmlst.org/plasmid/). 
Such schemes permit further analysis of genetic and epidemiological relations among plasmids from 
different bacterial species, sources or regions. 
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Table 11:  Methods for detection and classification of plasmids carrying ESBL and/or AmpC genes  
Method Specification Comments References 
Evaluation of 
plasmid content  
1. Crude plasmid DNA 
extraction followed by 
separation by vertical 
agarose gel 
electrophoresis  
2. DNA S1 nuclease 
treatment followed by 
Pulse Field Gel 
Electrophoresis (PFGE). 
Agarose plugs are 




3. Alkaline/SDS extraction 
followed by separation by 
horizontal agarose gel 
electrophoresis. Further 
purification of plasmid 
DNA is obtained by silica 
column-based purification 
kits  
1. Provides size and number of 
plasmids. Needs standard 
plasmids of known molecular 
mass  
 
2. Allows the conversion of 
circular plasmid DNA to the 
linear form visualized by PFGE 
for determination of high 
molecular weight plasmids. Low 
range PFGE markers are used as 
molecular weight markers. 
 
  
3. Rapid method for plasmid 
extraction but not recommended 
to generate unrestricted plasmids 
profiles  





2. (Barton et al., 
1995; Guerra et al., 
















S1-digested genomic DNA 
gels obtained as above are 
transferred onto membranes 
and hybridized by Southern 
blot with labelled probes 
specific for the different beta-
lactamase genes and plasmid 
replicons 
Allows to locate the β-lactamase 
genes on undigested plasmids 
profiles  
(Guerra et al., 2004; 
Sambrook et al., 1989; 




Broth mating experiments are 
performed in Luria-Bertani 
(LB) or TSB (trypticase soy 
broth) media using one ESBL- 
or AmpC- producer as donor 
and a plasmid free, indole-
negative E. coli, showing 
rifampicin, nalidixic acid, 
kanamycin or azide resistance 
as recipient.  
The transconjugants can be 
selected on Mueller–Hinton 
(MH), Brain heart infusion 
(BHI) , LB or MacConkey agar
media supplemented with 
 




Plasmids encoding the transfer 
functions can promote their own 
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Method Specification Comments References 
2. 2 mg/L cefotaxime  
 
3. 8.0 mg/L ceftiofur  
E. coli recipient resistance 
markers are usually selected as 
follows: 
32 mg/L nalidixic acid or  
25 mg/L rifampicin or 50mg/L 
kanamycin or 130mg/L azide 
2. Indicated for selection of CTX-
M-carrying plasmids  
3. Indicated for selection of CMY 
–carrying plasmids  
2. (Rodriguez et al., 
2006)  






Plasmids obtained by alkaline 
lyses and column purification 
kits are transformed into an 
electrocompetent recipient 
using a gene pulser or are 
transferred in chemically 
competent DH5alpha E. coli 
cells.  
Selection of transformants can 
be done on LB or BHI agar 
supplemented with  
1. 1-2 mg/L cefotaxime  
 
 
2. 100 mg/L ampicillin  
The transformation of in house-made 
or commercially available competent 
cells represents the easiest way to 
transfer a plasmid from the donor 
cell to the E. coli recipient strain. 
This procedure becomes necessary 
when the plasmid lacks the self-
transfer system or shows very low 
levels of conjugation efficiency.  
Selection on cefotaxime is suggested 








1. (Bortolaia et al., 
2010a; Dierikx et 
al., 2010a; 





Plasmid typing 1. Incompatibility tests by 
conjugation. Requires 
conjugation experiments 
performed with a 
reference plasmid for each 
Inc group.  
2. PCR-Based Replicon 
Typing (PBRT): 21 
replicons for 
Enterobacteriaceae and 
19 for Acinetobacter 
baumannii are tested by 
PCR on boiled cultures or 
total genomic DNA 
preparations  
3. Probe-Based Replicon 
Typing: plasmid gels 
obtained as above are 
transferred onto 
membranes and hybridized 
with probes for the 
different replicon types  
1. Not recommended for massive 





2. PBRT on 21 replicons is 
currently considered the 
reference method for plasmid 
typing. The modified multiplex 
array is suggested for massive 




3. Association of amplicons 
obtained by PCR with specific 
plasmids can be done by 
Southern hybridization using 
PCR-probes obtained by PBRT.  





2. (Bertini et al., 
2010; Carattoli et 
al., 2005; Garcia-
Fernandez et al., 
2009; Johnson et 
al., 2007b)  
 
 
3. (Couturier et al., 
1988)  
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Method Specification Comments References 
Plasmid sub-
typing  1. Fingerprinting: for restriction fragment length 
polymorphism (RFLP) 
analysis, plasmid DNA is 
extracted using column-
based purification kits. 
Restriction fragments are 
separated by agarose gel 
electrophoresis  
2. Plasmid Multilocus 
Sequence Typing 
(pMLST). It is based on 
amplification and 
sequencing of specific 
plasmid loci. Currently 
available for IncI1, 
IncHI2, IncHI1, IncF 
plasmids  
1. Different restriction enzymes 
can be used: PstI, HincII, 







2. Allows the assignation of 
plasmid alleles and Sequence 
Types (STs) at the 
http://pubmlst.org/ plasmid/ site 
(available databases for STs, 
ESBLs, AmpCs, sources etc.)  
1. (Garcia-Fernandez 
et al., 2009; Literak 








et al., 2008; 
Garcia-Fernandez 
et al., 2010; Phan 
et al., 2009; Villa 
et al., 2010)  
 Whole plasmid 
sequencing  
Genome Sequencers can be 
used for high-throughput 
sequencing of plasmids. It can 
be performed on column-
purified plasmid DNAs, 
adapting the manufacturer’s 
library construction and 
sequencing procedures  
Gives a complete analysis of the 
plasmid structure; requires 
bioinformatic expertise for 
annotation. A classification scheme 
has been proposed for fully 
sequenced plasmids based on 
phylogenetic analysis of the 
mobilization regions.  
(Carattoli et al., 2010; 
Garcillan-Barcia et al., 
2009; Smet et al., 2010; 
Smillie et al., 2010; 
Woodford et al., 2009) 
 
Characterization of plasmids on which ESBL and/or AmpC genes are located is an essential tool to 
study the epidemiology of these genes and plasmids. Since in Enterobacteriaceae often several 
different plasmids are present in each isolate, a structured approach is needed to identify the 
characteristics of the plasmid on which the β-lactamase genes are located. If by phenotypic and 
molecular tests described in paragraphs 4.1 and 4.3 the presence of an ESBL and/or AmpC gene in a 
bacteria is confirmed, plasmid isolation may be performed to determine the number and sizes of 
plasmids present. Subsequently by conjugation or electroporation, transconjugants or transformants 
are isolated on selective agar plates with only the plasmid that harbours the β-lactamase gene present. 
The plasmid can be typed using replicon typing and subtyped by fingerprinting or pMLST. 
Ultimately, whole plasmid sequence analyses may replace the current typing and subtyping 
techniques. 
4.5. Molecular typing of isolates 
The purpose of molecular typing of isolates is to determine genetic characteristics of isolates at the 
subspecies level in order to identify genetic relatedness and/or to allow source tracking/attribution. 
For these purpose several genotyping methods are available. The principles on which these methods 
are based on and their discriminatory power are very different, which greatly influences the choice of 
method according to the intended use. Phenotypic tests are relatively easy to perform, but lack 
discriminatory power. Within serotypes, and phage types many different genetically-related clusters 
of isolates can occur that can be identified by genotyping methods. PFGE is a band-based technique 
with generally a high discriminatory power. It allows identification of lineages or clusters of 
epidemiologically related isolates within eg. Salmonella sero-, or phage types. It is intended for 
tracing outbreaks in a limited time period and less suitable for performing phylogenetic analyses. 
MLVA was developed as a sequence-based method with similar discriminatory power as PFGE. 
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MLST is a sequence-based method targeting 5-7 highly conserved genes. This method has generally 
less discriminatory power than PFGE or MLVA but is the most reliable method to determine genetic 
relatedness of epidemiologically-unrelated isolates. As an example, ESBL-producing E. coli are 
currently assigned by MLST to a certain ST, and within those STs diverse clusters can be detected by 
PFGE. An example is the ‘pandemic’ E. coli ST131 which harbours CTX-M-15 on mostly IncF-
plasmids. Within ST131, epidemiologically-related clusters can be identified by PFGE. 
Table 12:  Methods for molecular typing of isolates (identification of clones)  
Method Specification Comments References 
Serotyping Serotyping is based on 
detecting specific surface 
components of the bacteria 
with corresponding 
antibodies. Serotyping 
schemes has been developed 
for E. coli, Klebsiella and 
Salmonella. 
Serotyping is most often used for initial 
characterisation of Salmonella isolates. 
Reproducibility between laboratories is 
high. 
Kaufmann-White scheme
Phage typing Phage typing is based on 
certain bacteriophages ability 
to lyse (infect and kill) the 
tested bacteria.  
Among the Enterobacteriaceae, phage 
typing is almost exclusively used to sub-






PFGE is a band-based method 
where chromosomal DNA is 
digested with a restriction 
enzyme and separated on 
agarose gels. It as been 
utilized for outbreak 
investigations for more than a 
decade. Especially for E. coli 
outbreaks, this method has 
been standardized as part of 
the Pulsenet network.  
The same method is applicable for 
outbreak investigations in other 
Enterobacteriaceae such as Salmonella, 
E. coli, Klebsiella. Reproducibility 
between laboratories is adequate. 
(Ribot et al., 2006; van Belkum 




MLVA is a method based on 
detecting the length of 
variable repeat regions 
located on the chromosome of 
many bacterial species. A 
specific MLVA scheme has 
been developed for E. coli and
Salmonella Typhimurium. In 
general, several repeat areas 
are examined in order to 
increase the discriminatory 
power of the analysis. 
MLVA requires specialized equipment  
(a sequencer) and software for analysis of 
results. Reproducibility between 
laboratories is high as long as the same 
equipment is used. 
(van Belkum et al., 2007)
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MLST is a sequence based 
method where 5-8 
“household” genes from the 
chromosome are amplified by 
PCR and these products are 
subsequently sequenced. 
Based on small genetic 
variations (point mutations) 
within these household genes, 
the ST is determined. Strains, 
which are clonally related 
often belongs to the same (or 
closely related) STs. 
As MLST is based on sequencing, the 
reproducibility between laboratories is 
high, however, the discriminatory power 
is not as high as e.g. PFGE (strains with 
the same ST can have different PFGE 
patterns). 
MLST typing of E. coli. Several MLST 
schemes have been developed although 




Correlation between these two schemes 
has not been extensively explored and ST 
designations can vary among studies 
MLST typing for Klebsiella pneumoniae. 
(http://www.pasteur.fr/recherche/genopol
e/PF8/mlst/Kpneumoniae.html)  
(Jaureguy et al., 2008; van 





FGS can also be used for 
bacterial typing studies. Here, 
the principle is similar to the 
MLST method (based on 
SNPs), however, the amount 
of DNA examined is much 
higher than in MLST. 
The discriminatory power is high. 
However different sequencing methods 
exist, which results in artificial variation 
due to methodological differences. 
  
 
The choice of the molecular typing method to be used is determined by epidemiological relatedness of 
the isolates. Next to phenotypic methods such as serotyping and phage typing, PFGE or MLVA can 
be used to identify clonal clusters of isolates that are related to a certain ‘outbreak’ in a restricted time 
frame. MLST is the method of choice to identify relatedness of isolates of the same species from 
different backgrounds (eg. animal versus human). 
5. RECOMMENDATIONS FOR A HARMONISED MONITORING OF RESISTANCE (PHENOTYPIC AND 
GENOTYPIC) CAUSED BY ESBL AND AMPC IN FOOD AND FOOD PRODUCING ANIMALS IN THE 
EU 
A harmonized monitoring programme will deliver important baseline information on the prevalence 
of and the trends in resistance. The basic general principles of harmonized monitoring of 
antimicrobial resistance in Salmonella and E.coli, as laid down in the EFSA’s recommendations20, 
also apply to monitoring resistance caused by ESBLs and AmpC. Some additional considerations are 
important for this type of resistance. The following sections address these specific considerations. 
5.1. Purpose of the suggested harmonised monitoring 
Harmonised monitoring of resistance caused by ESBLs and AmpC has several objectives: 
                                                     
 
20 Report from the Task Force on Zoonoses Data Collection including guidance for harmonized monitoring and reporting of 
antimicrobial resistance in commensal Escherichia coli and Enterococcus spp. from food animals. 
http://www.efsa.europa.eu/en/efsajournal/pub/141r.htm. Report of the Task Force on Zoonoses Data Collection including a 
proposal for a harmonized monitoring scheme of antimicrobial resistance in Salmonella in fowl (Gallus gallus), turkeys 
and pigs and Campylobacter jejuni and C. coli in broilers. http://www.efsa.europa.eu/en/efsajournal/pub/96r.htm. 
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• To determine the prevalence of resistance in bacteria from different animal populations and food, 
and describe the geographical distribution of resistance prevalence within Europe 
• To detect changes in prevalence of resistance in bacteria over time 
• To describe genotypic characteristics of ESBLs and AmpCs, and changes of these characteristics 
over time. 
• To detect emergence of new blaESBL/AmpC resistance genes with a potential relevance to public 
health 
These objectives may add to the general aims for monitoring antimicrobial resistance in bacteria of 
animal origin in the EU. Since the EFSA guidelines cover only phenotypic monitoring, reported data 
do not enable determination of the class or exact type of β-lactamase enzyme involved. In addition, 
the sample size recommended in the guidelines was determined for detecting trends in changes of 
prevalence over time. This sample size is not sufficient to timely detect emergence of new resistance 
patterns in the case of low prevalence (as observed for ESBLs in many EU countries). Consequently, 
harmonised monitoring of resistance caused by ESBL and AmpC needs to go beyond the existing 
recommendations for routine phenotypic surveillance. Specifically, we recommend that genotypic 
resistance testing should be performed in addition to the phenotypic testing foreseen in the existing 
recommendations. For surveillance schemes, we also recommend the analysis of isolates deriving 
from passive surveillance schemes (diagnostic submissions), from systematic sampling, and from 
targeted surveys. 
5.2. Recommendations for targeted surveys 
In order to increase the probability of detection of emerging resistance determinants, active surveys 
can target those animal categories where the risk of development and spread of resistant isolates is 
highest. For this, information on risk factors contributing to a high prevalence of resistance caused by 
ESBL and AmpC is important. For countries where detailed data on antimicrobial consumption are 
available, those animal species and farms with the highest consumption of third- and fourth-
generation cephalosporins should be included in the survey. For countries where these data are not 
available, risk factors which are a proxy for a high consumption of antimicrobials such as type of 
production, health status or holding size could be used for a targeted selection of samples instead. For 
animal categories where trade is suspected to be a risk factor, farms can be targeted according to the 
origin of the animals received. 
5.3. Recommendations for passive monitoring 
Enterobacteriaceae isolated at veterinary diagnostic laboratories that are classified resistant to third- 
or fourth-generation cephalosporins (ceftiofur, cefoperazone, cefquinome, cefovecin) should be 
subjected to phenotypic and molecular identification and characterization of the plasmid-mediated β-
lactamase genes present. If possible, isolates should be accompanied by information on the location of 
the farm of origin, data of sample collection, animal species and category, and rationale for isolation 
(e.g. type of disease and requested diagnostics). Diagnostic submissions are likely to originate from 
farms with a health problem which have often been treated with antimicrobials prior to sample 
collection. These samples are therefore well suited for early detection of emerging blaESBL/AmpC 
resistance genes.  
5.4. Recommendations for methods for selective enrichment and genotypic surveillance 
The preferred method for selective isolation of ESBL and/or AmpC producers is selective isolation on 
agar preceded by selective enrichment in a broth. The preferred method for selective isolation of 
ESBL/AmpC in food-producing animals and foods
 
EFSA Journal 2011;9(8):2322 46
ESBL and/or AmpC-producers is chromogenic (e.g. MacConkey agar) with 1 mg/L cefotaxime or 
ceftriaxone. Using low concentrations will result in optimum sensitivity to detect all relevant beta-
lactamase families. Pre-enrichment may be performed in a general purpose broth such as Mueller-
Hinton, Brain Heart Infusion or Luria-Bertani broth supplemented with 1 mg/L cefotaxime or 
ceftriaxone. 
 
Identification is performed by determination of susceptibility to cefotaxime, ceftazidime and 
cefoxitin. ESBL producers are resistant to cefotaxime, variably resistant to ceftazidime and 
susceptible to cefoxitin. Confirmation of ESBLs is performed by testing for synergy with clavulanic 
acid by combination disks, ESBL-etests or broth microdilution including cefotaxime, ceftazidime as 
single drugs and in combination with clavulanic acid. Confirmation of AmpC producers is performed 
by determination of susceptibility to cefepime. AmpC-producers are susceptible to cefepime and 
resistant to cefotaxime, ceftriaxone and cefoxitin. To identify ESBL and/or AmpC suspected 
Enterobacteriaceae by broth microdilution susceptibility tests, optimum interpretive criteria need to 
be used. Although CLSI has recently redefined MIC breakpoints for 3rd and 4th generation 
cephalosporins, the R-breakpoints for ceftazidime, cefoxitin and cefepime are still one to two dilution 
steps higher than those defined by EUCAST. To harmonize the interpretation of susceptibility data 
and for optimum phenotypic detection of ESBL and/or AmpC producers we advise to use EUCAST 
clinical breakpoints for interpretation of susceptibility or resistance and EUCAST ECOFF’s to 
determine if an isolate belongs to the wild-type population or not. 
 
All isolates phenotypically confirmed to be either ESBL or AmpC producers may be screened for β-
lactamase gene families using micro-array or (multiplex) PCR. The ESBL and/or AmpC subtypes may 
be identified by dedicated PCRs and sequence analysis of the amplicons. 
Characterization of plasmids on which ESBL and/or AmpC genes are located is an essential tool to 
study the epidemiology of these genes and plasmids. Since in Enterobacteriaceae often several 
different plasmids are present in each isolate, a structured approach is needed to identify the 
characteristics of the plasmid on which the β-lactamase genes are located. If by phenotypic and 
molecular tests described in paragraphs 4.1 and 4.3 the presence of an ESBL and/or AmpC gene in a 
bacterial sample is confirmed, plasmid isolation is performed to determine the number and sizes of 
plasmids present. Subsequently by conjugation or electroporation, transconjugants or transformants 
are isolated on selective agar plates with only the plasmid that harbours the β-lactamase gene present. 
The plasmid can be typed using replicon typing and subtyped by fingerprinting or MLST. Ultimately 
whole plasmid sequence analyses may replace the current typing and subtyping techniques. 
The choice of the molecular typing method to be used for isolates is determined by epidemiological 
relatedness of the isolates. Next to phenotypic methods such as sero-, and phage typing, PFGE or 
MLVA can be used to identify clusters of isolates (with the same fingerprint) in a restricted time 
frame. This cluster analysis complements traditional epidemiological outbreak investigations. MLST 
is the method of choice to identify relatedness of isolates of the same species from different 
backgrounds (eg. animal versus human). 
6. RISK FACTORS CONTRIBUTING TO THE OCCURRENCE, EMERGENCE AND SPREAD OF ESBL- 
AND/OR AMPC-PRODUCING BACTERIAL STRAINS IN FOOD PRODUCING ANIMALS AND FOOD 
The establishment of risk factors for occurrence of ESBL/AmpC-producing bacteria is particularly 
complicated by the data unavailability or lack of its accuracy. Few studies designed to assess risk 
factors for ESBL and/or AmpC occurrence in animals are available. The text below briefly 
summarises present knowledge in general terms. 
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6.1. Farm management 
ESBL- and AmpC-producing bacteria may enter and proliferate in a farm through the stocking of new 
animals, exposure to contaminated air, through water or feed, insect or rodent vectors, human-to-
animal and animal-to-animal transmission. The farm therefore has a significant role as an amplifier of 
resistance.  
A cross-sectional study on 32 different Belgian broiler farms identified risk factors for ceftiofur 
resistance in Escherichia coli, besides on-farm antimicrobial therapy, seven management factors were 
found to be associated with the occurrence of ESBL- and AmpC-producing E. coli (Persoons et al., 
2010; Smet et al., 2008). In contrast with the expected effect of biosecurity conditions for infection 
prevention (hygiene and sanitation), a clean environment was a risk factor for isolates producing these 
enzymes in broilers. The greater diversity of the intestinal microbiota, that is thought to occur in 
animals of dirty environments, could prevent the establishment or reduce the incidence of these 
resistant bacteria. Better sanitation measures were also associated with a higher rate of tetracycline-
resistant, lactose-positive coliforms in fattening pigs in Belgium (Dewulf et al., 2007). The other 
management factors that were found to be associated with the occurrence of ESBL/AmpC producers 
in E. coli from broilers included no acidification of drinking water, more than three feed changes 
during the production cycle, breed, and litter material used (Persoons et al., 2010; Smet et al., 2008). 
A variety of farm management factors may be involved in the occurrence of ESBL/AmpC-producing 
bacteria. Field surveys and experimental research will be needed to further elaborate the list of risk 
factors and their solutions. 
6.2. Use of antimicrobials  
The use of antimicrobials is a risk factor for emergence and spread of AMR clones. Most ESBL and 
AmpC-producing strains carry additional resistances such as to sulphonamides and other commonly-
used veterinary drugs. Generic antimicrobial use is therefore a risk factor for ESBL/AmpC and it is 
not restricted specifically to the use of cephalosporins. 
6.2.1. β-lactams authorised for animals in the EU 
β-lactams are among the most important group of antimicrobial agents in veterinary medicine. 
Penicillins, aminopenicillins (with or without clavulanic acid) and first- to fourth-generation 
cephalosporins are subgroups of β-lactam-authorised antimicrobials. 
Penicillin G (often formulated as a slow release injectable), Penicillin V (for oral use in poultry), and 
aminopenicillins (with and without clavulanic acid) are approved for use in both food producing and 
companion animal species in most European countries. As authorisations of these “old molecules” are 
at national level, the distribution of available formulations and their indications and indicated doses 
varies between EU countries. There are ongoing procedures aiming at harmonisation of marketing 
authorisations at EU level but numerous products do not yet have harmonised product information. 
Formulations are available both as injectables, as oral formulations and as intramammaries for local 
treatment of mastitis. 
Systemically-active cephalosporins have been authorised in the EU for use in animals via 
decentralised or centralised procedures (the former covers one or several EU countries, whereas the 
latter always covers all EU and EES counties although certain products might not be actively 
marketed everywhere). Ceftiofur (free acid) is centrally authorised (trade name: Naxcel see EPAR at 
www.ema.europa.eu) for subcutaneous administration in pigs for treatment of respiratory tract 
infections, septicaemia, polyarthritis and polyserositis caused by defined pathogens, and for cattle the 
indication is interdigital necrobacillosis (footrot). Ceftiofur (free acid) has an extended dosage 
interval (‘long acting’) in contrast with ceftiofur hydrochloride that is authorised in most EU countries 
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for intramuscular administration in cattle and pigs and horses with indications for treatment of 
respiratory diseases, and in cattle also for interdigital necrobacillosis and puerperal metritis. In some 
MS, ceftiofur was previously authorized for injection of day-old chickens for prevention of 
septicaemia (Bertrand et al., 2006). Cephalosporins have been used world-wide in poultry production 
since the 1990s, although precise information on usage in different countries is lacking. There are 
currently no cephalosporin-containing products authorized for poultry species in the EU. 
Cefquinome (a fourth-generation cephalosporin) is available in some MS for systemic use in cattle, 
pigs and horses. The indications for use are mainly respiratory infections, interdigital necrobacillosis 
in cattle, septicaemia caused by E. coli in calves and foals, and streptococcal infections in horses. 
Cefquinome can also be used for the treatment of mastitis metritis agalaxia syndrome in sows, 
exudative epidermitis, and meningitis. Cefquinome is also approved in many EU countries for local 
use following intramammary application to treat bovine mastitis and for dry-cow treatment. 
First generation cephalosporins (e.g. cephapirin, cephalexin, cephazolin), are also available mainly for 
local intramammary use. Cefalexin is also available for injection. In addition a few EU countries have 
cephalosporins approved for oral administration in milk replacers to calves. 
6.2.2. Use of β-lactams in EU outside approved indication 
The use of antimicrobials outside the approved use according to the label is regulated in Directive 
2001/82/EC as amended. According to articles 10 and 11 of this directive, use outside approved 
indication should only be considered by way of exception, under the veterinarian’s direct personal 
responsibility and in particular to avoid causing unacceptable suffering. In addition all treatment of 
food producing species must comply with MRL (maximum residue limits) regulations and only drugs 
that have set MRL (or are listed as substances for which there is no need to establish MRLs) are 
allowed to be used in food producing species.  
Use outside approved indication, as intended, is very restrictive as all routine treatment of groups of 
animals is excluded. Due to poor compliance with this regulation and possibly also differences at the 
level of national implementation, such use is probably much more comprehensive that foreseen in 
legislation. For instance, ceftiofur has been used prophylactically in 1-day-old piglets to prevent 
arthritis, meningitis, septicemia, and diarrhoea (Jorgensen et al., 2007), DANMAP21.There are also 
indications of widespread, off-label use of ceftiofur in poultry (e.g. in ovo use, or use as spray or by 
subcutaneous injection in hatcheries). FDA conducted inspections at USA poultry hatcheries in 2001 
and examined records relating to the hatcheries' antimicrobial use during the 30-day period prior to 
inspection. FDA found that six of the eight hatcheries inspected that used ceftiofur during that period 
were doing so in an extra-label manner. For example, ceftiofur was being administered at unapproved 
dosing levels or by unapproved methods of administration. In particular, ceftiofur was being 
administered by egg injection, rather than by the approved method of administering the drug to day-
old chicks (http://edocket.access.gpo.gov/2008/E8-15052.htm) (Dutil et al., 2010). 
6.2.3. Illegal use 
Besides off-label use of approved products unintended in legislation, there is the possibility of use of 
illegally-produced and/or imported antimicrobials. Namely, for ceftiofur, mentions of its unnecessary 
or off-label use in the poultry industry occur worldwide and are linked to cephalosporin resistance 
(Collignon and Aarestrup, 2007; Webster, 2009). This market has grown with the access to internet 
and there is today no data on the extent of illegal use. Notably, such use might be even more 
problematic than misuse of approved products as counterfeit drugs might vary in content and quality.  
                                                     
 
21 DANMAP 2007. http://www.danmap.org/pdfFiles/Danmap_2007.pdf 
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6.2.4. Quantity of use of cephalosporins for animals in the EU 
A project entitled: “The European Surveillance of Veterinary Antimicrobial Consumption (ESVAC)” 
was set up by the European Medicines Agency (EMA) at the end of 2009 to collect information on 
how antimicrobial medicines are used in animals across the EU. The project is collecting harmonised 
data from 2010. Historical data covering ten European countries have been published, of which eight 
are MS which have surveillance programs on the usage of veterinary antibacterial agents in place 
(Grave et al., 2010).  
The usage of antibacterial agents in the ten countries was reported as overall national sales, in weight 
of active substance, compiled for all animal species, including dogs and cats. Usage of cephalosporins 
cannot be identified for two of the countries as only total use of ß-lactams is given and sales figures of 
3rd and 4th generation of cephalosporins cannot be identified in any country. For those countries that 
report cephalosporin use in animals the percentage of such use varies between 1 to 7% of the total 
use. What this represents in daily doses is not known as daily doses are not defined in veterinary 
medicine. The species and the age of the animal will determine the amount needed to treat a certain 
number of individuals. Generally it can be assumed that 3rd- and 4th-generation cephalosporins would 
represent a group of antimicrobials where the number of doses are high in relation to the amount sold 
as they are given by injection (and not orally) and this is highly potent molecules. Overall the sales 
figures should be interpreted with great care as the number/biomass of animals at risk for treatment 
with antibacterial agents varies tremendously between the different countries. It is therefore not 
possible to compile comparable and relevant data on the use of cephalosporins of different 
generations in the MSs at the present time. There is some evidence pointing at large differences in 
antimicrobial use pattern between some European countries (Czech Republic, Sweden and 
Switzerland) that cannot be explained by differences in the disease situation (Greko et al., 2010). 
Available data on use of all cephalosporins in some MSs reveals that a significant part of 
cephalosporins used in these countries is for pets (55% to 98%) (DANMAP 200922, FINRES-vet 
2005-200623, SVARM 200624, AFSSA 200525). In addition some countries have products for 
intramammary use on their market and this may have large impact on the sales figures26 .   
6.2.5. Cephalosporin use and evolution of genes encoding β-lactamases 
The use of 3rd- and 4th-generation cephalosporins can influence emergence of ESBLs and/or AmpC 
enzymes either by selecting for emerging mutants, or by giving selective advantage to bacteria 
producing these enzymes.  
Human clinical evidence supports the impact of the selective pressure exerted by use of oximino-β-
lactams on the evolution of ESBLs (Gniadkowski, 2008). Recently, (Novais et al., 2010) 
experimentally demonstrated that exposure of bacterial populations carrying CTX-M enzymes to 
challenges with ceftazidime and cefotaxime seems to have played a critical role in the diversification 
of these enzymes. In addition, constant pressure by the use of various β-lactams, including penicillins 
and first-generation cephalosporins, could have contributed to the in vivo evolution of ESBLs 
(Blazquez et al., 2000). As a result of use, mutations occurring in AmpC-encoding genes can extend 
their spectrum of activity to fourth generation cephalosporins, giving rise to the Extended Spectrum 
Cephalosporinases (ESCs) (Ahmed and Shimamoto, 2008; Mammeri et al., 2008; Mammeri et al., 
2007; Wachino et al., 2006).  
                                                     
 
22 DANMAP 2009. http://www.danmap.org/pdfFiles/Danmap_2009.pdf.  
23 FINRES-vet 2005-2006. http://www.evira.fi/uploads/WebShopFiles/1198141211941.pdf. 
24 SVARM. http://www.sva.se/en/Target-navigation/Animal-health/Antibiotic-Resistance/Monitoring-of-antimicrobial-
resistance/SVARM-reports/.  
25 AFSSA. Suivi des ventes de médicaments vétérinaires contenant des antibiotiques en France en 2005. http://www.afssa.fr 
26 EMA(EMEA/CVMP/SAGAM/81730/2006 rev 1). 
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6.2.6. Impact of cephalosporin use on selection and amplification of ESBL and/or AmpC 
The use of cephalosporins and/or aminoglycosides was considered a risk factor for ESBL producing 
bacteria in human infections until the end of the 1990's when ESBLs of TEM and SHV-types were 
predominant. In the last few years, with the increasing observation of CTX-M enzymes prior 
fluoroquinolone use was identified as a new risk factor (Canton et al., 2008; Zahar et al., 2009).  
A strong correlation between reduction in ceftiofur-resistant S. Heidelberg and ceftiofur-resistant E. 
coli (both producing AmpC) from both human infections and retail poultry in different regions of 
Canada and withdrawal of ceftiofur for disease prophylaxis in hatcheries was reported (Dutil et al., 
2010). This use of ceftiofur is extra-label and involves injection of hatching eggs. 
Some evidence of correlation between the use of cephalosporin antibiotics and ESBLs or AmpC- 
producing bacteria taken from treated animals is available. Studies conducted in Denmark 
demonstrated a correlation between the increased occurrence of E. coli with CTX-M-1 or AmpC and 
ceftiofur treatment in piglets (Jorgensen et al., 2007). (Dolejska et al., 2011) in a study conducted on a 
conventional dairy cattle farm with high consumption of parenteral and intramammary cephalosporins 
and on an organic dairy farm with no cephalosporin use, verified a correlation between cephalosporin 
use and prevalence of ESBL-producing E. coli. 
Using an experimental study (Cavaco et al., 2008) demonstrated that ceftiofur and cefquinome exerted 
larger selective effects than amoxicillin in pigs colonized and/or inoculated with CTX-M-1-producing 
coliforms. Significantly higher counts of cefotaxime-resistant coliforms were observed in all treated 
groups compared with controls for up to 22 days after the end of treatment.  
Experimentally administration of ceftiofur to feedlot cattle was also associated with an increase in the 
population of ceftiofur-resistant isolates (Lowrance et al., 2007). It has been argued that active 
concentrations of ceftiofur and cefquinome in the intestines of treated animals are very low, as they 
are mainly excreted in urine with a limited portion, excreted in faeces (Hornish and Kotarski, 2002); 
see also MRL summary reports available at www.ema.europa.eu). In the intestines ceftiofur is rapidly 
metabolised by the intestinal microbiota (Hornish and Kotarski, 2002). Undesirably the available 
information does not permit estimation of the exposure of the gastrointestinal microbiota to these 
drugs or active metabolites. Nevertheless, correlation between the use of ceftiofur and the occurrence 
of resistance at herd level has been documented (Jorgensen et al., 2007; Tragesser et al., 2006), 
showing that the concentrations are sufficient namely to select for E. coli and Salmonella with 
resistance to 3rd generation cephalosporins. 
Cephalosporins are widely used as lactating or dry cow therapy in many EU MSs. Intramammary use 
of cephalosporins is generally considered to have less impact on the selection of resistant bacteria as a 
lesser exposure of the normal microbiota of the target animal occur. Nevertheless, besides the 
possibility of selection of resistance in target bacteria, the use of recently treated cows to fed calves 
before the withdrawal time has elapsed could also impose a selective pressure to the intestinal 
microbiota of the latter. 
6.2.7. Other antimicrobials and selection and amplification of ESBL and/or AmpC 
ESBL- and AmpC-producing bacteria often present resistance to multiple agents used in veterinary 
medicine, e.g. amoxicillin, amoxicillin-clavulanate, tetracycline, trimethoprim, sulphonamides, 
quinolones, phenicols, and streptomycin (Blanc et al., 2006; Carattoli et al., 2005; Machado et al., 
2008; Smet et al., 2008). This frequent occurrence of resistance to several antibiotics implies that 
once ESBL- or AmpC-producing isolates have entered a production unit, a broad range of 
antimicrobials can favour their selection and spread between animals. Amoxicillin treatment proved 
to be a significant risk factor for emergence of ESBL- or AmpC-producing E. coli in broilers in 
Belgium (Persoons et al., 2010; Smet et al., 2008). Cross-resistance to these compounds is known, i.e. 
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amoxicillin and amoxicillin–clavulanic acid may select for isolates producing ESBLs or AmpC β-
lactamases.  
Resistance to several non-β lactams have been associated with isolates producing ESBLs or AmpC, 
being more frequently observed to tetracycline, streptomycin, trimethoprim, sulfamethoxazole and 
nalidixic acid. Genetic linkage between some resistance determinants (e.g. dfrA and sul genes 
conferring resistance to trimethoprim and sulphamethoxazole, respectively) and ESBLs/AmpC 
resistance genes favours the occurrence of ESBL/AmpC producers (Blanc et al., 2006; Machado et 
al., 2008; Persoons et al., 2010; Smet et al., 2008). 
In addition to antimicrobials used in veterinary medicine, other chemicals used in animal production, 
as antiseptics, disinfectants and metals, might contribute to the selection of such resistant isolates 
(Aarestrup and Hasman, 2004; Cavaco et al., 2010; Hasman and Aarestrup, 2002). 
6.3. Trade and movement of animals  
An extensive trade of animals occurs in EU MS, with few countries leading the production and the 
export, and with a reduced number of companies producing pure line grandparent stock. How 
widespread are ESBL-carrying bacteria in food-producing animals in the breeding/rearing/fattening 
sectors is generally unknown, although few reports suggest that ESBL/AmpC are not uncommon in 
the top of some production pyramids (breeding) as presented in the sections bellow. 
During the post-harvest phase including manufacturing and retail there is a constant flow of products 
in all directions in EU. This may have a significant impact in the dissemination of bacterial flora 
associated with food. Recent EFSA Opinions27 have highlighted the importance of these factors in the 
spread of food-borne pathogens. Because of the complexity of this information, we will not further 
consider the trade of food in this document. 
6.3.1. Swine 
Pig farming is divided into two parts, farrowing sows, and their rearing (growing and finishing 
fattening pigs for slaughtering). The majority of smaller farms producing meat for household 
consumption and the local market are situated in the “new” EU countries, whereas overall in Europe 
75 % of fattening pigs are reared by just 1.5 % of the largest production units28. Most transports 
between EU countries of live pigs are between neighbouring countries with Germany being the major 
importer and Denmark the main exporter of weaners. The Netherlands is a substantial exporter of 
finishing pigs for slaughter. 
6.3.2. Poultry 
Broiler farming is built upon a pyramidal hierarchy with a very narrow top29. It starts with the 
breeding company at which from pure line grandparent stock is produced and sold as day old chicks 
to rearing farms which produces the parent generation to the broilers. There are few breeding 
organisations worldwide and two companies have more than 85 % of the European market.  
                                                     
 
27  EFSA Panel on Biological Hazards (BIOHAZ); Scientific Opinion on a quantitative estimation of the public health 
impact of setting a new target for the reduction of Salmonella in broilers. EFSA Journal 2011;9(7):2106. 
www.efsa.europa.eu/en/efsajournal/pub/2106.htm 
28  Eurostat8/2010: Pig farming in the EU, a changing sector. http://epp.eurostat.ec.europa.eu/cache/ITY_OFFPUB/KS-SF-
10-008/EN/KS-SF-10-008-EN.PDF  
29  Development of new integrated strategies for prevention, control and monitoring of epizootic poultry diseases) 
Commission of the European Communities, Project no.: SSPE-CT-2004-513737: Chapter 4 Trade in live poultry within 
the European Union. 
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Farming of layers follows a similar structure. Two companies in the Netherlands and France supply 
more than 90% of the layer stock in Europe. 
The main flow of trade of fattening broilers is between the three neighbouring countries Belgium, the 
Netherlands and Germany, whereas France is biggest in slaughter of chicken. The main transport 
routes for breeding poultry are from the Netherlands to Germany, from Czech Republic to Slovakia 
and Poland and from France to Spain. The trade can be either day-old chicks for broilers farms or day-
old chicks of parent- or grandparent stock. 
To understand more about the spread of ESBL- and/or AmpC-producing E. coli in the Dutch broiler 
industry, different levels in the broiler production chain were examined for the presence and 
prevalence of these bacteria. ESBL- and/or AmpC-producing E. coli were present at every level that 
was examined, including imported day old chickens from great grand parent stock, sampled on the 
day of arrival in the Netherlands. Prevalence seemed lower in day-old parents and day-old broiler 
chickens and higher in day-old grandparent chickens, which are derived from outside the Netherlands 
(UK and USA). The low prevalence in day-old broiler chickens is unexpected as previous research 
showed that these animals at 6 weeks of age are almost all positive for ESBL and/or AmpC-producing 
E. coli (Dierikx et al., 2010a), (MARAN-2009)30. .  
Grandparents at weeks 18 and 31 of age were found positive at moderate level, which indicates that 
especially on Dutch broiler production farms optimum circumstances are present to multiply ESBL- 
and/or AmpC-producing bacteria. Preliminary data on genetic analysis of these isolates show that 
throughout the production chain blaCTX-M, blaTEM and blaCMY are the predominant β-lactamase families 
present (MARAN-2009).  
The data from this study indicate that ESBL- and/or AmpC-producing E. coli are introduced in the 
Dutch poultry production chain through imported day-old grandparent chickens. Moreover the data 
indicate that the occurrence of these organisms in the different levels layers of the Dutch poultry 
production chain is the result of vertical transmission, local recirculation and selection. Further 
research is currently being conducted to understand more about the driving forces that have led to a 
rapid spread of ESBL- and/or AmpC-producing E. coli in broilers at the broiler production farms 
(MARAN-2009). 
In Sweden cephalosporins are not used in broilers; thus, occurrence of E. coli of CTX-M-1 and CMY-
2 genotypes is not associated with a selection pressure through use of such antimicrobials in that 
country. Instead, transmission of resistant bacteria from breeding stock was suspected. This was 
supported by findings of E. coli carrying genes coding for CMY-2 or CTX-M-1 in environmental 
samples from hatcheries hatching production animals or breeding-stock (parent animals) of both 
hybrids produced in Sweden, collected in May to June 2010. Moreover, E. coli carrying blaCMY-2 were 
found in intestinal content of day-old chickens imported as breeding stock (grand parents) in July to 
December 2010 and sampled on arrival to Sweden. These findings indicate a spread of cephalosporin-
resistant E. coli from imported breeding stock into Swedish broiler production. The temporal variation 
in proportion of CMY-2 or CTX-M-1 genotypes among Swedish broilers might reflect dissemination 
of different lineages of resistant bacteria from different batches of imported breeding stock (SVARM 
2010)31. 
                                                     
 
30  MARAN-2009 Monitoring of Antimicrobial Resistance and Antibiotic Usage in Animals in the Netherlands in 2009. 
http://www.lei.wur.nl/NR/rdonlyres/4ED137F2-5A0D-4449-B84E-61A3A8AC4A42/135753/MARAN_2009.pdf 
31  SVARM 2010, Swedish Veterinary Antimicrobial Resistance Monitoring. The National Veterinary Institute 
(SVA), Uppsala, Sweden, 2011. www.sva.se. 
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(Weill et al., 2004) have described CTX-M-producing S. Virchow in six chicken farms and one 
hatchery supplying these farms, as well as from poultry meat. (Persoons et al., 2010) also associated 
the presence in poultry of ESBL-producing E. coli with the hatchery supplying these farms. 
6.3.3. Cattle 
Cattle production is divided in dairy and beef. Trade of live animals occurs for all categories of 
animals but is likely to be most pronounced for male calves from dairy farms which are sold to veal 
production. 
6.4. Post-harvest risk factors 
Since bacteria that could carry ESBL or AmpC genes are known as common inhabitants of the 
intestinal tract of animals, it is expected that they contaminate carcasses during the slaughtering 
process. Any measure by which microbial contamination is reduced at slaughter, or during further 
processing and retailing will also indirectly help to contain the spread of ESBL/AmpC-producing 
bacteria to humans. 
6.4.1. Food handling 
Contamination of meat products, with resistant bacteria from human or animal reservoirs may 
contribute to further spread within human population. Although it may be assumed that AMR bacteria 
will follow the same principles as the corresponding antimicrobial-sensitive strain, there may be 
additional risks related to resistant bacteria. This is because the resistance genes may transfer from 
food-borne commensals to non-food-borne human pathogens. Thus commensals are a part of the 
overall risk pattern. This has been shown to be particularly applicable to ESBLs (Lavilla et al., 2008; 
Mesa et al., 2006) 
6.5. Risk factors associated with food of plant origin  
Contamination of fresh food of plant origin have been increasingly recognized in many parts of the 
world as a source of pathogens (Lynch et al., 2009). Moreover, these food products may serve as a 
vehicle of ESBLs, as demonstrated by the recent description of Enterobacteriaceae carrying CTX-M 
genes in spinach, parsnip, bean sprouts and radish (Raphael et al., 2011; Reuland et al., 2011a) and 
SHV-2 in ready-to-eat salads (Campos et al., 2011).  
ESBLs have been detected in Dutch vegetables. Out of 79 analyzed samples, four yielded ESBL-
producing Enterobacteriaceae (5%). ESBLs were found in parsnip, bean sprouts and radish; this 
means that three (17,6%) of the vegetable types were contaminated with ESBLs. Of the four positive 
samples, three were from vegetables of organic origin. The ESBL-producing strains were 
Enterobacter cloacae (in two samples), Citrobacter braakii (in one sample) and Klebsiella 
pneumoniae (in one sample). Three strains carried a blaCTX-M-1, and one a blaSHV gene (Reuland et al., 
2011b). 
Recently a large outbreak produced by CTX-M-15-producing E. coli O104:H4, and linked to the 
consumption of contaminated sprouts has occurred in Northern Europe 
(http://ecdc.europa.eu/en/healthtopics/escherichia_coli/epidemiological_data/Pages/Epidemiological_
updates.aspx). 
The possibility of human acquisition of bacteria producing ESBL or AmpC, may also be influenced 
by the increasing consumption of fresh produce (Lynch et al., 2009). Nevertheless, as yet few studies 
have addressed the impact of these factors. 
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7. POSSIBLE CONTROL OPTIONS (IDENTIFICATION AND RANKING) TO REDUCE THE PUBLIC 
HEALTH RISK CAUSED BY ESBL- AND/OR AMPC-PRODUCING BACTERIAL STRAINS 
TRANSMITTED VIA THE FOOD CHAIN OR VIA FOOD ANIMAL PRODUCTION ENVIRONMENT 
The assessment of the efficiency of control options to reduce the public health risk caused by 
ESBL/AmpC-producing food-borne bacteria is particularly complicated by data unavailability. The 
section below summarises the present knowledge in general terms, and based on best available 
evidence and expert opinion. 
During recent years a number of different bodies have discussed and proposed control options to 
minimise public health risks related to AMR. For instance OIE have, in their terrestrial code, 
published a chapter 6.9 entitled “responsible and prudent use of antimicrobial agents in veterinary 
medicine (http://www.oie.int/international-standard-setting/terrestrial-code/) and Codex Alimentarius 
are about to finalise their taskforce of antimicrobial resistance 
(http://www.codexalimentarius.net/web/index_en.jsp) where a list of possible control options will be 
presented. Recently the BIOHAZ panel has described the need to control the spread of antimicrobial 
resistant organisms and resistance genes (http://www.efsa.europa.eu/en/efsajournal/doc/765.pdf). In 
the above report control options for spread of AMR bacteria and/or resistance genes from animals, 
plants and derived foods were described, and prudent use policies for antimicrobial usage were 
discussed in general terms.  
The effect of reducing the prevalence of ESBL- and/or AmpC-producing bacteria in animals/food on 
public health risks is difficult to assess. Although there is evidence of the contribution of AMR 
microorganisms transmitted via food-producing animals/food to public health risks, it is currently 
difficult to quantify that risk. Moreover the magnitude of the contribution from animals/foods to 
public health risks and the perception of the risks for humans will be greatly influenced by the local 
epidemiology of ESBL- and/or AmpC-producing organisms in health care and in the community. This 
epidemiology may vary greatly by country. In countries where human associated ESBL- and/or 
AmpC-producing clones have spread endemically in health care and the community, contaminated 
animals/foods will have a minor relative importance compared to countries where these organisms 
occur only incidentally in health care and the community. 
In the present report these control options are more explicitly aimed at control of the emergence and 
spread of ESBL and/or AmpC-producing bacteria in animals and foods and their transmission to 
humans are discussed. Public health risks caused by ESBL- and/or AmpC-producing bacteria are 
determined by the frequency of the occurrence (prevalence) and the quantity of these organisms in 
food-producing animals and food, the genetic characteristics of the β-lactamase genes involved, and 
the transmission from animals/foods to humans. Mitigation measures should therefore aim to reduce 
the prevalence in animals, and food and to reduce transmission from contaminated animals/foods to 
humans. 
The prevalence of resistant organisms in a certain niche (animals or foods) is determined by two basic 
mechanisms: selection and dissemination.  
7.1. Selection 
Selection of resistant bacteria and/or resistance determinants is primarily caused by usage of 
antibiotics. The usage of 3rd- and 4th-generation cephalosporins in animals will specifically select for 
ESBL- and or AmpC-producing Enterobacteriaceae in the gastrointestinal tract. Due to the 
multiresistant nature of these organisms many other drugs also indirectly co-select for them. Such 
drugs include (fluoro)quinolones, aminopenicillins, trimethoprim, sulphonamides, aminoglycosides 
and tetracyclines. These drug classes include the vast majority of the antibiotics used in food-
producing animals, demonstrating the complexity of the problem once ESBL- and/or AmpC-
producing bacterial populations have been established in animal production sectors. Selection may 
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also occur through disinfectants (e.g. quaternary ammonium derivatives), or metals (e.g. mercury and 
copper), because genes encoding for resistance to these compounds are known to occur in 
multiresistant organisms. As yet, the in vivo effects of these compounds on these bacterial populations 
are unknown. 
The current systems for marketing authorisation approval of antimicrobials in the EU include a 
microbial safety assessment and instruction for restrictive and appropriate usage is included in the 
summary of product characteristics (SPC) and on the label. Once a product is licensed for usage in 
food animals the control over its usage, according to the label instructions, is limited as legislation 
allows for use outside approved indications in certain cases (see 6.2.2 above) and it can be that the use 
in practice is much more extensive than what would be expected from the conditions of the 
authorisation. For this reason full transparency of antimicrobial usage in food-producing animals, 
together with increased control of that usage are crucial aspects of any policy to improve the quality 
of usage and decrease the exposure of animals and animal flora to antimicrobials.  
In order to reduce the selection pressure there is a need to reduce the overall antimicrobial burden, 
with a special focus on restriction of use of systemically active 3rd- and 4th-generation cephalosporins 
and restriction of all use of antimicrobials that are not strictly needed for animal health. 
7.1.1. Restrictive usage of systemically active 3rd- and 4th-generation cephalosporins in 
animals 
In 2007, recommendations on the use of 3rd- and 4th-generation cephalosporins in food producing 
animals (EMEA/CVMP/SAGAM/81730/2006) were presented by EMA (www.ema.europa.eu), 
following a consultation a revised document was published in 2009 
(EMEA/CVMP/SAGAM/81730/2006 rev 1). The recommendations covered systemic use and it was 
concluded that systemic 3rd- and 4th-generation cephalosporins are to be reserved for the treatment of 
clinical conditions in animals which have responded poorly, or are expected to respond poorly, to 
more narrow spectrum antimicrobials. In addition it was recommended that prophylactic use of 
systemically administered cephalosporins should always be limited to specific circumstances. Oral 
use for group medication in food-producing animals and off label use was strongly discouraged. The 
recommendations are implemented as specific texts in the SPCs for centrally-approved products but 
not yet for national products in all member states. Notably there are approved indications such as 
metritis and interdigital necrobacillosis, which are normally mixed infections where the causative 
agents (and its resistance pattern) are rarely known. In practice the recommendation given are not 
applicable for such indications. 
In some MSs there are national recommendations/regulations for the use of cephalosporins. National 
legislation in Finland prohibits the use of 3rd- and 4th-generation cephalosporins for animals (with the 
exception of use according to label where there is a market authorisation or a special licence). In 
Denmark and France pig producers have in 2010 agreed to a two year moratorium on the use of 
cephalosporin antibiotics. 
Possible control options on EU level would be to stop all uses of cephalosporins/systemically active 
cephalosporins/systemically active 3rd- 4th-generation cephalosporins in animals, or to restrict their 
use (i.e., use only allowed under specific circumstances). The more comprehensive the restriction, the 
more prominent the effect on selection pressure would be, although a very restrictive policy might 
have unintended consequences on animal health and welfare if effective antimicrobials are not 
available for treatment. 
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Examples (partly overlapping and not in a priority order): 
 
• Systemic usage (oral or by injection): 
 
o Restriction of systemic use of 3rd-4th generation cephalosporins for treatment of individual 




Advantages and disadvantages: 
  
 Effective implementation would result in substantial reduction of the exposure of 
animals and their bacterial flora and less opportunities for selection of 
ESBL/AmpC producers. 
 If the use of cephalosporins is replaced with use of other antimicrobials the effect 




 As long as there are alternatives available in veterinary medicine the negative 
impact on animal health is likely to be minor. There is today no infectious disease 
where cephalosporins are approved for use and where they are the sole available 
treatment. 
 Recommendations for this measure have already been given by EMA/CVMP. 
Implementation has proven to be difficult as there is to day no means to measure 
compliance. 
 
o Prohibition of systemic usage for prevention or metaphylaxis. 
 
Advantages and disadvantages: 
 
 This would result in reduced selection of resistant organisms or genes and would 
not interfere with therapeutic efficacy during treatment  
 If use of cephalosporins is replaced with use of other antimicrobials the effect on 




 There is currently no definition for metaphylaxis. The expression includes both 
strategic treatment and unnecessary routine use. 
 As long as there are alternatives available in veterinary medicine, the negative 
impact on animal health and welfare is likely to be minor. 
 Of special concern are the long-acting formulations where one injection is a full 
course of treatment, they can be more frequently used for convenience reasons, 
and exert a long lasting selective pressure in bacterial flora. 
 
 
o Measures to discourage/prohibit use as group, or flock medication  
 
Advantages and disadvantages: 
 
ESBL/AmpC in food-producing animals and foods
 
EFSA Journal 2011;9(8):2322 57
 Group or flock medication of cephalosporins will select for ESBL/AmpC 




 This kind of use is not approved in EU today and is only allowed according to 
the cascade (see section 6.2.2 above) by way of exception if there are no 
approved alternatives available. It is believed that mass medication with 
cephalosporins is quite common in piglets and day-old chickens.  
 
o Restriction of use of products with prolonged elimination half-life for limited indications 
in individual animals and where no alternatives are available. 
 
Advantages and disadvantages: 
 
 Application of products with prolonged elimination half life will result in 




 There are few (if any) occasions where no alternatives are available. 
 Currently, there is at least one such product approved but its approved use 
includes a warning sentence to restrict its use in accordance with the above. 
There are anecdotal data that the compliance with this restriction is poor.  
  
• Topical or local administration (e.g. intra-uterine, intramammary) 
 
o Restriction of use for clinical cases of mastitis, and for dry cow treatment in individual 





 Local application of cephalosporins in the udder may have less selective effect 
on the microbial flora of animals outside the udder, than after systemic or oral 
administration. 
 It is believed that restrictions in topical use will, to some degree, reduce exposure 
of bacterial flora in the farm environment to these antimicrobials. 
 
• Off-label usage  
 
o Implement control measures covering all off-label usage of 3rd and 4th generation 
cephalosporins in food-producing animals, including all types of usage at hatcheries (in 
ovo, injection, spray) 
 
Advantages and disadvantages: 
 
 Effective implementation would result in substantial reduction of the exposure of 
animals and their bacterial flora and less opportunities for selection of 
ESBL/AmpC producers (and MRSA) or ESBL/AmpC-genes. 
 
ESBL/AmpC in food-producing animals and foods
 
EFSA Journal 2011;9(8):2322 58
Comment: 
 
 There is some off-label use in minor species (e.g. multiresistant infections of foal 
septicaemia), which is justified. 
 It is likely that most off-label use in EU today is not in accordance with current 
legislation (if strictly interpreted) and this includes all uses to poultry. 
 Interpretation of the cascade rule is problematic. 
7.1.2. Restrictive usage of all antimicrobials in food-producing animals 
With the exception of some products for companion animals, all antimicrobials in EU are prescription 
only. Some countries (e.g. Denmark and Sweden) have special legislation to separate prescription and 
sales of antimicrobials to avoid economical incentives for prescription.  
Prudent use guidelines have been available since the early 1990s, but their implementation and 
adoption has not been consistent. In general there is a need to take measures to increase compliance 
with appropriate prudent use policies in EU-MSs (e.g. OIE, see above). Many prudent use policies 
have been documented. Implementation is complex and control on its effectiveness is limited. To 
apply such control there is a need for improvement of transparency in antimicrobial usage by the 
development and implementation of antimicrobial usage registration systems at the national and EU-
level. 
An essential part of the implementation process is full transparency in antibiotic prescription and 
usage data. This would allow the identification of frequent prescribers or users and targeted 
intervention measures. These systems could e.g. aim at: 
• quantify the exposure of food-animal species to antibiotics 
• identify users (veterinarians or farms) with a high consumption patterns 
• determine and report trends in usage by food-animal species and country 
• identify inappropriate, off-label and/or illegal usage 
Measures to increase awareness about AMR related risks and to promote the use of appropriate 
diagnostics could in some settings reduce the total use of antimicrobials.  
Comment: 
 
 There are numerous different possible measures to promote implementation of 
prudent use principles, to increase awareness about AMR-related risks and to 
promote the use of vaccines and appropriate diagnostics to reduce the total use of 
antimicrobials 
7.1.3. Improved control on antimicrobial usage in animals in MS 
Control on antibiotic prescription and usage is complex and mostly limited to the inspection services 
of national authorities, and aimed at illegal practices. There are also differences in interpretation of 
what is legal or appropriate according to prudent use policies. There is no comprehensive information 
on usage practices in the EU, which may encourage propagation of uncontrolled use. Countries that 
have implemented such a strict control system have lower usage of antimicrobials. As an example, in 
order to increase compliance with their national treatment guidelines, Denmark has recently 
introduced a “yellow card system” (Government Order No. 1319 of December 1st 2010 on special 
provisions for the reduction of the consumption of antibiotics in pig holdings) where farmers sign a 
contract and allow inspections on their use of antimicrobials. 
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The review of the legal framework on authorisation and use of veterinary medicinal products is on-
going. Antimicrobial resistance is one of the issues addressed and the impact of different policy 
options to tackle it are assessed. The summary of the comments received in public consultation and 
the impact assessment will be published in 2011 and proposals for legislation can be expected in latter 
half of 2012. 
Examples of control activities could be: 
• Setting of targets for quantity and quality of antibiotic usage allowed in food-producing 
animals 
• Analyse and report of usage data on farms and by veterinarians  
• Identification high users and/or prescribers 
• Suggestion of strategies to improve usage/prescription practices 
• Identification of illegal, off-label and inappropriate use practices 
• Independent drug authorities could define clear targets for appropriate usage, and target 
strategies for improvement to high users or prescribers. 
7.2. Dissemination 
Dissemination of ESBL- and/or AmpC-producing bacteria occurs within the gut of animals, and by 
cross-contamination with faecal material between animals. In the modern intensive animal production 
systems the possibilities for transmission of enteric organisms between animals is virtually unlimited. 
Moreover, in all major food-animal production systems massive movement of young animals from 
reproduction farms to fattening farms occur within and between countries, facilitating continuous 
transfer of organisms between farms and countries. Trade of food products is a global industry and 
also contributes to global distribution of AMR organisms and resistance genes.  
Because ESBLs are found in certain animals/animal products where antimicrobials are not used in the 
species in question, measures need to consider both selection and dissemination to be effective.  
7.2.1. Prevention of dissemination of antimicrobial resistance 
 
• Within farms 
 
o Optimize biosecurity and farm management to prevent dissemination of resistant bacteria 
and/or resistance genes by considering: 
 
 Numbers of animals per square meter 
 Movements of animals within farms  
 Hygiene at farms 
 Avoid mix of animals of different age 
 Use of “all in–all out” systems 
 
Advantages and disadvantages: 
 




 The lower the density of the animal population, the fewer the opportunities for 
contacts between groups of animals, therefore resulting in reduced spread of 
AMR. 
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 Much could be achieved by including biosecurity considerations already when 
buildings and production units are planned. 
   
  
• Between farms and regions/countries 
 
o Stimulation of more local, or closed production systems. 
o Improved control of presence of antimicrobial resistant bacteria (like ESBL and/or 
AmpC producers) at breeder and reproduction farms, and hatcheries to prevent 
transmission in production pyramids. 
o Definition of acceptable quantitative limits for the presence of resistance genes and/or 
resistant bacteria in young animals at breeder/reproduction farms. 
o Introduction of systems to certify animals/farms which are documented free from ESBL- 
and AmpC-producing micro-organims. 
 
Advantages and disadvantages: 
 




 As a starting point it may be valuable to have a voluntary system for trade of 
AMR-free animals. 
 
• Into the environment 
o Optimized management of farm waste and prevention of contamination of arable crops 




 Due to the complexity of the issue there are little data that would allow 
estimation of the magnitude of the related risk.  
7.2.2. Post-harvest measures 
Improved hygiene at all steps of the food chain is effective in reducing the number of micro-
organisms in food. This will also reduce the numbers of micro-organisms that are resistant to 
antimicrobials including ESBL- and/or AmpC-producing microorganism. The sustained application of 
good hygienic practices throughout the food chain provides a varying degree of assurance against the 
introduction of AMR bacteria onto or into food32. There are no indications that AMR strains behave 
differently in the food chain compared to their sensitive counterparts. Hence, effect estimates of 
interventions along the food chain for antimicrobial-sensitive and antimicrobial-resistant strains will 
be similar.  
Advantages: 
 
 Post-harvest measures would be effective without delay in case of rapid alerts 
nationally, and when appropriate internationally through the EU Rapid Alert 
System for Food and Feed (RASFF). 
                                                     
 
32 Foodborne antimicrobial resistance as a biological hazard-Scientific Opinion of the Panel on Biological Hazards. 
http://www.efsa.europa.eu/en/efsajournal/pub/765.htm 
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 These measures are expected to have a more immediate impact (short-term) in 




 Improved hygiene as a sole measure will not mitigate the selection at source 
(primary production) of AMR rmicroorganisms/resistance genes.  
7.2.3. Measures to reduce trade of ESBL/AmpC-contaminated food-producing animals and 
derived food 
 
• Introduction of trade restrictions (imports/exports) of animals and food carrying bacteria that 
harbour ESBL/AmpC-encoding genes. 
 
o Screening of imported foods and food animals for defined organisms and resistance traits  
7.3. Prioritisation of measures 
There are no data on the comparative efficiency of the individual control options presented in this 
document in reducing public health risks caused by ESBL and/or AmpC-producing bacteria related to 
food-producing animals. Prioritisation is complex.The effectiveness of measures discussed here are 
based on the best available evidence and expert opinion.  
Cephalosporins (especially 3rd- and 4th-generation) specifically select for ESBLs. It is considerered 
that a control option that is likely to be highly effective in reducing selection of ESBL/AmpC-
producing bacteria at an EU level is stopping/reducing the use of cephalosporins in food animals. 
Provided adequate compliance, the measure would be more effective the more comprehensive the 
restrictions. The restrictions could range from stopping all uses of cephalosporins/systemically active 
3rd/4th generation cephalosporins, to more or less strict restriction of their use, allowing use only 
under specific circumstances. 
Off label use of veterinary medicinal products, including cephalosporins, is restricted according to 
articles 10 and 11 of Directive 2001/82/EC as amended. Such use should be limited to use by way of 
exception, under the veterinarian’s direct personal responsibility and in particular to avoid causing 
unacceptable suffering. Therefore, the use of cephalosporins could be reduced by measures intended 
to minimize such use should focus on increase the compliance with existing legislation e.g. by:  
• Inspections to investigate use of cephalosporins aiming at minimizing unnecessary and illegal 
use. 
• Inspection of status of national competent authorities’ implementation of aiming at ensuring 
compliance with the original intension of the legislator. 
• Reinforcement by adding a specific piece of legislation to stop off-label cephalosporin use in 
group or flock medication.    
As co-resistance is an important issue, it is unlikely that restriction of cephalosporin use will be 
completely effective in reducing public health risks caused by ESBL and/or AmpC-producing bacteria 
related to food-producing animals. Therefore, risk managers would need to consider uses of all 
antimicrobials. The most radical measure is to stop all uses. As an alternative, there are other 
measures likely to be effective to decrease the total antimicrobial use in animal production in the 
EU, for example: 
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• Implementation of systems to monitor and control antimicrobial usage at MS and EU level. 
• Implementation of measures to ensure transparency in antimicrobial usage (at farm and 
prescriber level). 
• Promotion of more tailored treatments by implementation of adequate diagnostic tools. 
• Information campaigns on prudent use principles targeting farmers and responsible 
veterinarians.  
• Stopping antimicrobial use at hatcheries. 
Also of importance (especially after the ESBLs/AmpC-producing microorganisms have emerged) are 
measures to control dissemination, by for example:  
• Promotion of closed production systems with high biosecurity standards. 
• Introduction of EU monitoring systems to control trade of ESBL/AmpC-contaminated food-
producing animals in production pyramids. 
• Improved hygiene throughout the food chain. 
• Other general post-harvest controls for food-borne pathogens. 
Because most evidence is available for high prevalence of ESBL/AmpC-producing bacteria in the 
poultry production pyramid, and their consequent involvement in public health, it is of high 
priority: 
• To reduce selection pressure impossed by the use of antimicrobials. 
• To prevent vertical transmission from the top of the poultry production pyramid. 
• To prevent local recirculation within subsequent flocks.  
CONCLUSIONS AND RECOMMENDATIONS 
CONCLUSIONS 
ESBL- and AmpC-producing bacterial strains and genes relevant for public health and linked 
to food producing animals or food borne transmission 
• The potential contribution of food-producing animals or foods to public health risks by ESBL 
and/or AmpC-producing bacteria is related to specific plasmid-mediated ESBL and/or AmpC 
genes encoded by a number of organisms.  
• The predominant ESBL families encountered are CTX-M, TEM, and SHV. The predominant 
AmpC-family is CMY. By far the most common genes associated with this resistance in 
animals are blaCTX-M-1 (the most commonly identified ESBL), and blaCTX-M-14, followed by 
blaTEM-52 and blaSHV-12. Among the genes encoding AmpC-type β-lactamases, blaCMY-2 is the 
most common. 
• The bacterial species most commonly identified with these genes are Escherichia coli and non-
typhoidal Salmonella. 
• Among E. coli, the clonal lineages: phylogroup B2-E. coli O25:H4-ST131, phylogroup D-E. 
coli O25a-ST648 and phylogroup D- E. coli-ST69, -ST393, are being increasingly detected 
among both humans and animals. Among Salmonella the most common serovars are 
Typhimurium, Newport, and Heidelberg. 
• ESBL/AmpC transmission is mainly driven by integrons, insertion sequences, transposons and 
plasmids, some of which are homologous in isolates from both food-producing animals and 
humans. While ESBL genes are mainly spread by plasmids of IncFII, IncA/C, IncL/M, IncN, 
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IncK, and IncI1 groups, AmpC genes are mainly associated with IncA/C, IncI1 or IncI2 
plasmids. 
The epidemiology of acquired resistance to broad spectrum cephalosporins in food-producing 
animals and food 
• Cefotaxime is used as the drug of choice for optimum detection of blaESBL and/or blaAmpC genes 
in Salmonella and E. coli. From the results presented in the Community Summary Report it can 
be concluded that the prevalence of resistance to cefotaxime in food-producing animals varies 
by country and animal species. High prevalences are observed in E. coli and Salmonella in 
poultry in Spain, Italy, the Netherlands and Poland. In raw meat from poultry only limited 
cefotaxime resistance prevalence data are available. Belgium and the Netherlands reported high 
to moderate cefotaxime resistance prevalences in Salmonella and E. coli from poultry meat. In 
pigs and cattle the prevalences were low.  
• Since 2000, the presence of ESBL- and/or AmpC-producing Salmonella and E. coli in animals 
and food has been increasingly reported in both Europe and globally. Although these enzymes 
have been described in bacteria from all major food-producing animals, poultry and poultry 
products are most frequently reported to carry ESBL and/or AmpC-producing bacteria. 
• The most frequently reported ESBL subtypes in the EU in both Salmonella and E. coli in food-
producing animals and foods are CTX-M-1, CTX-M-14, TEM-52 and SHV-12; the 
predominant plasmidic AmpC variant described globally to occur in Salmonella and E. coli 
from food-producing animals or foods since the mid-1990s is CMY-2. 
• A wide range of additional CTX-M subtypes (CTX-M-1, -2, -3, -8, -9, -14, -15, -17/18, -20, -32, 
-53) have been detected in food-producing animals and food in European countries.  
• A range of additional TEM (TEM-20, -52, -106, -126) and SHV (SHV-2, -5, -12) variants have 
similarly been detected in different European countries.  
• Epidemic plasmids belonging to the incompatibility groups F, A/C, N, HI2, I1 and K groups 
carrying particular ESBL-encoding genes (blaTEM-52, blaCTX-M-1, -9, -14, -32,) or AmpC-encoding 
genes (blaCMY-2) have been detected among farm and companion animals, food products and 
humans.  
• There are few studies that describe clear evidence of direct transmission of ESBL or AmpC-
producing E. coli isolates from food-producing animals or food to humans. Data do exist about 
common clones of ESBL- and/or AmpC-producing E. coli isolates in humans and food-
producing animals and foods, which provide indirect evidence about this transmission. 
• Comparison of E. coli derived from humans and poultry has shown that antibiotic-resistant E. 
coli isolates from both reservoirs are more frequently genetically related than antibiotic-
susceptible isolates. Recent findings indicate transmission of ESBL genes, plasmids and clones 
from poultry to humans is most likely to occur through the food chain. 
• There is limited evidence for spread of ESBL/AmpC-carrying organisms via direct contact with 
animals or indirectly via the environment. Nevertheless people working with poultry have a 
higher risk for intestinal carriage of ESBL/AmpC-producing bacteria. 
Methods for detection (isolation and identification) and characterisation of ESBL and/or 
AmpC-producing bacteria, encoding genes and associated mobile elements 
• The preferred method for selective isolation of ESBL- and/or AmpC producers is selective 
isolation on agar preceded by selective enrichment in a broth. The preferred method for 
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selective isolation of ESBL- and/or AmpC producers is chromogenic (e.g. MacConkey agar) 
with 1 mg/L cefotaxime or ceftriaxone. Using low concentrations will result in optimum 
sensitivity to detect all relevant ß-lactamase families. Pre-enrichment may be performed in a 
general broth like Mueller-Hinton, Brain Heart Infusion or Luria-Bertani broth with 1 mg/L 
cefotaxime or ceftriaxone. 
• Identification is performed by determination of susceptibility to cefotaxime, ceftazidime and 
cefoxitin. ESBL-producers are resistant to cefotaxime, variably resistant to ceftazidime and 
susceptible to cefoxitin. Confirmation of ESBLs is performed by testing for synergy with 
clavulanic acid by combination disks, ESBL-etests or broth micro-dilution including 
cefotaxime, and ceftazidime as single drugs, and in combination with clavulanic acid. 
Confirmation of AmpC producers is performed by determination of susceptibility to cefepime. 
AmpC producers are susceptible to cefepime and resistant to cefotaxime, ceftriaxone and 
cefoxitin. 
• To identify ESBL and/or AmpC-suspected Enterobacteriaceae by broth micro-dilution 
susceptibility tests, optimum breakpoints or interpretive criteria need to be used. Although 
CLSI has recently redefined MIC breakpoints for 3rd- and 4th-generation cephalosporins, the R-
breakpoints for ceftazidime, cefoxitin and cefepime are still one to two dilution steps higher 
than those defined by EUCAST. In order to harmonize the interpretation of susceptibility data 
and for optimum phenotypic detection of ESBL and/or AmpC producers, it is important to use 
EUCAST clinical breakpoints for interpretation of susceptibility or resistance and EUCAST 
ECOFFs to determine if an isolate belongs to the wild-type population or not. 
• All isolates phenotypically confirmed to be either ESBL or AmpC-producers may be screened 
for β-lactamase gene families using micro-array or (multiplex) PCR. The ESBL and/or AmpC 
subtypes may be identified by dedicated PCRs and sequence analysis of the amplicons. 
• Characterization of plasmids on which blaESBL and/or blaAmpC-genes are located is essential to 
study the epidemiology of these genes and plasmids. Since in Enterobacteriaceae several 
different plasmids are often present in each isolate, a structured approach is needed to identify 
the characteristics of the plasmid on which the β-lactamase genes are located. If the presence of 
an ESBL and/or AmpC gene in a bacterial isolate is confirmed, plasmid isolation is performed 
to determine the number and sizes of plasmids present. Subsequently, by conjugation or 
electroporation, tranconjugants or transformants are isolated on selective agar plates with only 
the plasmid that harbours the β-lactamase gene present. The plasmid can be typed using 
replicon typing and sub-typed by fingerprinting or MLST. Ultimately whole plasmid sequence 
analyses may replace the current typing and subtyping techniques. 
• The choice of the molecular typing method to be used for isolates is determined by 
epidemiological relatedness of the isolates. Next to phenotypic methods such as serotyping, and 
phage typing, PFGE or MLVA can be used to identify clusters of isolates that are related to a 
certain ‘outbreak’ in a restricted time frame. MLST is generally the method of choice to 
identify relatedness of isolates of the same species from different backgrounds (eg. animal 
versus human). 
Risk factors contributing to the occurrence, emergence and spread of ESBL- and/or AmpC-
producing bacteria 
• The establishment of risk factors for occurrence of ESBL/AmpC-producing bacteria is 
particularly complicated by the data unavailability or lack of its accuracy. Few studies designed 
to assess risk factors for ESBL and/or AmpC occurrence in animals are available. 
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• The use of antimicrobials is a risk factor for emergence and spread of resistant clones. Most 
ESBL- and AmpC-producing strains carry additional resistances such as to sulphonamides and 
other commonly-used veterinary drugs. Therefore, generic antimicrobial use is a risk factor for 
ESBL/AmpC and it is not restricted specifically to the use of cephalosporins. 
• Currently there are no pan-European data available on the use of antimicrobials. The European 
Surveillance of Veterinary Antimicrobial Consumption (ESVAC), coordinated by EMA, is 
collecting information. 
•  An extensive trade of animals occurs in EU MS, with few countries leading the production and 
the export, and with a small number of companies producing pure line grandparent stock. How 
widespread are ESBL-carrying bacteria in food-producing animals in the 
breeding/rearing/fattening sectors is generally unknown, although few reports suggest that 
ESBL/AmpC are not uncommon in the top of some production pyramids (breeding). 
• ESBL- and/or AmpC-producing E. coli are disseminated in the poultry production chain 
through day-old grandparent chickens. Moreover, some data indicate that the occurrence of 
these organisms in the different levels of the poultry production chain is the result of vertical 
transmission, local recirculation and selection. 
Identification and ranking of possible control options taking into account the expected 
efficiency in reducing public health risk caused by ESBL and/or AmpC-producing bacterial 
strains transmitted via the food chain or via food animal production environment 
There are no data on the comparative efficiency of individual control options presented in this 
document in reducing public health risks caused by ESBL and/or AmpC-producing bacteria related to 
food-producing animals. Prioritisation is complex, and the effectiveness of measures discussed in this 
Opinion are based on the best available evidence and expert opinion.  
• It is considered that a highly effective control option to reduce selection of ESBL/AmpC-
producing bacteria at an EU level, would be to stop all uses of cephalosporins/systemically 
active 3rd-4th generation cephalosporins, or to restrict their use (use only allowed under specific 
circumstances). 
• It is important to implement control measures covering all off-label usage of cephalosporins in 
food-producing animals.  
• Measures intended to minimize off label use of antimicrobials should focus on increased 
compliance with existing legislation. 
• As co-resistance is an important issue, it is of high priority to decrease the total antimicrobial 
use in animal production in the EU. 
• Also of importance (more so after the ESBL/AmpC-producing microorganisms have emerged) 
are the measures to control dissemination, for example, by implementing increased farm 
biosecurity and controls on animal trade (of ESBL/AmpC carriers), by improving hygiene 
throughout the food chain, and by implementing other general post-harvest controls for food-
borne pathogens. 
• Because most evidence is available for high prevalence of ESBL/AmpC-producing bacteria  in 
the poultry production pyramid, and their consequent involvement in public health, it is of high 
priority: 
o To reduce selection pressure impossed by the use of antimicrobials. 
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o To prevent vertical transmission from the top of the poultry production pyramid.  
o To prevent local recirculation within subsequent flocks. 
RECOMMENDATIONS 
Harmonised monitoring of resistance caused ESBL- and/or AmpC-producing bacteria 
• Harmonised monitoring of resistance caused by ESBLs and AmpC will need to go beyond the 
existing recommendations for routine phenotypic surveillance. Specifically, genotypic 
resistance testing should be performed in addition to the phenotypic testing foreseen in the 
existing recommendations. 
• For surveillance schemes, the analysis of isolates deriving from passive surveillance schemes 
(diagnostic submissions), from systematic sampling, and from targeted surveys, using selective 
isolation methods and pre-enrichment of samples, should be undertaken. 
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Table 13:  Resistance (%) to cefotaxime among Salmonella spp. isolates from poultry, pigs and cattle, and meat thereof in 2007, 2008 and 2009, using 
harmonised epidemiological cut-off values 
N is the number of isolates tested 
Ceftiofur and ceftazidime susceptibility test results are additionally mentioned in blue and in red, respectively, in the table. 
Green shading: resistance detected to cefotaxime was not detected to ceftazidime / Red shading: resistance detected to ceftazidime was not detected to cefotaxime 
  
N % N % N % N % N % N % N % N % N % N % N % N % N % N % N %
Austria Dil 96* 0 230 0 15* 0 11* 0
Belgium Dil 148* 1 226* 26 162 9 70* 0 200 4
Czech Republic Dil 234 0 106* 0 508 3 61* 0 26 0 16* 0 17 0 24 0 42* 0 20 0 25* 0
Denmark Dil, Dil 20 0 1150 0 525** 0 393** 0 26 0 31** 0 18** 0 71 0 126** 0.8 100** 0
Estonia Dil 19 5.3 18 0 26 0
Finland Dil 10 0 48 0 18 0 18 0 11 0
France Dil 334* 1 360 1 183* 1 14 0
Germany Dil, Dil 364 1 581 0.2 343 2 221 1 199 4 214 4 166 1
Greece Dil 31 0
Ireland Dil 40* 0 66* 1.5 255* 0 25 0 25 0 79 5 44 0
Italy Dil 136* 2.9 144* 12 414 2 140* 0.7 384* 1 76 0 20* 0 21* 0 22 0 45* 2 18 0 231* 0 219* 0 42 0
Latvia Dil, Dil 73 0 26 0 16 6 12 0
Netherlands Dil 164* 13.4 423* 13 302 12 144* 0 332* 0 87 0 78* 0 57* 0 82 0 26 4 11 0
Poland Dil 195* 0 234 0.4 32* 0 107* 0
Portugal Dil 104 0 34 0 27 4 33 0
Slovakia Dil 137* 0 191* 0 109 0 77* 0 44* 0 20 0 17* 0 10 0 10* 0
Slovenia DD, Dil 33 0 25* 0 49 0 22 0 14* 0
Spain Dil 295* 7.8 252* 1 287 2 167* 0.6 384* 2 112 1 30 0 47* 0 29 0
Sweden Dil 15 0 14 0 29 0 23 0 10 0 20 0 39 0 43 0
United Kingdom Dil 55 0 326 0
‐ ‐ 2217 4 3539 2 ‐ ‐ ‐ ‐ 1136 1 ‐ ‐ ‐ ‐ 457 0.4 ‐ ‐ ‐ ‐ 533 5 ‐ ‐ ‐ ‐ 575 2
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Table 14:  Resistance (%) to cefotaxime among indicator E. coli isolates from poultry, pigs and cattle, and meat thereof in 2007, 2008 and 2009, using 
harmonised epidemiological cut-off values 
N is the number of isolates tested 
Ceftiofur and ceftazidime susceptibility test results are additionally mentioned in blue and in red, respectively, in the table. 
Green shading: resistance detected to cefotaxime was not detected to ceftazidime / Red shading: resistance detected to ceftazidime was not detected to cefotaxime  
N % N % N % N % N % N % N % N % N % N % N % N % N % N %
Austria Dil 43 0 170 2.9 170 2.4 46 0 170 0.6 162 0.6 43 0 170 0 168 0
Denmark Dil, Dil 114 1.8 114** 0 152** 0 150 0.7 151** 0 150** 0 98 0 97** 0 94** 0 143** 0 66** 0 106** 0.9 32** 0
Estonia Dil 19** 0 10** 0 17** 0 25** 4 10** 0 23** 4.3
Finland Dil 388 1.3 135 0 272 0
France Dil 101*/** 2 146* 6.2 189* 2.6126*/** 0.8 137* 0.7 155* 1.3103*/** 1 118* 0.8 151* 3.3 155* 1.9 102* 1 100* 5
Germany Dil, Dil 514* 2.5 76 11.8 361* 1.4 194* 6.2 203* 1 46* 2.2 51* 0
Hungary DD (bp: 27) 176 4.5 317** 3.8 340 6.5
Italy Dil 54* 11.1 149* 0.7
Netherlands Dil 43* 20.9 440* 15 291 17.9 169* 1.2 296* 1 296 3.7 432* 2.3 301* 1.7 307 1.6 17* 0
Poland Dil 356 11.2 184 3.8 173 0.6
Slovenia DD, DD (bp: 14) 34 3 22 0 18 0
Spain Dil 113* 30.1 197* 26.4 229 0.9 168* 0.6 278* 1.1 158 0 167* 0 256* 0.4
Sweden Dil 296** 1 349 0 223 0 19 0
‐ ‐ ‐ ‐ 2045 8.5 ‐ ‐ ‐ ‐ 1559 2.3 ‐ ‐ ‐ ‐ 2217 1.6 ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
Norway Dil 162 0 198** 0.5 258 0
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B.  DETECTION OF ESBLS AND AMPC IN ENTEROBACTERIACEAE RECOVERED FROM FOOD-PRODUCING ANIMALS OR FOOD OF ANIMAL ORIGIN  
Table 15:  Detection of ESBLs in Enterobacteriaceae recovered from food-producing animals or food of animal origin  
Animal Type of ESBL  Species 
 
Year of isolation Country Reference 
 
Healthy animals or food of animal origins 
 




     
 CTX-M-14 , SHV-12  E. coli 2000-2001 Spain (Brinas et al., 2003b) 
 CTX-M-2, CTX-M-14  E. coli 1999-2002 Japan (Kojima et al., 2005) 
 CTX-M-14, SHV-12, CTX-M-9  E. coli 2003 Spain (Brinas et al., 2005) 
 TEM-52 E. coli 2005 Portugal (Machado et al., 2008) 
 CTX-M-1, -9, -14, -32 
SHV-2, -5, -12 
TEM-52 
E. coli 2003 Spain (Blanc et al., 2006) 
 TEM-52, CTX-M-14, CTX-M-32  E. coli 2004 Portugal (Costa et al., 2009) 
 CTX-M-1 E. coli 2005 France (Girlich et al., 2007) 
 TEM-52, TEM-106, CTX-M-1, CTX-
M-2, CTX-M-14, CTX-M-15  
E. coli 2007 Belgium (Smet et al., 2008) 
 CTX-M groups -1, -2 and -9 E. coli 2009 Denmark (Bortolaia et al., 2010a) 
 CTX-M-1, CTX-M-32, SHV-12 E. coli 2007 Italy (Bortolaia et al., 2010b) 
 CTX-M-1, -2, TEM-52 and SHV-2 E. coli 2006 Netherlands (Dierikx et al., 2010a) 
 CTX-M-14, CTX-M-65, CTX-M-55, 
CTX-M-24, CTX-M-3, CTX-M-15 (1 
strain), CTX-M-64. 
E. coli 2006-2007 China (Li et al., 2010a) 
 CTX-M-1 and SHV-12 E. coli 2008 Czech Republic (Kolar et al., 2010) 
 TEM-52 Salmonella. 2001-2005 Belgium (Cloeckaert et al., 2007) 
 SHV-12 Salmonella. 2005-2006 Italy (Chiaretto et al., 2008) 
 CTX-M-1 Salmonella 2006 France (Cloeckaert et al., 2010) 
 CTX-M-1, -2, TEM-52 and TEM-20 Salmonella 2006 Netherlands (Dierikx et al., 2010a) 
Broiler and turkey CTX-M-1, -3, -14, -15, -55, TEM-52 E. coli 2006-2009 Great Britain (Randall et al., 2011) 
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Animal Type of ESBL  Species 
 
Year of isolation Country Reference 
Broiler and lay hens CTX-M-9 Salmonella 2003-2004 Spain (Riano et al., 2006) 
Poultry meat TEM-52, CTX-M-1, SHV-2 E. coli, K. pneumoniae 2003-2005 Portugal (Machado et al., 2008) 
Poultry and poultry meat CTX-M-2, 
TEM-52, TEM-20, SHV-2, SHV-12 
Salmonella  2001-2002 The Netherlands (Hasman et al., 2005) 
Poultry and poultry meat CTX-M-2 Salmonella 2000-03 Belgium (Bertrand et al., 2006) 
Poultry and poultry meat CTX-M-9 Salmonella  2003 France (Weill et al., 2004) 
Poultry and poultry meat CTX-M Salmonella 2004-2008 Korea (Hur et al., 2010) 
Sick and healthy poultry CTX-M-14, CTX-M-15, TEM-52, 
SHV-12, CTX-M-65, and CTX-M-3 
(CTX-M: 75%) 




China (Li et al., 2010a) 
Poultry meat CTX-M-8, CTX-M-14 , SHV-5  E. coli 2006 Tunisia (Jouini et al., 2007) 
Poultry meat CTX-M-1  E. coli 2007 Tunisia (Ben Slama et al., 2010) 
Poultry meat CTX-M-14 
(recovered in 2004) 
Salmonella  1999-2005 
 
Japan (Matsumoto et al., 2007) 
Poultry meat CTX-M-1 
CTX-M-2 
CTX-M-14 and CTX-M-8 
E. coli 2006 UK (imported and not 
imported meat) 
(Warren et al., 2008) 
Poultry meat Group 2 CTX-M 
Group 8 CTX-M 
E. coli 2008 raw chicken imported to 
UK 
(Dhanji et al., 2010) 
poultry SHV-12 Salmonella 2008-2009 Ireland (Boyle et al., 2010) 
Poultry meat SHV-12 Salmonella 2000 Senegal (Cardinale et al., 2001) 
Poultry meat CTX-M-32 Salmonella 2001 Greece (Politi et al., 2005) 




     
 CTX-M-1, CTX-M-14, SHV-12  E. coli 2006 France (Madec et al., 2008) 
 CTX-M-1  E. coli 2006 Tunisia (Jouini et al., 2007) 
 CTX-M-2 E. coli 2000-2001 Japan (Shiraki et al., 2004) 
 CTX-Ma E. coli 2004 United Kingdom (Liebana et al., 2006) 
 CTX-M-1 E. coli 2007 Tunisia (Ben Slama et al., 2010) 
 CTX-M-2 E. coli 2000-2001 Japan (Shiraki et al., 2004) 
 CTX-M-13 E. coli 2002 Hong Kong (Duan et al., 2006) 
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Animal Type of ESBL  Species 
 
Year of isolation Country Reference 
 TEM-52 E. coli 2004 Denmark (Jensen et al., 2006) 
 CTX-M-1 CTX-M-29 E. coli 2009 USA (Wittum et al., 2010) 
 SHV-1, -25, -26, -110, -111 
CTX-M-14  
Enterobacteria  Egypt - Japan (Hammad et al., 2009) 
 CTX-M-1 E. coli 2009 USA (Wittum et al., 2010) 




     
 CTX-M-15, CTX-M-22, SHV-2  E. coli 2002-2007 China (Tian et al., 2008) 
 CTX-M-1, CTX-M-9, CTX-M-14, 
SHV-12  
E. coli 2004 Spain (Escudero et al., 2010) 
 CTX-M-1 
SHV-5, -12 
E. coli 2003 Spain (Blanc et al., 2006) 
 CTX-M-1  E. coli  2007 Portugal (Goncalves et al., 2010) 
 CTX-M-1 E. coli 2005-2006 Denmark (Wu et al., 2008) 
 SHV-12 Salmonella 2003 Spain (Riano et al., 2006) 
 SHV-12 Citrobacter freundi 2004 Portugal (Machado et al., 2008) 




     
Sheep-meat CTX-M-1, TEM-20  E. coli 2007 Tunisia (Ben Slama et al., 2010) 
Pigeon CTX-M-14 E. coli 2002 Hong Kong (Duan et al., 2006) 
Rabbit  CTX-M-9, -14 E. coli 2003 Spain (Blanc et al., 2006) 
Ostrich CTX-M-14, TEM-52  E. coli Not specified Portugal (Carneiro et al., 2010) 
Cockles CTX-M-53 
(Asp240Gly as CTX-M-15) 
Salmonella  France 2004 (Doublet et al., 2009) 
Various food samples CTX-M-1 and -9 groups 
SHV-12 
E. coli Non specified Spain  (Doi et al., 2009) 
Various food samples CTX-M-1 group E. coli Non specified USA (Doi et al., 2009) 
Various livestock and 
food samples 
CTX-M-1, CTX-M-15, TM-52, TEM-
20 
Salmonella 2003-2007 Germany (Rodriguez et al., 2009) 
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Animal Type of ESBL  Species 
 




     
Various species SHV-12 E. coli 1997-2001 Spain (Brinas et al., 2003a) 
Various species CTX-M-14, -9, -32, -1, TEM-52, SHV-
12 
E. coli 2003 Spain (Brinas et al., 2005) 
Cattle CTX-M-1, CTX-M-14 , CTX-M-15, 
TEM-126  
E. coli 2006 France (Madec et al., 2008) 
Pigs TEM-20, TEM-52, SHV-28, SHV-33  E. coli, K. pneumoniae 1999-2006 Korea (Rayamajhi et al., 2008) 
Poultry CTX-M-1 E. coli 2003-2004 France (Meunier et al., 2006) 
Pigs CTX-M-1 E. coli 2000-2004 France (Meunier et al., 2006) 
Cattle CTX-M-1, -15 E. coli 2004 France (Meunier et al., 2006) 
Pigs CTX-M-1 E. coli 2005 Denmark (Aarestrup et al., 2006) 
Cattle  CTX-M-14 E. coli 2004-2005 UK (Hopkins et al., 2006) 
Poultry  CTX-M-2 Salmonella  unknown Ireland (Hopkins et al., 2006) 
Poultry  TEM-52 Salmonella 2003 Ireland (Morris et al., 2009) 
Cattle TEM-20 Salmonella 2001 Ireland (Morris et al., 2009) 
Horse  SHV-12 Salmonella 2003 USA (Rankin et al., 2005) 
Cows and pigs CTX-M 14 CTX-M-15 E. coli 2003-2006 Korea (Lim et al., 2009) 
Bovine CTX-M-1, -3, -14, -15, -20, -32 ESBL producers 2006-2008 UK (Hunter et al., 2010) 
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Table 16:  Detection of plasmidic AmpC beta-lactamases in Enterobacteriaceae recovered from food-producing animals or food of animal origin  
Animal Type of AmpC Species 
 
Year of isolation Country Reference 
 
Healthy animals or food of animal origin 
 
     
Poultry      
 CMY-2  E. coli 2000-2001 Spain (Brinas et al., 2003b) 
 CMY-2  E. coli 1999-2002 Japan (Kojima et al., 2005) 
 CMY-2  E. coli 2003 Spain (Brinas et al., 2005) 
 CMY-2 E. coli 2003 Spain (Blanc et al., 2006) 
 CMY-2  E. coli 2007 Belgium (Smet et al., 2008) 
 CMY-2 E. coli Not specified Taiwan (Yan et al., 2004) 
 CMY-2 E. coli  (2004-2007) China (Li et al., 2010b) 
 CMY-2 E. coli 2006 Netherlands (Dierikx et al., 2010a) 
 CMY-2 E. coli 2008 Czech Republic (Kolar et al., 2010) 
 CMY-2 Salmonella 1994-1999 Canada (Allen and Poppe, 2002) 
Retail meat (poultry) CMYa Salmonella 2002-2006 United States (Zhao et al., 2008) 
 CMY-2 Salmonella 2004-2005 Japan (Taguchi et al., 2006) 
Poultry CMY-2 Salmonella 2008-2009 Ireland (Boyle et al., 2010) 
Poultry (and humans) ACC-1 Salmonella 2002/2006 Netherlands (Dierikx et al., 2010a; Hasman et al., 2005) 
Cattle      
 CMY-2 E. coli 2003 United States (Donaldson et al., 2006) 
 CMY-2 Salmonella  1994-1999 Canada (Allen and Poppe, 2002) 
Pigs      
 CMY-2 E. coli Not specified Canada (Kozak et al., 2009) 
 CMY-2 E. coli Not specified Taiwan (Yan et al., 2004) 
 CMY-2 Salmonella. 2000-2005 Mexico (Zaidi et al., 2007) 
Rabbit CMY-2 E. coli 2003 Spain (Blanc et al., 2006) 
Various food samples CMY-2 E. coli Non specified USA (Doi et al., 2009) 
Various livestock and food samples CMY-2 Salmonella  2003-2007 Germany (Rodriguez et al., 2009) 
Various livestock and food samples CMY-2 and  
CMY-2-like 
E. coli and 
Salmonella 
None specified USA (Heider et al., 2009) 
Food of chicken and pork origin CMY-2 E. coli None specified Taiwan (Yan et al., 2004) 
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Animal Type of AmpC Species 
 




     
Various species CMY-2 E. coli 1997-2001 Spain (Brinas et al., 2003a) 
Various species CMY-2 E. coli 2003 Spain (Brinas et al., 2005) 
Pigs CMY-2 , DHA-1 K. pneumoniae 1999-2006 Korea (Rayamajhi et al., 2008) 
Cattle CMY-2 Salmonella. 2000-2004 United States (Frye et al., 2008) 
Cattle AmpCa Salmonella  1999-2001 United States (Gupta et al., 2003) 
Cattle & pigs CMY-2 E. coli, 
Salmonella 
1998-1999 United States (Winokur et al., 2000) 
aNot genotypically characterized 
